

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
17 January 2002 (17.01.2002)

PCT

(10) International Publication Number  
**WO 02/03917 A2**

(51) International Patent Classification<sup>7</sup>: **A61K**

(21) International Application Number: PCT/US01/21701

(22) International Filing Date: 9 July 2001 (09.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/216,995 7 July 2000 (07.07.2000) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:  
US 60/216,995 (CIP)  
Filed on 7 July 2000 (07.07.2000)

(71) Applicants (for all designated States except US): **ALPHA VAX, INC.** [US/US]; P.O. Box 110307, 2 Triangle Drive, Research Triangle Park, NC 27709-0307 (US). **UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL** [US/US]; 308 Bynum Hall, Campus Box 4105, Chapel Hill, NC 27599-4105 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **OLMSTED, Robert** [US/US]; 420 Bayberry Drive, Chapel Hill, NC 27514 (US). **KEITH, Paula** [US/US]; 5004 Sadelia Place, Holly Springs, NC 27540 (US). **DRYGA, Sergey** [RU/US]; 211 Bonsail Place, Chapel Hill, NC 27514 (US). **CALEY, Ian** [GB/US]; 2 Triangle Drive, P.O. Box 110307, Research Triangle Park, NC 27709-0307 (US). **MAUGHAN,**

**Maureen** [US/US]; 2532 Wrightwood Avenue, Durham, NC 27705 (US). **JOHNSTON, Robert** [US/US]; 101 Marin Place, Chapel Hill, NC 27516 (US). **DAVIS, Nancy** [US/US]; 132 New Castle Drive, Chapel Hill, NC 27514 (US). **SWANSTROM, Ronald** [US/US]; 7021 Knotty Pine Drive, Chapel Hill, NC 27514-8659 (US).

(74) Agents: **MILLER, Mary, L.** et al.; Needle & Rosenberg, P.C., 127 Peachtree Street, N.E., Suite 1200, Atlanta, GA 30303-1811 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **ALPHAVIRUS VECTORS AND VIROSOMES WITH MODIFIED HTV GENES FOR USE AS VACCINES**

(57) Abstract: The present invention provides methods and compositions comprising a population of alphavirus replicon particles comprising two or more isolated nucleic acids selected from 1) an isolated nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, 2) an isolated nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and 3) an isolated nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof is modified to inhibit integrase, RNase H and/or reverse transcriptase activity, and wherein the nucleic acids are each contained within a separate alphavirus replicon particle.

BEST AVAILABLE COPY

WO 02/03917 A2

**THIS PAGE BLANK (USPTO)**

## ALPHAVIRUS VECTORS AND VIROSOMES WITH MODIFIED HIV GENES FOR USE AS VACCINES

This application claims priority to U.S. Provisional Application No. 60/216,995,  
5 filed July 7, 2000 which is hereby incorporated by reference in its entirety.

### BACKGROUND OF THE INVENTION

#### Field of the Invention

10

The present invention relates to vaccines using viral antigens, and in particular,  
to vaccines for the treatment and prevention of human immunodeficiency virus (HIV)  
infection. The vaccines of this invention comprise alphavirus RNA replicon systems  
which contain nucleic acid sequence encoding antigens for eliciting an immune  
15 response to HIV.

#### Background

The successful control of the AIDS epidemic will require an effective vaccine  
20 for human immunodeficiency virus type 1 (HIV) that significantly reduces or prevents  
the spread of infection. Currently, several viral vector systems as well as naked DNA  
are at various stages of pre-clinical and clinical evaluation as candidate HIV vaccines.  
Recombinant poxviruses are the most widely studied virus vectors and are furthest  
along in clinical development (e.g., ALVAC).

25

The alphavirus-based replicon particle systems, such as the ones described in  
U.S. Patent No. 5,792,462 and herein referred to as "VRPs," have multiple distinct  
properties that make them attractive as an HIV-vaccine delivery technology. These  
properties include: natural targeting to and expression in lymphoid tissues (an optimal  
30 site for induction of an immune response); high antigen expression levels, e.g., up to  
20% of total cell protein; induction of balanced humoral, cellular, and mucosal immune  
responses; sustained efficacy over multiple simultaneous or sequential inoculations of

the vector; and a high margin of safety.

Venezuelan equine encephalitis virus (VEE) is a member of the Alphaviruses group, which also includes the prototype Sindbis virus (SIN) and Semliki Forest virus (SFV), and is comprised of enveloped viruses containing plus-stranded RNA genomes within icosahedral capsids (Strauss, 1994). Alphavirus genomes are: approximately 11.5 kb long, capped, polyadenylated, and infectious under appropriate transfection conditions. The nucleocapsid is composed of 240 molecules of the capsid protein arranged as a T=4 icosahedron, and is surrounded by a lipoprotein envelope (Paredes *et al.*, 1993). Protruding from the virion surface are 80 glycoprotein spikes, each of which is a trimer of virally encoded E1 and E2 glycoprotein heterodimers. The virions contain no host proteins.

Alphaviruses share replication strategies and genomic organization. The complete replicative cycle of alphaviruses occurs in the cytoplasm of infected cells. Expression from the alphavirus genome is segregated into two regions. The four enzymatic nonstructural proteins (nsP1-nsP4) are synthesized from the 5' two-thirds of the genome-length RNA and are required for RNA replication. Immediately following infection, the nsPs are produced by translation of parental genomes and catalyze the synthesis of a full-length negative-sense copy of the genome. This serves as a template for the synthesis of progeny plus-stranded genomes.

The negative-sense copy of the genome also serves as the template for the synthesis of subgenomic mRNA at approximately 10-fold molar excess relative to genomic RNA in infected cells (Schlesinger and Schlesinger, 1990). Synthesis of subgenomic 26S mRNA is initiated from the highly active internal 26S mRNA promoter, which is functional only on the negative-sense RNA. The subgenomic mRNA corresponds to the 3' one-third of the genome and encodes the alphavirus structural proteins.

Full-length, infectious cDNA clones of the RNA genome of VEE (Davis *et al.*, 1989) have been constructed, a panel of mutations which strongly attenuate the virus have been identified (Johnston and Smith, 1988; Davis *et al.*, 1990), and various constellations of these attenuating mutations have been inserted into the clones to  
5 generate several live attenuated VEE vaccine candidates (Davis *et al.*, 1991; 1995b; Grieder *et al.*, 1995). The resulting vaccine candidates are avirulent and provide complete protection against lethal virus challenge in rodents, horses and nonhuman primates.

10 The alphavirus VRPs are propagation defective, single cycle vectors that contain a self-amplifying alphavirus RNA (replicon RNA) in which the structural protein genes of the virus are replaced by a heterologous antigen gene to be expressed. Alphavirus VRPs are typically made in cultured cells, referred to as packaging cells. Following introduction into mammalian cells, the replicon RNA is packaged into VRP  
15 by supplying the structural proteins in "trans," i.e. the cells are co-transfected with both replicon RNA and one or more separate helper RNAs which together encode the full complement of alphavirus structural proteins. Importantly, only the replicon RNA is packaged into VRP, as the helper RNA(s) lack the *cis*-acting packaging sequence required for encapsidation. Thus, the VRPs are defective, in that they can only infect  
20 target cells in culture or *in vivo*, where they express the heterologous antigen gene to high level, but they lack critical portions of the VEE genome (i.e., the VEE structural protein genes) necessary to produce virus particles which could spread to other cells.

Delivery of the replicon RNA into target cells (for vaccination) is facilitated by  
25 the VRP following infection of the target cells. In the cytoplasm of the target cell, the replicon RNA is first translated to produce the viral replicase proteins necessary to initiate self-amplification and expression. The heterologous antigen gene is encoded by a subgenomic mRNA, abundantly transcribed from the replicon RNA, leading to high level expression of the heterologous antigen gene product. Since the VEE structural  
30 protein genes are not encoded by the replicon RNA delivered to the target cell, progeny

virion particles are not assembled, thus limiting the replication to a single cycle within the infected target cell. Experimental VRP vaccines have been successful in vaccinating rodents against influenza virus, Lassa fever virus and Marburg virus (Pushko *et al.*, 1997; Hevey *et al.*, 1998). In nonhuman primates, VRP vaccines have  
5 demonstrated complete efficacy against lethal Marburg virus challenge (Hevey *et al.*, 1998), shown partial but significant protection against SIV infection and disease (Davis *et al.*, 2000) and induced an anti-HA response at a level consistent with protection of humans against influenza virus infection.

10 The alphavirus based replicon vector systems, and in particular the VEE-based systems, present several advantages in vaccination, including safety and high immunogenicity/efficacy. VEE is unique among the alphaviruses in that a live attenuated IND VEE vaccine, TC-83, (Kinney *et al.*, 1989; Kinney *et al.*, 1993) has been inoculated into approximately 8,000 humans. This allows direct safety and  
15 efficacy comparisons between human, nonhuman primate and rodent responses to the same VEE derivative. A large body of experience strongly suggests that the animal models generally reflect the human susceptibility and disease course, except that mice are far more susceptible to lethal VEE disease than humans or nonhuman primates. Furthermore, the VEE replicon vectors express high levels of the gene of interest in cell  
20 culture, and *in vivo* expression is targeted to lymphoid tissues, reflecting the natural tropism mediated by the VEE glycoproteins. Cells in the draining lymph node of VRP-inoculated mice contain detectable amounts of the desired gene product within hours of inoculation. This expression continues for up to five days.

25 To date, VRP vector vaccines have been used in over 2000 rodents and in 94 macaques at doses up to  $5 \times 10^8$  i.u., with no indication of any clinical manifestations.

In work reported by Pushko *et al.* (1997), individual mice were immunized sequentially with Lassa virus N-VRP and influenza virus HA-VRP. Groups of mice,  
30 which received two inoculations of  $3 \times 10^4$  or  $3 \times 10^6$  i.u. of Lassa N-VRP followed by

two inoculations of  $2 \times 10^5$  i.u. of HA-VRP, all responded with serum antibodies to both antigens. The level of anti-influenza antibody induced in these sequentially inoculated mice was equivalent to a control group, which received two inoculations of buffer followed by two inoculations of  $2 \times 10^5$  i.u. of HA-VRP. All HA-VRP immunized mice were completely protected against influenza virus challenge. Furthermore, sequential immunization of mice with two inoculations of N-VRP prior to two inoculations of HA-VRP induced an immune response to both HA and N equivalent to immunization with either VRP construct alone. Primary and booster immunization with a VRP preparation expressing an immunogen from one pathogen did not interfere with the development of a protective response to subsequent primary immunization and boosting with VRP expressing an immunogen from a second pathogen, thus showing that the VRP-based system can be used to induce immunity to a variety of pathogens in the same individual over time.

Four macaques were inoculated subcutaneously at week 0 with  $10^5$  i.u. each of SIV-gp160-VRP (*env*) and SIV MA/CA-VRP (*gag*), boosted by the same route at week 7 with  $10^7$  i.u. of each VRP vaccine, and intravenously at weeks 12 and 20 with  $5 \times 10^8$  i.u. of each VRP. Two control animals were inoculated with equivalent doses of HA-VRP (haemagglutinin, a glycoprotein from influenza virus), and two with the vehicle only. The four SIV-VRPs immunized monkeys received subcutaneously an additional dose of  $2 \times 10^7$  i.u. of gp140-VRP at week 41, followed by a final boost of  $2 \times 10^7$  i.u. each of gp140-VRP and MA/CA-VRP at week 49. Four weeks after the final immunization, all eight macaques were challenged intravenously with the pathogenic virus, SIVsmE660.

25

After these inoculations, three of four test macaques had measurable CTL-specific killing directed against both SIV *gag* and *env*, all four had gp160 IgG antibody by ELISA, and the three animals which harbored SIV-specific CTL also showed neutralizing antibody to SIVsmH-4.

30

Four of four vaccinated animals were protected against disease for at least 16 months following intravenous challenge with the pathogenic SIV swarm, while the two vehicle controls required euthanasia at week 10 and week 11, post challenge. In two of the vaccinees, plasma virus levels were below the limit of detection by branched chain  
5 DNA assay. At 64 weeks post challenge, all four vaccinated animals showed no clinical signs of disease. One animal remained vDNA negative at 64 weeks.

The results of this highly pathogenic challenge demonstrated that the immune response induced by vaccination with SIV-VRP was effective in preventing early  
10 mortality and increasing the ability to suppress challenge virus replication. The ability to control SIV replication and reduce viral load to undetectable levels was closely correlated with the strongest measurable antibody and cellular immune responses.

While these results are encouraging, the level of protection obtained would not  
15 be acceptable for a human vaccine against HIV infection. Thus, there remains a need for a robust, effective and safe vaccine against HIV infection in humans. Development of a HIV vaccine comprising the complete, or immunogenic fragments of the, *gag* gene (Gag-VRP), an immunogenic portion of the *pol* gene (Pol-VRP), and the complete, or immunogenic fragments of the, *env* gene (Env-VRP), would increase the diversity of  
20 available CTL epitopes substantially and thus address this need.

### SUMMARY OF THE INVENTION

The present invention provides a composition comprising two or more isolated  
25 nucleic acids selected from the group consisting of an isolated nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, an isolated nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles  
30 containing the *gag* gene product or the immunogenic fragment thereof and their release

a cell, and an isolated nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* product or immunogenic fragment thereof is modified to inhibit reverse transcriptase activity.

Also provided is a composition comprising a population of alphavirus replicon particles comprising two or more isolated nucleic acids selected from the group consisting of 1) an isolated nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, 2) an isolated nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, 3) an isolated nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof is modified to inhibit reverse transcriptase activity, and wherein the nucleic acids are each contained within a separate alphavirus replicon particle.

In addition, the present invention provides a composition comprising a population of alphavirus replicon particles comprising two or more isolated nucleic acids selected from the group consisting of 1) an isolated nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, 2) an isolated nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and 3) an isolated nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof is modified to inhibit reverse

transcriptase activity, and wherein the nucleic acids are each contained within a separate alphavirus replicon particle, and further wherein the alphavirus replicon particles comprise a replicon RNA or at least one structural protein which comprises one or more attenuating mutations.

5

10. A method of making a population of alphavirus replicon particles of this invention is provided herein, comprising:

A) (a) providing a first helper cell for producing a first population of infectious, replication defective alphavirus particles, comprising in an alphavirus-permissive cell:

10 (i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

15 (ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and

20 (iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

25 wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the first population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture;

30 (b) producing the alphavirus particles in the helper cell; and

(c) collecting the alphavirus particles from the helper cells;

B) (a) providing a second helper cell for producing a second population of infectious, replication defective alphavirus particles, comprising in an alphavirus-

5 permissive cell:

(i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

10

(ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and

15

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

20

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the second population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture;

25

(b) producing the alphavirus particles in the helper cell; and

30

(c) collecting the alphavirus particles from the helper cells;

C) (a) providing a third helper cell for producing a third population of infectious, replication defective alphavirus particles, comprising in an alphavirus-permissive cell:

5

(i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof is modified to inhibit reverse transcriptase activity, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

10

(ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and

15

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

20

and with at least one of said helper RNAs lacking an alphavirus packaging

signal;  
wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the third population contains no detectable replication-competent alphavirus particles as determined by passage on

25

permissive cells in culture;

(b) producing the alphavirus particles in the helper cell; and

(c) collecting the alphavirus particles from the helper cells; and

D) combining the first population of alphavirus particles produced from the first  
30 helper cell, the second population of alphavirus particles produced from the second

helper cell and the third population of alphavirus particles produced from the third helper cell, thereby producing the population of alphavirus replicon particles.

Also provided is a method of making a population of alphavirus replicon  
5 particles, comprising:

A) (a) providing a first helper cell for producing a first population of infectious, replication defective alphavirus particles, comprising in an alphavirus-permissive cell:

10 (i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

15 (ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and

20 (iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

25 wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the first population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture, and further wherein at least one of said replicon RNA, said first helper RNA, and said one or more additional helper RNA(s) comprises one or more attenuating mutations;

30 (b) producing the alphavirus particles in the helper cell; and

(c) collecting the alphavirus particles from the helper cells;

B) (a) providing a second helper cell for producing a second population of infectious, replication defective alphavirus particle, comprising in an alphavirus-permissive cell:

(i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

(ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the second population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture, and further wherein at least one of said replicon RNA, said first helper RNA, and said one or more additional helper RNA(s) comprises one or more attenuating mutations;

- (b) producing the alphavirus particles in the helper cell; and
- (c) collecting the alphavirus particles from the helper cells;

C) (a) providing a third helper cell for producing a third population of  
5 infectious, replication defective alphavirus particles, comprising in an alphavirus-permissive cell:

(i) an alphavirus replicon RNA, wherein the replicon RNA  
comprises an alphavirus packaging signal and a nucleic acid encoding a  
*pol* gene product or an immunogenic fragment thereof of a human  
10 immunodeficiency virus, wherein the *pol* gene product or immunogenic  
fragment thereof is modified to inhibit reverse transcriptase activity, and  
wherein the replicon RNA lacks sequences encoding alphavirus  
structural proteins;

(ii) a first helper RNA separate from said replicon RNA, said first  
15 helper RNA encoding at least one alphavirus structural protein and  
furthermore not encoding at least one other alphavirus structural protein;  
and

(iii) one or more additional helper RNA(s) separate from said  
replicon RNA and separate from said first helper RNA, said additional  
20 helper RNA(s) encoding at least one other alphavirus structural protein  
not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging  
signal;

wherein the combined expression of the alphavirus replicon RNA and the helper  
25 RNAs produces an assembled alphavirus particle which is able to infect a cell, and is  
unable to complete viral replication, and further wherein the third population contains  
no detectable replication-competent alphavirus particles as determined by passage on  
permissive cells in culture, and further wherein at least one of said replicon RNA, said  
first helper RNA, and said one or more additional helper RNA(s) comprises one or  
30 more attenuating mutations;

- (b) producing the alphavirus particles in the helper cell; and
- (c) collecting the alphavirus particles from the helper cells; and

D) combining the first population of alphavirus particles produced from the first  
5 helper cell, the second population of alphavirus particles produced from the second  
helper cell and the third population of alphavirus particles produced from the third  
helper cell, thereby producing the population of alphavirus replicon particles.

Furthermore, the present invention provides a composition comprising two or  
10 more isolated nucleic acids selected from the group consisting of an isolated nucleic  
acid encoding an *env* gene product or an immunogenic fragment thereof of a human  
immunodeficiency virus, an isolated nucleic acid encoding a *gag* gene product or an  
immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag*  
15 gene product or immunogenic fragment thereof is modified to inhibit formation of  
virus-like particles containing the *gag* gene product or the immunogenic fragment  
thereof and their release from a cell, and an isolated nucleic acid encoding a *pol* gene  
product or an immunogenic fragment thereof of a human immunodeficiency virus,  
wherein the *pol* gene product or immunogenic fragment thereof comprises a  
20 transcriptase functions in the *pol* gene product or immunogenic fragment thereof.

In addition, the present invention provides a composition comprising a  
population of alphavirus replicon particles comprising two or more isolated nucleic  
acids selected from the group consisting of 1) an isolated nucleic acid encoding an *env*  
25 gene product or an immunogenic fragment thereof of a human immunodeficiency virus,  
2) an isolated nucleic acid encoding a *gag* gene product or an immunogenic fragment  
thereof of a human immunodeficiency virus, wherein the *gag* gene product or  
immunogenic fragment thereof is modified to inhibit formation of virus-like particles  
containing the *gag* gene product or the immunogenic fragment thereof and their release  
30 from a cell, and 3) an isolated nucleic acid encoding a *pol* gene product or an

immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof, and wherein the nucleic acids are  
5 each contained within a separate alphavirus replicon particle.

Also provided herein is a composition comprising a population of alphavirus replicon particles comprising two or more isolated nucleic acids selected from the group consisting of 1) an isolated nucleic acid encoding an *env* gene product or an  
10 immunogenic fragment thereof of a human immunodeficiency virus, 2) an isolated nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell,  
15 and 3) an isolated nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof, and wherein the nucleic acids are each  
20 contained within a separate alphavirus replicon particle, and further wherein the alphavirus replicon particles comprise a replicon RNA or at least one structural protein which comprises one or more attenuating mutations.

In these embodiments, the *gag* gene product or immunogenic fragment thereof  
25 can be modified by mutation of the second codon, whereby a glycine is changed to an alanine and the *pol* gene product or immunogenic fragment thereof can be modified by mutation of the nucleotide sequence encoding the active site motif, whereby YMDD is changed to YMAA or HMAA. In addition, the *pol* gene product or immunogenic fragment thereof is modified to produce only p51 of the *pol* gene product or  
30 immunogenic fragment thereof.

The present invention provides a method of making a population of alphavirus replicon particles, comprising:

A) (a) providing a first helper cell for producing a first population of infectious, replication defective alphavirus particles, comprising in an alphavirus-permissive cell:

5 (i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

10 (ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and

15 (iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

20 wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the first population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture;

25 (b) producing the alphavirus particles in the helper cell; and  
(c) collecting the alphavirus particles from the helper cells;

B) (a) providing a second helper cell for producing a second population of infectious, replication defective alphavirus particles, comprising in an alphavirus-permissive cell:  
30

- 5 (i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;
- 10 (ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and
- 15 (iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;
- and with at least one of said helper RNAs lacking an alphavirus packaging signal;
- 20 wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the second population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture;
- 25 (b) producing the alphavirus particles in the helper cell; and
- (c) collecting the alphavirus particles from the helper cells;
- C) (a) providing a third helper cell for producing a third population of infectious, replication defective alphavirus particles, comprising in an alphavirus-permissive cell:
- 30 (i) an alphavirus replicon RNA, wherein the replicon RNA

- comprises an alphavirus packaging signal and a nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;
- (ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and
- (iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;
- and with at least one of said helper RNAs lacking an alphavirus packaging signal;
- wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the third population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture;
- (b) producing the alphavirus particles in the helper cell; and
- (c) collecting the alphavirus particles from the helper cells; and
- D) combining the first population of alphavirus particles produced from the first helper cell, the second population of alphavirus particles produced from the second helper cell and the third population of alphavirus particles produced from the third helper cell, thereby producing the population of alphavirus replicon particles.

An additional method of making a population of alphavirus replicon particles is provided, comprising:

A) (a) providing a first helper cell for producing a first population of infectious, replication defective alphavirus particles, comprising in an alphavirus-permissive cell:

- 5 (i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;
- 10 (ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and
- 15 (iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

- 20 wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the first population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture, and further wherein at least one of said replicon RNA, said
- 25 first helper RNA, and said one or more additional helper RNA(s) comprises one or more attenuating mutations;

- (b) producing the alphavirus particles in the helper cell; and
- (c) collecting the alphavirus particles from the helper cells;

- 30 B) (a) providing a second helper cell for producing a second population of

infectious, replication defective alphavirus particle, comprising in an alphavirus-permissive cell:

- 5 (i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;
- 10 (ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and
- 15 (iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging  
20 signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the second population contains no detectable replication-competent alphavirus particles as determined by passage on  
25 permissive cells in culture, and further wherein at least one of said replicon RNA, said first helper RNA, and said one or more additional helper RNA(s) comprises one or more attenuating mutations;

- (b) producing the alphavirus particles in the helper cell; and
- (c) collecting the alphavirus particles from the helper cells;

C) (a) providing a third helper cell for producing a third population of infectious, replication defective alphavirus particles, comprising in an alphavirus-permissive cell:

(i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

(ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the third population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture, and further wherein at least one of said replicon RNA, said first helper RNA, and said one or more additional helper RNA(s) comprises one or more attenuating mutations;

(b) producing the alphavirus particles in the helper cell; and

- (c) collecting the alphavirus particles from the helper cells; and
- D) combining the first population of alphavirus particles produced from the first helper cell, the second population of alphavirus particles produced from the second helper cell and the third population of alphavirus particles produced from the third helper cell, thereby producing the population of alphavirus replicon particles.

In each of the methods above, the alphavirus replicon RNA of at least one of the first helper cell, the second helper cell and the third helper cell can comprise  
10 sequence encoding at least one alphavirus structural protein and the first helper RNA and the one or more additional helper RNA(s) in the at least one of the first helper cell, the second helper cell and the third helper cell, can encode at least one other alphavirus structural protein not encoded by the replicon RNA.

15 Furthermore, in the methods above which recite attenuating mutations, only at least one of the first population of alphavirus particles, the second population of alphavirus particles and the third population of alphavirus particles can comprise particles wherein at least one of the replicon RNA, the first helper RNA, and the one or more additional helper RNA(s) comprises one or more attenuating mutations.

20

The present invention further provides alphavirus particles produced by any of the methods of this invention.

The present invention further provides a method of inducing an immune  
25 response to human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the populations and/or compositions of this invention, in a pharmaceutically acceptable carrier.

Also provided herein is a method of treating or preventing infection by human  
30 immunodeficiency virus in a subject, comprising administering to the subject an

immunogenic amount of the populations and/or compositions of this invention, in a pharmaceutically acceptable carrier.

Also provided by the present invention is an alphavirus replicon virosome  
5 comprising an alphavirus replicon RNA encapsidated by a lipid bilayer comprising alphavirus glycoproteins, E1 and E2, which in one embodiment, can be Venezuelan Equine Encephalitis glycoproteins E1 and E2.

A method of producing an alphavirus replicon virosome is further provided,  
10 comprising: a) combining alphavirus replicon RNA, alphavirus glycoproteins E1 and E2, non-cationic lipids and detergent; and b) gradually removing detergent, whereby alphavirus replicon virosomes are produced. Also provided is a virosome produced by this method.

15 Furthermore, the present invention provides a method of eliciting an immune response in a subject, comprising administering to the subject an immunogenic amount of the alphavirus replicon virosome of this invention in a pharmaceutically acceptable carrier.

20 The present invention additionally provides a method of treating or preventing infection by human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the alphavirus replicon virosome of this invention, wherein the virosome comprises alphavirus replicon RNA encoding one or more HIV immunogens.

25

In further embodiments, the present invention provides a composition a population of alphavirus replicon virosomes comprising two or more isolated nucleic acids selected from the group consisting of 1) an isolated nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus,  
30 2) an isolated nucleic acid encoding a *gag* gene product or an immunogenic fragment

thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and 3) an isolated nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof, and wherein the nucleic acids are each contained within a separate alphavirus replicon virosome.

10

Additionally provided herein is a composition comprising a population of alphavirus replicon virosomes comprising two or more isolated nucleic acids selected from the group consisting of 1) an isolated nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, 2) an isolated nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and 3) an isolated nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in inactivation of reverse transcriptase activity in the *pol* gene product or immunogenic fragment thereof, and wherein the nucleic acids are each contained within a separate alphavirus replicon virosome.

25

A method of producing a population of alphavirus replicon virosomes is provided herein, comprising:

- A) (a) producing a first population of alphavirus replicon virosomes by combining alphavirus replicon RNA comprising nucleic acid encoding and *env* gene product or immunogenic fragment thereof, alphavirus glycoproteins E1 and E2, non-

30

cationic lipids and detergent; and

b) gradually removing detergent, whereby alphavirus replicon virosomes are produced;

5

B) (a) producing a second population of alphavirus replicon virosomes by combining alphavirus replicon RNA comprising nucleic acid encoding and *gag* gene product or immunogenic fragment thereof, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, alphavirus glycoproteins E1 and E2, non-cationic lipids and detergent; and

b) gradually removing detergent, whereby alphavirus replicon virosomes are produced;

15

C) (a) producing a third population of alphavirus replicon virosomes by combining alphavirus replicon RNA comprising nucleic acid encoding the *pol* gene product or immunogenic fragment thereof, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof, alphavirus glycoproteins E1 and E2, non-cationic lipids and detergent; and

b) gradually removing detergent, whereby alphavirus replicon virosomes are produced; and

25

D) combining the first population of alphavirus replicon virosomes, the second population of alphavirus replicon virosomes and the third population of alphavirus replicon virosomes to produce the population of alphavirus replicon virosomes.

In addition, a method of producing a population of alphavirus replicon virosomes is provided, comprising:

- 5     A)     (a)     producing a first population of alphavirus replicon virosomes by combining alphavirus replicon RNA comprising nucleic acid encoding and *env* gene product or immunogenic fragment thereof, alphavirus glycoproteins E1 and E2, non-cationic lipids and detergent; and
- 10           b)     gradually removing detergent, whereby alphavirus replicon virosomes are produced;
- 15     B)     (a)     producing a second population of alphavirus replicon virosomes by combining alphavirus replicon RNA comprising nucleic acid encoding and *gag* gene product or immunogenic fragment thereof, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles
- 20           b)     gradually removing detergent, whereby alphavirus replicon virosomes are produced;
- 25     C)     (a)     producing a third population of alphavirus replicon virosomes by combining alphavirus replicon RNA comprising nucleic acid encoding the *pol* gene product or immunogenic fragment thereof, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in inactivation of reverse transcriptase activity in the *pol* gene product or immunogenic fragment thereof, alphavirus glycoproteins E1 and E2, non-cationic lipids and detergent; and
- 30           b)     gradually removing detergent, whereby alphavirus replicon virosomes are produced; and
- D)     combining the first population of alphavirus replicon virosomes, the second population of alphavirus replicon virosomes and the third population of alphavirus

replicon virosomes to produce the population of alphavirus replicon virosomes of claim 48.

Furthermore, the present invention provides a method of inducing an immune  
5 response in a subject, comprising administering to the subject an immunogenic amount of the virosomes of this invention, in a pharmaceutically acceptable carrier.

Also provided is a method of treating or preventing infection by human immunodeficiency virus in a subject, comprising administering to the subject an  
10 immunogenic amount of the virosomes of this invention, in a pharmaceutically acceptable carrier.

Additionally provided by this invention is a composition comprising heparin affinity-purified alphavirus replicon particles, wherein the alphavirus replicon particles  
15 comprise at least one structural protein which comprises one or more attenuating mutations, as well as a method of preparing heparin affinity-purified alphavirus particles, comprising:

- a) producing alphavirus replicon particles, wherein the alphavirus replicon particles comprise at least one structural protein which comprises one or  
20 more attenuating mutations;
- b) loading the alphavirus replicon particles of step (a) in a heparin affinity chromatography column; and
- c) collecting the fraction from the column which contains the heparin affinity-purified alphavirus replicon particles.

25

In further embodiments, the present invention provides a method of producing VRP for use in a vaccine comprising:

- a) producing a plasmid encoding the nucleotide sequence of an alphavirus replicon RNA;
- 30 b) producing a plasmid encoding the nucleotide sequence of one or more

helper RNAs;

c) transcribing the plasmids of steps (a) and (b) into RNA *in vitro*;

d) electroporating the RNA of step (c) into a Vero cell line; and

e) purifying VRP from the Vero cell line of step (d) by heparin affinity chromatography. By this method, VRPs can be produced in large-scale.

In additional embodiments, the present invention provides an isolated nucleic acid encoding a *pol* gene product or immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof. This nucleic acid can be present in a composition and in a vector. Such a vector can be present in a cell. This nucleic acid can also be present in an alphavirus replicon particle.

The present invention further provides a method of making an alphavirus replicon particle comprising nucleic acid encoding a *pol* gene product or immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof, comprising

a) providing a helper cell for producing an infectious, defective alphavirus particle, comprising in an alphavirus-permissive cell:

(i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in deletion or

inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

5 (ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional  
10 helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper  
15 RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture;

(b) producing the alphavirus particles in the helper cell; and  
20 (c) collecting the alphavirus particles from the helper cell.

In the method described above, at least one of the replicon RNA, the first helper RNA, and the one or more additional helper RNA(s) can comprises one or more attenuating mutations. The present invention additionally provides alphavirus  
25 replicon particle produced according to the above methods.

Further provided is a method of inducing an immune response in a subject, comprising administering to the subject an immunogenic amount of a composition comprising alphavirus replicon particles encoding a *pol* gene product or an  
30 immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol*

gene product or immunogenic fragment thereof comprises a modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof in a pharmaceutically acceptable carrier.

5

### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1. DNA plasmid map of VEE replicon RNA expressing the HIV *gag* gene (p3-40.1.6). The plasmid is 12523 base pairs in length and encodes a single  
10 polyprotein expressing the four non-structural genes nsP1-4, the Clade C *gag* gene and antibiotic resistance marker, Kanamycin KN(R). The plasmid contains two promoter regions, the T7 polymerase promoter and the 26S RNA promoter. The unique NotI restriction enzyme site used to linearize prior to *in vitro* transcription is also noted.

15 Figure 2. DNA plasmid map of the capsid helper construct (p3-13.2.2). The plasmid is 5076 base pairs in length and encodes the VEE capsid gene (C) and antibiotic resistance marker, Kanamycin KN(R). The plasmid contains two promoter regions, the T7 polymerase promoter and the 26S RNA promoter. The unique NotI restriction enzyme site used to linearize prior to *in vitro* transcription is also noted.

20

Figure 3. DNA plasmid map of the glycoprotein helper construct (p3-13.4.6). The plasmid is 6989 base pairs in length and encodes the VEE glycoprotein genes (E3, E2, 6K and E1) and antibiotic resistance marker, Kanamycin KN(R). The plasmid  
25 contains two promoter regions, the T7 polymerase promoter and the 26S RNA promoter. The unique NotI restriction enzyme site used to linearize prior to *in vitro* transcription is also noted.

Figure 4. DNA plasmid map of VEE replicon RNA expressing HIV *pol* (p51) gene (p13-60.2.14). The plasmid is 12379 base pairs in length and encodes a single  
30 polyprotein expressing the four non-structural genes, nsP1-4, the Clade C *pol* (p51)

gene and antibiotic resistance marker, Kanamycin KN(R). The plasmid contains two promoter regions, the T7 polymerase promoter and the 26S RNA promoter. The unique NotI restriction enzyme site used to linearize prior to *in vitro* transcription is also noted.

5

Figure 5. DNA plasmid map of VEE replicon RNA expressing HIV *env* gene (pERK-DU151env). The plasmid is 13584 base pairs in length and encodes a single polyprotein expressing the four non-structural genes, nsP1-4, the Clade C *env* gene and antibiotic resistance marker, Kanamycin KN(R). The plasmid contains two promoter  
10 regions, the T7 polymerase promoter and the 26S RNA promoter. The unique NotI restriction enzyme site used to linearize prior to *in vitro* transcription is also noted.

Figure 6. Western immunoblot, demonstrating the expression of HIV proteins in baby hamster kidney (BHK) cells infected with VRPs. The outer lanes of the panel  
15 are standard molecular weight markers. Lane 1 is the expression from VRPs encoding the p51 (*pol*) gene. Lane 2 is the expression from VRPs encoding the GP-160 (*env*) gene. Lane 3 is the expression from VRPs encoding the p55 (*gag*) gene. Arrows indicate proteins migrating with the apparent molecular weight of each respective protein.

20

Figure 7. Western immunoblot of cells infected with the Du151env VRP. At 18 hr post infection, the cells were lysed and the lysate run in a denaturing polyacrylamide gel. Proteins were transferred out of the gel onto a filter and the filter was probed with serum from subject Du151 using Western immunoblot methods. Lane  
25 1, uninfected U87.CD4-CXCR4 cells. Lane 2, uninfected U87.CD4-CCR5 cells. Lane 3, infection of a mixed culture of U87.CD4-CXCR4 cells and BHK cells (mixtures were used as a positive control in case the U87 cells were refractory to infection by the VRP, which did not turn out to be the case). Lane 4, infected U87.CD4-CXCR4 cells. Lane 5, infected BHK cells. Lane 6, infection of a mixture of BHK cells and  
30 U87.CD4-CCR5 cells. Lane 7, infected U87.CD4-CCR5 cells. The positions of

molecular weight of markers run in the same gel are shown on the right, and the inferred positions of gp160 and gp120 are shown on the left.

Figure 8. Micrographs of U87.CD4-CCR and BHK cells used to examine expression and syncytium formation of DU151 envelope expressed from the VEE replicon. U87.CD4-CCR5 cells alone (panel 1), or a mixture of U87.CD4-CCR5 and BHK cells (Panel 2), BHK cells alone (Panel 3) and U87.CD4-CXCR4 cells (panel 4) were infected with DU151 env VRP at a multiplicity of infection of 3 i.u. per cell. At 18 hours post infection, the cells were examined using light microscopy for the presence of syncytia. The U87.CD4-CCR5 in panel 1 and 2 show clear syncytia, which was absent in the control cell types in the lower panels. In addition, no syncytia were seen in uninfected control cells or VRP-GFP infected cells (data not shown).

Figures 9A-C. Antigen-specific CTL response in mice to the HIV-1 Clade C VRP-gag vaccine. Eight BALB/c mice were immunized twice, first at day 0 and again at day 28 with  $10^3$  i.u. (Panel A) or  $10^5$  i.u. (panels B and C) VRP-gag. Eight days (Panels A and B) or 49 days (Panel C) post-boost, spleen cells were isolated and stimulated *in vitro* with vaccinia virus expressing HIV Gag for 1 week. Chromium release assays were performed using vaccinia-Gag infected target cells (diamond symbols) or control vaccinia alone-infected sc11 target cells (square symbols). Clear HIV Gag-specific lysis was detected in animals vaccinated with the VRP-gag vaccine.

Figure 10. Diagrammatic representation of the HIV-1 genome. Black bars indicate relative regions of the genome sequenced to generate phylogenetic sequence comparative data for Clade C *gag*, *pol* and *env* gene isolates.

Figure 11. Phylogenetic comparison of DU422 Clade C Gag isolate with referenced Clade C strains. Consensus clade A, B, D, Mal and SA strains are also shown. DU422 the vaccine strain had 95% amino acid sequence homology to the South African consensus Clade C sequence.

Figure 12. Phylogenetic comparison of DU151 Clade C isolate Env isolate with referenced Clade C strains. DU422 the vaccine strain had 93% amino acid sequence homology to the South African consensus Clade C sequence.

5        Figure 13. Phylogenetic comparison of DU151 Clade C isolate Pol isolate with referenced Clade C strains. DU422 the vaccine strain had 99% amino acid sequence homology to the South African consensus Clade C sequence.

10       Figure 14. DU422 HIV Gag expression as detected by immunofluorescence following electroporation with Gag replicon RNA. BHK cells were electroporated and subjected to immunofluorescence staining with an anti-Gag monoclonal antibody at 24 hours post-electroporation, to demonstrate expression of the Clade C protein.

15       Figure 15. Immunofluorescence detection of DU422 Gag protein expression in BHK cells. BHK cells were infected with VRP-Gag particles and subjected to immunofluorescence staining with an anti-Gag monoclonal antibody at 24 hours post-infection, to demonstrate expression of the Clade C protein.

## DETAILED DESCRIPTION OF THE INVENTION

20

As used in the specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a pharmaceutical carrier” can mean a single pharmaceutical carrier or mixtures of two or more such carriers.

25

The present invention is based on the discovery of a vaccine for the treatment and/or prevention of infection by HIV, comprising novel combinations of isolated nucleic acids encoding two or more distinct antigens which elicit an immune response in a subject which is effective in treating and/or preventing infection by HIV. In a particular embodiment, the nucleic acids encoding the antigens of the vaccine are

30

modified to enhance the immunogenicity of the antigen, improve the safety of the vaccine, or both.

As used herein, the term "isolated nucleic acid" means a nucleic acid separated  
5 or substantially free from at least some of the other components of the naturally  
occurring organism, for example, the cell structural components commonly found  
associated with nucleic acids in a cellular environment and/or other nucleic acids. The  
isolation of nucleic acids can be accomplished by well known techniques such as cell  
lysis or disruption of virus particles, followed by phenol plus chloroform extraction,  
10 followed by ethanol precipitation of the nucleic acids (Sambrook *et al.*, latest edition).  
The nucleic acids of this invention can be isolated according to methods well known in  
the art for isolating nucleic acids. Alternatively, the nucleic acids of the present  
invention can be synthesized according to standard protocols well described in the  
literature for synthesizing nucleic acids.

15

#### **HIV-VRP Vaccines**

The antigens of this invention can be gene products which are complete proteins  
or any fragment of a protein determined to be immunogenic by methods well known in  
20 the art. Modifications are made to the antigens of this invention to enhance  
immunogenicity and/or improve the safety of administration of a vaccine containing the  
antigen. Examples of such modifications are described in the Examples section herein.  
Furthermore, it is understood that, where desired, other modifications and changes  
(e.g., substitutions, deletions, additions) may be made in the amino acid sequence of the  
25 antigen of the present invention, which may not specifically impart enhanced  
immunogenicity or improved safety, yet still result in a protein or fragment which  
retains all of the functional characteristics by which the protein or fragment is defined.  
Such changes may occur in natural isolates, may be introduced by synthesis of the  
protein or fragment, or may be introduced into the amino acid sequence of the protein  
30 or fragment using site-specific mutagenesis of nucleic acid encoding the protein or

fragment, the procedures for which, such as mis-match polymerase chain reaction (PCR), are well known in the art.

The nucleic acids of this invention can be present in a vector and the vector of  
5 this invention can be present in a cell. The vectors and cells of this invention can be in a composition comprising the cell or vector and a pharmaceutically acceptable carrier.

The vector of this invention can be an expression vector which contains all of the genetic components required for expression of the nucleic acids of this invention in  
10 cells into which the vector has been introduced, as are well known in the art. For example, the expression vector of this invention can be a vector comprising the helper RNAs of this invention. Such an expression vector can be a commercial expression vector or it can be constructed in the laboratory according to standard molecular biology protocols. The expression vector can comprise viral nucleic acid including, but  
15 not limited to, alphavirus, flavivirus, adenovirus, retrovirus and/or adeno-associated virus nucleic acid. The nucleic acid or vector of this invention can also be in a liposome or a delivery vehicle which can be taken up by a cell via receptor-mediated or other type of endocytosis.

20 In another embodiment, the nucleic acids of this invention can be present in a composition comprising a population of alphavirus replicon particles which comprise two or more distinct isolated nucleic acids of this invention and wherein the nucleic acids are each contained within a separate alphavirus replicon particle (herein referred to as a "VRP"). Thus, the expression vector of the present invention can be an  
25 alphavirus replicon particle comprising a nucleic acid encoding an antigen of this invention.

In a particular embodiment, the present invention provides a composition comprising two or more isolated nucleic acids selected from the group consisting of an  
30 isolated nucleic acid encoding an *env* gene product or an immunogenic fragment

thereof of a human immunodeficiency virus, an isolated nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of particles, e.g., virus-like particles, containing the *gag* gene product or the immunogenic fragment thereof, and their release from a cell, and an isolated nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof is modified to inhibit reverse transcriptase activity.

10 In a preferred embodiment, the invention provides alphavirus replicon particles (VRPs) that can be administered as an HIV vaccine. These HIV-VRPs are propagation defective, single cycle vectors that contain a self-amplifying RNA (replicon RNA, e.g., from VEE, in which the structural protein genes of the virus are replaced by a HIV-1 Clade C *gag* gene or any other HIV antigen to be expressed. Following introduction  
15 into packaging (or helper) cells *in vitro*, the replicon RNA is packaged into VRPs by supplying the viral structural proteins in *trans* (helper RNAs).

The present invention further provides a population of alphavirus replicon particles comprising two or more isolated nucleic acids selected from the group  
20 consisting of 1) an isolated nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, 2) an isolated nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of particles, such as virus-like  
25 particles, containing the *gag* gene product or the immunogenic fragment thereof, from a cell, and 3) an isolated nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof is modified to inhibit reverse transcriptase activity, and wherein the nucleic acids are each contained within a separate alphavirus replicon  
30 particle.

It is also contemplated that the compositions of this invention comprise alphavirus replicon particles in which either the replicon RNA or at least one structural protein comprises one or more attenuating mutations. Thus, the present invention additionally provides a population of alphavirus replicon particles comprising two or more distinct types of such particles selected from the group consisting of 1) particles expressing a nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, 2) particles expressing a nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit release of particles, such as virus-like particles, containing the *gag* gene product or the immunogenic fragment thereof, from a cell, and 3) particles expressing a nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof is modified to inhibit reverse transcriptase activity; and wherein the nucleic acids are each contained within a separate alphavirus replicon particle and further wherein the alphavirus replicon particles comprise a replicon RNA or at least one structural protein which comprises one or more attenuating mutations.

In a preferred embodiment, the population of alphavirus replicon particles comprises particles expressing the nucleic acids encoding *pol*, *env*, and *gag* gene products. In this embodiment, vigorous antigen-specific cellular (e.g., CTL, NK cell and T-helper) and/or humoral (e.g., antibody) responses can be obtained when such particle populations are administered to a subject.

In the compositions described above, the *gag* gene product or immunogenic fragment thereof can be modified by mutation of the second codon, whereby a glycine is changed to an alanine. Alternatively, the *gag* gene product or immunogenic fragment thereof can be modified by any other means known in the art for inhibiting the release of particles containing the *gag* gene product or immunogenic fragment thereof from a cell.

Furthermore, in the compositions of this invention, the *pol* gene product or immunogenic fragment thereof can be modified by mutation of the nucleotide sequence encoding the active site motif, whereby YMDD is changed to YMAA or HMAA (the latter providing a convenient site for cloning, see SEQ ID NO:16). The *pol* gene product or immunogenic fragment thereof can also be modified by any means known in the art for inhibiting reverse transcriptase activity.

The *pol* gene product or immunogenic fragment thereof of this invention may be further modified such that the coding sequences for integrase and RNase H are removed, inactivated and/or modified, e.g., by producing only the p51 region of the *pol* gene product. This modification has been shown in some studies to reduce the possibility of formation of replication competent alphavirus particles during production of alphavirus replicon particles comprising the *pol* gene product or immunogenic fragment thereof. This modification can be of the nucleic acid encoding the *pol* gene product or immunogenic fragment thereof according to methods known in the art. Thus, the particles and compositions of this invention can comprise nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof.

In the compositions of this invention, the *gag*, *env* or *pol* gene products or immunogenic fragments thereof can be from any HIV isolate or consensus sequence derived from HIV primary isolates now known or later identified, the isolation and characterization of which are well known in the art. Also, in the compositions of this invention, the *gag*, *env* or *pol* gene products or immunogenic fragments thereof can be produced from the same HIV isolate or HIV consensus sequence or from any combination of HIV isolates or HIV consensus sequences. In the Examples provided herein, the nucleic acid sequences encoding the *env*, *gag* and *pol* gene products of this

invention were selected based on a consensus sequence generated from primary isolates obtained from recent seroconvertors in Kwazulu/Natal in South Africa. Sequence analysis of these isolates identified them as subtype (or clade) C, and in preferred embodiments of the invention, the *env*, *gag* and *pol* genes are from Clade C isolates of  
5 HIV.

In preferred embodiments, each of the three HIV genes are derived from one or more of the South African isolates obtained from recent seroconverters in Kwazulu/Natal as described herein (see Figures 11-13 for isolate names). In a further  
10 embodiment, the *gag* gene or gene fragment is from a *gag* sequence having 95% or greater amino acid identity with the South African consensus sequence for the *gag* gene. In a specific embodiment, the *gag* gene or fragment thereof is derived from HIV Subtype Clade C isolate DU422 and the *env* and *pol* genes or fragments thereof are derived from HIV isolate DU151.

15 The term "alphavirus" has its conventional meaning in the art and includes the various species of the alphavirus genus, such as Eastern Equine Encephalitis virus (EEE), Venezuelan Equine Encephalitis virus (VEE), Western Equine Encephalitis virus (WEE), Everglades virus, Mucambo virus, Pixuna virus, Sindbis virus, Semliki  
20 Forest virus, South African Arbovirus No. 86, Middleburg virus, Chikungunya virus, O'nyong-nyong virus, Ross River virus, Barmah Forest virus, Getah virus, Sagiya virus, Bebaru virus, Mayaro virus, Una virus, Aura virus, Whataroa virus, Babanki virus, Kyzylagach virus, Highlands J virus, Fort Morgan virus, Ndumu virus, Buggy Creek virus, as well as any specific strains of these alphaviruses (e.g., TR339;  
25 Girdwood) and any other virus classified by the International Committee on Taxonomy of Viruses (ICTV) as an alphavirus.

An "alphavirus replicon particle" as used herein is an infectious, replication defective, alphavirus particle which comprises alphavirus structural proteins and further  
30 comprises a replicon RNA. The replicon RNA comprises nucleic acid encoding the

alphavirus packaging segment, nucleic acid encoding alphavirus non-structural proteins and a heterologous nucleic acid sequence encoding an antigen of this invention. The non-structural proteins encoded by the replicon RNA may be such proteins as are required for replication and transcription. In a specific embodiment of this invention, 5 the structure of the replicon RNA, starting at the 5' end, comprises the 5' untranslated region of the alphavirus RNA, the non-structural proteins (e.g., nsPs1-4) of the alphavirus, the 26S promoter (also known as the "subgenomic promoter"), the heterologous nucleic acid encoding an HIV antigen, and the 3' untranslated region of the alphavirus RNA. An example of a nucleic acid encoding alphavirus nonstructural 10 proteins that can be incorporated into the embodiments of this invention is SEQ ID NO:2, which encodes the amino acid sequence of SEQ ID NO:3.

Although the alphavirus replicon RNA can comprise nucleic acid encoding one or two alphavirus structural proteins, the replicon RNA does not contain nucleic acid 15 encoding all of the alphavirus structural proteins. The replicon RNA can lack nucleic acid encoding any alphavirus structural protein(s). Thus, the resulting alphavirus replicon particles of this invention are replication defective inasmuch as the replicon RNA does not encode all of the structural proteins required for encapsidation of the replicon RNA and assembly of an infectious virion.

20

As used herein, "alphavirus structural protein" or "structural protein" means the alphavirus proteins required for encapsidation of alphavirus replicon RNA and packaging of the encapsidated RNA into a virus particle. The alphavirus structural proteins include PE2, E2, E3, 6K and E1.

25

The alphavirus replicon particles of this invention can comprise replicon RNA from any of the alphaviruses of this invention. Furthermore, the alphavirus replicon particles of this invention can comprise alphavirus structural proteins from any of the alphaviruses of this invention. Thus, the replicon particles can be made up of replicon 30 RNA and structural proteins from the same alphavirus or from different alphaviruses,

the latter of which would be chimeric alphavirus replicon particles (e.g., a particle comprising Sindbis virus replicon RNA and VEE structural proteins).

The alphavirus replicon particles of this invention can be made by employing a helper cell for expressing an infectious, replication defective, alphavirus particle in an alphavirus-permissive cell. The helper cell includes (a) a first helper RNA encoding (i) at least one alphavirus structural protein, and (ii) not encoding at least one alphavirus structural protein; and (b) a second helper RNA separate from the first helper RNA, the second helper RNA (i) not encoding the at least one alphavirus structural protein encoded by the first helper RNA, and (ii) encoding at least one alphavirus structural protein not encoded by the first helper RNA, such that all of the alphavirus structural proteins assemble together into alphavirus particles in the cell.

The alphavirus structural protein genes can be present on the helper RNAs of this invention in any combination. For example, the helper RNA of this invention can encode the alphavirus capsid and E1, capsid and E2, E1 and E2, capsid only, E1 only, E2 only, etc. It is also contemplated that the alphavirus structural proteins are provided in *trans* from genes located on three separate RNA molecules within the helper cell.

In a preferred embodiment, the helper cell also includes a replicon RNA, which encodes the alphavirus packaging segment and an inserted heterologous RNA. In the embodiment wherein the helper cell also includes a replicon RNA, the alphavirus packaging segment may be, and preferably is, deleted from both the first helper RNA and the second helper RNA. For example, in an embodiment wherein the helper cell includes a replicon RNA encoding the alphavirus packaging segment and an inserted heterologous RNA, the first helper RNA encodes the alphavirus E1 glycoprotein and the alphavirus E2 glycoprotein, and the second helper RNA encodes the alphavirus capsid protein. In a preferred embodiment, the first helper RNA encodes the E3-E2-6k-E1 cassette from an alphavirus. In an alternative embodiment, the cassette encoded on the first helper RNA is referred to as the E3-E2-E1 cassette. A specific embodiment of this aspect of the invention is diagrammed in Figure 3, and an exemplary nucleotide

sequence is SEQ ID NO:11. The replicon RNA, first helper RNA, and second helper RNA are all on separate molecules and are cotransfected, e.g., by electroporation, into the helper cell, which can be any alphavirus permissive cell, as is well known in the art.

5           In an alternative embodiment, the helper cell includes a replicon RNA encoding the alphavirus packaging segment and an inserted heterologous RNA and also includes the alphavirus capsid protein otherwise encoded by the second helper RNA. The first helper RNA encodes the alphavirus E1 glycoprotein and the alphavirus E2 glycoprotein. Thus, the replicon RNA and the first helper RNA are on separate  
10       molecules, and the replicon RNA and the second helper RNA are on a single molecule.

          The RNA encoding the structural proteins, i.e., the first helper RNA and the second helper RNA, can include one or more attenuating mutations. In a preferred  
15       embodiment, either one or both of the first helper RNA and the second helper RNA include at least one attenuating mutation. The attenuating mutations provide the advantage that in the event of RNA recombination within the cell, the coming together of the structural and non-structural genes will produce a virus of decreased virulence.

20           The alphavirus replicon particles of this invention can be made by a) transfecting a helper cell as given above with a replication defective replicon RNA, b) producing the alphavirus particles in the transfected cell, and c) collecting the alphavirus particles from the cell. The replicon RNA encodes the alphavirus packaging segment and a heterologous RNA. The transfected helper cell further includes the first  
25       helper RNA and second helper RNA as described above.

          As described hereinabove, the structural proteins used to assemble the alphavirus replicon particles of this invention are distributed among one or more helper RNAs (i.e., a first helper RNA and a second helper RNA). As noted herein, one or  
30       more structural protein genes may be located on the replicon RNA, provided that at

a structural protein gene is deleted from the replicon RNA such that the replicon and resulting alphavirus particle are replication defective. As used herein, the "deleted" or "deletion" mean either total deletion of the specified nucleic acid or deletion of a sufficient portion of the specified nucleic acid to render the nucleic acid or its resultant gene product inoperative or nonfunctional, in accordance with common usage. (See, e.g., U.S. Pat. No. 4,650,764 to Temin *et al.*) The term "replication defective" as used herein means that the replicon RNA cannot replicate in a cell (i.e., produce infectious viral particles) in the absence of the helper RNA. A replicon RNA is replication defective inasmuch as the replicon RNA does not contain all of the alphavirus structural protein genes required for replication, at least one of the required structural protein genes being deleted therefrom.

In one embodiment, the packaging segment or "encapsidation sequence" is deleted from at least the first helper RNA. In a preferred embodiment, the packaging segment is deleted from both the first helper RNA and the second helper RNA. In another embodiment, the second helper RNA is constructed from a VEE cDNA clone, which encodes all non-structural proteins (i.e., nsPs1-4), the packaging signal, and the structural protein cassette (E3-E2-E1). An example of a plasmid encoding such a second helper RNA is provided in Figure 2, and an exemplary nucleotide sequence for such a second helper RNA is SEQ ID NO:8.

In the preferred embodiment wherein the packaging segment is deleted from both the first helper RNA and the second helper RNA, preferably the helper cell is transfected with a replicon RNA in addition to the first helper RNA and the second helper RNA. The replicon RNA encodes the packaging segment and an inserted heterologous gene product encoding an HIV antigen or a fragment thereof. Typically, the inserted heterologous RNA encodes a gene product which is expressed by the target cell, and the replicon RNA also contains the promoter and regulatory segments necessary for the expression of that gene product in that cell.

In another preferred embodiment, the replicon RNA, the first helper RNA and the second helper RNA are provided on separate molecules such that a first molecule, i.e., the replicon RNA, encodes the packaging segment and the inserted heterologous RNA, a second molecule, i.e., the first helper RNA, encodes at least one but not all of the required alphavirus structural proteins, and a third molecule, i.e., the second helper RNA, encodes at least one but not all of the required alphavirus structural proteins. For example, in one preferred embodiment of the present invention, the helper cell includes a set of RNAs which include (a) a replicon RNA encoding an alphavirus packaging sequence and an inserted heterologous RNA, (b) a first helper RNA encoding the alphavirus E1 glycoprotein and the alphavirus E2 glycoprotein, and (c) a second helper RNA encoding the alphavirus capsid protein, so that the alphavirus E1 glycoprotein, the alphavirus E2 glycoprotein and the capsid protein assemble together into alphavirus particles containing the replicon RNA in the helper cell.

In an alternate embodiment, the replicon RNA and the first helper RNA are on separate molecules, and the replicon RNA and the second helper RNA are on a single molecule together, thereby providing a first molecule, i.e., the first helper RNA, encoding at least one but not all of the required alphavirus structural proteins, and a second molecule, i.e., the replicon RNA and second helper RNA, encoding the packaging segment, the inserted heterologous gene product and the structural protein(s) not encoded by the first helper. Thus, one or more structural protein(s) is encoded by the second helper RNA, but the second helper RNA is located on the second molecule together with the replicon RNA. For example, in one preferred embodiment of the present invention, the helper cell includes a set of RNAs including (a) a replicon RNA encoding an alphavirus packaging sequence, an inserted heterologous RNA, and an alphavirus capsid protein, and (b) a first helper RNA encoding the alphavirus E1 glycoprotein and the alphavirus E2 glycoprotein so that the alphavirus E1 glycoprotein, the alphavirus E2 glycoprotein and the capsid protein assemble together into alphavirus particles in the helper cell.

The present invention also contemplates alphavirus replicon particles which comprise replicon RNA encoding more than one heterologous gene product. For expression of more than one heterologous nucleic acid from a single replicon RNA, a promoter can be inserted upstream of each heterologous nucleic acid on the replicon RNA, such that the promoter regulates expression of the heterologous nucleic acid, resulting in the production of more than one antigen from a single replicon RNA. Another embodiment contemplates the insertion of an IRES sequence, such as the one from the picornavirus, EMC virus, between the heterologous genes downstream from a 26S promoter of the replicon, thus leading to translation of multiple antigens from a single replicon.

In one preferred embodiment of the present invention, the RNA encoding the alphavirus structural proteins, i.e., the capsid, E1 glycoprotein and/or E2 glycoprotein, contains at least one attenuating mutation. It is further contemplated that the RNA encoding the non-structural proteins can contain at least one attenuating mutation. The phrases "attenuating mutation" and "attenuating amino acid," as used herein, mean a nucleotide mutation or an amino acid coded for in view of such a mutation which result in a decreased probability of causing disease in its host (i.e., a loss of virulence), in accordance with standard terminology in the art, See, e.g., Davis *et al.* (1980). The mutation can be, for example, a substitution mutation or an in-frame deletion mutation. The phrase "attenuating mutation" excludes mutations which would be lethal to the virus. Thus, according to this embodiment, the E1 RNA and/or the E2 RNA and/or the capsid RNA can include at least one attenuating mutation. In a more preferred embodiment, the E1 RNA and/or the E2 RNA and/or the capsid RNA includes at least two, or multiple, attenuating mutations. The multiple attenuating mutations may be positioned in either the first helper RNA or in the second helper RNA, or they may be distributed randomly with one or more attenuating mutations being positioned in the first helper RNA and one or more attenuating mutations positioned in the second helper RNA. Appropriate attenuating mutations will be dependent upon the alphavirus used,

as is well known in the art.

For example, when the alphavirus is VEE, suitable attenuating mutations can be in codons at E2 amino acid position 76 which specify an attenuating amino acid, preferably lysine, arginine, or histidine as E2 amino acid 76; codons at E2 amino acid position 120 which specify an attenuating amino acid, preferably lysine as E2 amino acid 120; codons at E2 amino acid position 209 which specify an attenuating amino acid, preferably lysine, arginine, or histidine as E2 amino acid 209; codons at E1 amino acid 272 which specify an attenuating mutation, preferably threonine or serine as E1 amino acid 272; codons at E1 amino acid 81 which specify an attenuating mutation, preferably isoleucine or leucine as E1 amino acid 81; and codons at E1 amino acid 253 which specify an attenuating mutation, preferably serine or threonine as E1 amino acid 253; and the combination mutation of the deletion of E3 codons 56-59 together with codons at E1 amino acid 253 which specify an attenuating mutation, as provided herein. Other suitable attenuating mutations within the VEE genome will be known to those skilled in the art.

In an alternate embodiment, wherein the alphavirus is the South African Arbovirus No. 86 (S.A.A.R.86), suitable attenuating mutations can be, for example, in codons at nsP1 amino acid position 538 which specify an attenuating amino acid, preferably isoleucine as nsP1 amino acid 538; codons at E2 amino acid position 304 which specify an attenuating amino acid, preferably threonine as E2 amino acid 304; codons at E2 amino acid position 314 which specify an attenuating amino acid, preferably lysine as E2 amino acid 314; codons at E2 amino acid position 376 which specify an attenuating amino acid, preferably alanine as E2 amino acid 376; codons at E2 amino acid position 372 which specify an attenuating amino acid, preferably leucine as E2 amino acid 372; codons at nsP2 amino acid position 96 which specify an attenuating amino acid, preferably glycine as nsP2 amino acid 96; codons at nsP2 amino acid position 372 which specify an attenuating amino acid, preferably valine as nsP2 amino acid 372; in combination, codons at E2 amino acid residues 304, 314, 372

and 376; codons at E2 amino acid position 378 which specify an attenuating amino acid, preferably leucine as E2 amino acid 378; codons at nsP2 amino acid residue 372 which specify an attenuating mutation, preferably valine as nsP2 amino acid 372; in combination, codons at nsP2 amino acid residues 96 and 372 attenuating substitution mutations at nsP2 amino acid residues 96 and 372; codons at nsP2 amino acid residue 529 which specify an attenuating mutation, preferably leucine, at nsP2 amino acid residue 529; codons at nsP2 amino acid residue 571 which specify an attenuating mutation, preferably asparagine, at nsP2 amino acid residue 571; codons at nsP2 amino acid residue 682 which specify an attenuating mutation, preferably arginine, at nsP2 amino acid residue 682; codons at nsP2 amino acid residue 804 which specify an attenuating mutation, preferably arginine, at nsP2 amino acid residue 804; codons at nsP3 amino acid residue 22 which specify an attenuating mutation, preferably arginine, at nsP3 amino acid residue 22; and in combination, codons at nsP2 amino acid residues 529, 571, 682 and 804, and at nsP3 amino acid residue 22, specifying attenuating amino acids at nsP2 amino acid residues 529, 571, 682 and 804 and at nsP3 amino acid residue 22. Other suitable attenuating mutations within the S.A.A.R.86 genome will be known to those skilled in the art.

The alphavirus capsid gene used to make alphavirus replicon particles can also be subjected to site-directed mutagenesis. The altered capsid protein provides additional assurance that recombination to produce the virulent virus will not occur. The altered capsid protein gene which functions in particle assembly but not in autoproteolysis provides helper function for production of replicon particles, but does not allow for production of a viable recombinant. The capsid residues required for proteolytic function are known (Strauss *et al.*, 1990).

Suitable attenuating mutations useful in embodiments wherein any of the alphaviruses of this invention are employed are known to or can be identified by those skilled in the art using routine protocols. Attenuating mutations may be introduced into the RNA by performing site-directed mutagenesis on the cDNA which encodes the

RNA, in accordance with known procedures. See Kunkel (1985), the disclosure of which is incorporated herein by reference in its entirety. Alternatively, mutations may be introduced into the RNA by replacement of homologous restriction fragments in the cDNA which encodes for the RNA, in accordance with known procedures. The  
5 identification of a particular mutation in an alphavirus as attenuating is done using routine experimentation according to methods well known in the art.

Preferably, the helper RNA of this invention includes a promoter. It is also preferred that the replicon RNA includes a promoter. Suitable promoters for inclusion  
10 in the helper RNA and replicon RNA are well known in the art. One preferred promoter is the alphavirus 26S promoter, although many suitable promoters are available, as is well known in the art.

In the system wherein a first helper RNA, a second helper RNA, and a replicon  
15 RNA are all on separate molecules, if the same promoter is used for all three RNAs, then a homologous sequence between the three molecules is provided. Thus, it is advantageous to employ different promoters on the first and second helper RNAs to provide further impediment to RNA recombination that might produce virulent virus. It is preferred that the selected promoter is operative with the non-structural proteins  
20 encoded by the replicon RNA molecule.

The infectious, replication defective, alphavirus particles of this invention are prepared according to the methods disclosed herein in combination with techniques known to those skilled in the art. The methods include, for example, transfecting an  
25 alphavirus-permissive cell with a replication defective replicon RNA including the alphavirus packaging segment and an inserted heterologous RNA, a first helper RNA encoding at least one alphavirus structural protein, and a second helper RNA encoding at least one alphavirus structural protein which is different from that encoded by the first helper RNA; producing the alphavirus particles in the transfected cell; and  
30 collecting the alphavirus particles from the cell.

Methods for transfecting the alphavirus-permissive cell with the replicon RNA and helper RNAs can be achieved, for example, by (i) treating the cells with DEAE-dextran, (ii) by lipofection, by treating the cells with, for example, LIPOFECTIN, and (iii) by electroporation, with electroporation being a preferred  
5 means of achieving RNA uptake into the alphavirus-permissive cells. Examples of these techniques are well known in the art, see e.g., U.S. Pat. No. 5,185,440 to Davis *et al.*, and PCT Publication No. WO 92/10578 to Bioption AB, the disclosures of which are incorporated herein by reference in their entirety.

10 The steps of producing the infectious viral particles in the cells may also be carried out using conventional techniques. See e.g., U.S. Patent No. 5,185,440 to Davis *et al.*, PCT Publication No. WO 92/10578 to Bioption AB, and U.S. Patent No. 4,650,764 to Temin *et al.* (although Temin *et al.*, relates to retroviruses rather than alphaviruses). The infectious viral particles may be produced by standard cell culture  
15 growth techniques.

The steps of collecting the infectious alphavirus particles may also be carried out using conventional techniques. For example, the infectious particles may be collected by cell lysis, or collection of the supernatant of the cell culture, as is known in  
20 the art. See e.g., U.S. Patent No. 5,185,440 to Davis *et al.*, PCT Publication No. WO 92/10578 to Bioption AB, and U.S. Patent No. 4,650,764 to Temin *et al.* (although Temin *et al.* relates to retroviruses rather than alphaviruses). Other suitable techniques will be known to those skilled in the art. Optionally, the collected infectious alphavirus particles may be purified, if desired. Purification techniques for viruses are well known  
25 to those skilled in the art, and these are suitable for the purification of small batches of infectious alphavirus particles.

Thus, the present invention provides a method of making the populations of alphavirus replicon particles of this invention comprising:

30 A) (a) providing a first helper cell for producing a first population of infectious,

defective alphavirus particles, comprising in an alphavirus-permissive cell:

- 5 (i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;
- 10 (ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and
- (iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;
- 15 and with at least one of said helper RNAs lacking an alphavirus packaging signal;
- wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the first population contains
- 20 no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture;
- (b) producing the alphavirus particles in the helper cell; and
- (c) collecting the alphavirus particles from the helper cells;
- B) (a) providing a second helper cell for producing a second population of
- 25 infectious, defective alphavirus particles, comprising in an alphavirus-permissive cell:
- (i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles
- 30

containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

5 (ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional  
10 helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

15 wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the second population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture;

20 (b) producing the alphavirus particles in the helper cell; and

(c) collecting the alphavirus particles from the helper cells;

C) providing a third helper cell for producing a third population of infectious, defective alphavirus particles, comprising in an alphavirus-permissive cell:

(i) an alphavirus replicon RNA, wherein the replicon RNA  
25 comprises an alphavirus packaging signal and a nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof is modified to inhibit reverse transcriptase activity or is modified to inactivate or delete integrase, RNase H and reverse  
30 transcriptase functions in the *pol* gene product or immunogenic fragment

thereof, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

(ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and unable to complete viral replication, and further wherein the third population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture;

(b) producing the alphavirus particles in the helper cell; and

(c) collecting the alphavirus particles from the helper cells; and

D) combining the first population of alphavirus particles produced from the first helper cell, the second population of alphavirus particles produced from the second helper cell and the third population of alphavirus particles produced from the third helper cell, thereby producing the populations of alphavirus replicon particles.

In a preferred embodiment, as noted above, the method provided also includes a mutation in the *pol* gene product or immunogenic fragment thereof resulting in inactivation or deletion of integrase and RNase H functions of the *pol* gene product or immunogenic fragment thereof. In a specific embodiment of this method, the region of the *pol* gene encoding the RNase H and integrase function of the *pol* gene product or immunogenic fragment thereof has been deleted.

A method of making the populations of alphavirus replicon particles of this invention, wherein the particles comprise at least one attenuating mutation, is also provided, comprising:

- A) (a) providing a first helper cell for producing a first population of infectious,  
5 defective alphavirus particles, comprising in an alphavirus-permissive cell:
- (i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, and wherein the replicon RNA lacks sequences  
10 encoding alphavirus structural proteins;
  - (ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and
  - 15 (iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;
- and with at least one of said helper RNAs lacking an alphavirus packaging  
20 signal;
- wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the first population contains no detectable replication-competent alphavirus particles as determined by passage on  
25 permissive cells in culture, and further wherein at least one of said replicon RNA, said first helper RNA, and said one or more additional helper RNA(s) comprises one or more attenuating mutations;
- (b) producing the alphavirus particles in the helper cell; and
  - (c) collecting the alphavirus particles from the helper cells;
- 30 B) providing a second helper cell for producing a second population of infectious,

defective alphavirus particles, comprising in an alphavirus-permissive cell:

(i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit release of particles, such as virus-like particles, containing the *gag* gene product or the immunogenic fragment thereof from a cell, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

(ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the second population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture, and further wherein at least one of said replicon RNA, said first helper RNA, and said one or more additional helper RNA(s) comprises one or more attenuating mutations;

(b) producing the alphavirus particles in the helper cell; and

(c) collecting the alphavirus particles from the helper cells;

C) providing a third helper cell for producing a third population of infectious,

defective alphavirus particles, comprising in an alphavirus-permissive cell:

- (i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof is modified to inhibit reverse transcriptase activity or is modified to inactivate or delete integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;
- (ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and
- (iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;
- and with at least one of said helper RNAs lacking an alphavirus packaging signal;
- wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the third population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture, and further wherein at least one of said replicon RNA, said first helper RNA, and said one or more additional helper RNA(s) comprises one or more attenuating mutations;
- (b) producing the alphavirus particles in the helper cell; and
- (c) collecting the alphavirus particles from the helper cells; and
- D) combining the first population of alphavirus particles produced from the first helper cell, the second population of alphavirus particles produced from the second

helper cell and the third population of alphavirus particles produced from the third helper cell, thereby producing the populations of alphavirus replicon particles of the present invention comprising at least one attenuating mutation.

5           In a preferred embodiment, as noted above, the method provided above can include a further mutation in the *pol* gene product or immunogenic fragment thereof resulting in inactivation or deletion of integrase and RNase H functions of the *pol* gene product or immunogenic fragment thereof. In a specific embodiment of this method, the region of the *pol* gene encoding the RNase H and integrase function of the *pol* gene  
10           product or immunogenic fragment thereof has been deleted.

          It is also contemplated regarding the method described above, that not all of the first, second and third populations of alphavirus particles do not all have to comprise an attenuating mutation. For example, the first population may comprise attenuating  
15           mutations, but the second and third populations may not, etc.

          The present invention further provides the compositions of the present invention which are produced by the methods of this invention.

20           The compositions and methods of this invention which incorporate attenuating mutations into the alphavirus replicon particles forming the composition and/or produced by the methods include purified compositions and methods of purification based on the presence of the attenuating mutations. In particular, certain attenuating mutations in the alphavirus structural proteins introduce heparin binding sites into these  
25           proteins which are present on the surface of the alphavirus replicon particles. As an example, the V3014 E2 glycoprotein (SEQ ID NO:12 and SEQ ID NO:13) has a mutation in which a lysine is substituted for the glutamic acid at amino acid position 209. This mutation, which creates a more positively charged glycoprotein, increases the affinity of this protein for heparin. Thus, it is possible to purify such particles using  
30           heparin affinity chromatography. Such chromatography can be performed using any of

several commercially available resins to which heparin has been bound. The source of heparin is variable; the commercially available resins currently use porcine heparin. The choice of resin will be based on its relative ease of use in a scaled-up, GMP-compliant process, e.g., price, column packing limitations, and potential for easy sanitization. The use of heparin affinity chromatography results in a substantial purification of the VRPs with very little loss of material, and it is a scalable purification step. In a preferred embodiment, a heparin affinity chromatography step results in between an 8- to 27-fold reduction in total protein per ml, or from a 300- to 1000-fold reduction in total protein per VRP. Thus, the present invention provides heparin affinity-purified alphavirus replicon particles containing attenuating mutations which are useful as clinical trial material and commercial product. The present invention also provides methods for preparing purified alphavirus replicon particles containing attenuating mutations comprising the use of heparin affinity chromatography, as described in the Examples provided herein. These particles can also be present in a composition of this invention.

The alphavirus replicon particles of this invention can also be made in a cell free system. Such replicon particles are herein referred to as virosomes. In a specific embodiment of the method, such particles are constructed from a mixture containing replicon RNA that does not encode all of the alphavirus structural proteins, purified glycoproteins E1 and E2, one or more non-cationic lipids, such as lecithin, and detergent. Detergent is slowly removed from the mixture to allow formation of lipid bilayers with incorporated RNA and glycoproteins.

In preferred embodiments of the methods of this invention, the glycoproteins E1 and E2 could be expressed in any recombinant protein expression system capable of glycosylation of mammalian proteins, such as stably transformed cell lines, for example CHO cells, or viral vector expression systems such as vaccinia, baculovirus, herpes virus, alphavirus or adenovirus. In a preferred embodiment, following expression of the proteins; the E1 and E2 glycoproteins are purified from contaminating cellular

proteins in the expression supernatant. The purification of these glycoproteins can be achieved by affinity chromatographic column purification, for example using lectin-, heparin-, or antibody-affinity columns. This affinity purification step may be preceded by selective precipitation or selective extraction from the expression system supernatant  
5 by methods including, but not limited to, ammonium sulfate precipitation or detergent extraction respectively. Final polishing steps of purification may include ion-exchange chromatography or buffer exchange, for example, and tangential flow methods to generate purified glycoproteins suitable for virosome assembly.

10 Thus, the present invention provides a method of producing alphavirus replicon virosomes, comprising: a) combining alphavirus replicon RNA, alphavirus glycoproteins E1 and E2, non-cationic lipids and detergent; and b) gradually removing detergent, whereby alphavirus replicon virosomes are produced. This method is described in more detail in the Examples section herein.

15 The present invention also provides alphavirus replicon virosomes comprising an alphavirus replicon RNA encapsidated by a lipid bilayer in which alphavirus glycoproteins are embedded. The replicon RNA can be from any alphavirus and the glycoproteins can be from any alphavirus. In a specific embodiment, the alphavirus  
20 glycoproteins are VEE E1 and E2. The advantage of the alphavirus replicon virosomes is the ease of preparation, their stability, and their purity, since they are devoid of any cellular components being made in a cell free system.

The helper cells, RNAs and methods of the present invention are useful in *in vitro*  
25 *vitro* expression systems, wherein the inserted heterologous RNA located on the replicon RNA encodes a protein or peptide which is desirably produced *in vitro*. The helper cells, RNAs, methods, compositions and pharmaceutical formulations of the present invention are additionally useful in a method of administering a protein or peptide to a subject in need of the desired protein or peptide, as a method of treatment  
30 or otherwise.

It is contemplated that the nucleic acids, vectors and alphavirus replicon particles of this invention can be administered to a subject to impart a therapeutic or beneficial effect. Therefore, the nucleic acids, vectors and particles of this invention can be present in a pharmaceutically acceptable carrier. By "pharmaceutically acceptable" is meant a material that is not biologically or otherwise undesirable, i.e., the material may be administered to a subject, along with the nucleic acid or vector of this invention, without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained. The carrier would naturally be selected to minimize any degradation of the active ingredient and to minimize any adverse side effects in the subject, as would be well known to one of skill in the art (see, e.g., *Remington's Pharmaceutical Science*; latest edition).

Pharmaceutical formulations of this invention, such as vaccines, of the present invention can comprise an immunogenic amount of the alphavirus replicon particles as disclosed herein in combination with a pharmaceutically acceptable carrier. An "immunogenic amount" is an amount of the infectious alphavirus particles which is sufficient to evoke an immune response (humoral and/or cellular immune response) in the subject to which the pharmaceutical formulation is administered. An amount of from about  $10^3$  to about  $10^7$  replicon-containing particles, and preferably, about  $10^4$  to about  $10^6$  replicon-containing particles per dose is believed suitable, depending upon the age and species of the subject being treated. Exemplary pharmaceutically acceptable carriers include, but are not limited to, sterile pyrogen-free water and sterile pyrogen-free physiological saline solution.

25

Subjects which may be administered immunogenic amounts of the infectious, replication defective alphavirus particles of the present invention include, but are not limited to, human and animal (e.g., horse, donkey, mouse, hamster, monkey) subjects. Administration may be by any suitable means, such as intraperitoneal or intramuscular injection.

30

Pharmaceutical formulations for the present invention can include those suitable for parenteral (e.g., subcutaneous, intradermal, intramuscular, intravenous and intraarticular) administration. Alternatively, pharmaceutical formulations of the present invention may be suitable for administration to the mucous membranes of a subject  
5 (e.g., intranasal administration). The formulations may be conveniently prepared in unit dosage form and may be prepared by any of the methods well known in the art.

Thus, the present invention provides a method for delivering nucleic acids and vectors (e.g., alphavirus replicon particles; virosomes) encoding the antigens of this  
10 invention to a cell, comprising administering the nucleic acids or vectors to a cell under conditions whereby the nucleic acids are expressed, thereby delivering the antigens of this invention to the cell. The nucleic acids can be delivered as naked DNA or in a vector (which can be a viral vector) or other delivery vehicles and can be delivered to cells *in vivo* and/or *ex vivo* by a variety of mechanisms well known in the art (e.g.,  
15 uptake of naked DNA, viral infection, liposome fusion, endocytosis and the like). The cell can be any cell which can take up and express exogenous nucleic acids.

Further provided herein is a method of inducing an immune response to an HIV antigen of this invention in a subject, comprising administering to the subject an  
20 immunogenic amount of the particles, virosomes and/or composition of this invention, in a pharmaceutically acceptable carrier.

A method of treating and/or preventing infection by HIV in a subject is also provided herein, comprising administering to the subject an effective amount of the  
25 particles, virosomes and/or compositions of this invention, in a pharmaceutically acceptable carrier.

The subject of this invention can be any animal in which an immune response can be induced or in which an infection by HIV can be treated and/or prevented. In a  
30 preferred embodiment, the subject of this invention is a mammal and most preferably is

a human.

Protocols and data regarding the testing of the compositions of this invention in animals and protocols for administration to humans are provided in the Examples  
5 herein.

In a particular embodiment, the present invention provides an isolated nucleic acid encoding a *pol* gene product or immunogenic fragment thereof of a human immunodeficiency virus, wherein the integrase, RNase H and reverse transcriptase  
10 functions of the *pol* gene product or immunogenic fragment thereof have been inactivated or deleted. Such a modification has been shown in some studies to facilitate inhibition of the formation of replication competent alphavirus particles during production of alphavirus replicon particles comprising the *pol* gene product or immunogenic fragment thereof.

15

Also provided herein is a composition comprising the *pol*-expressing nucleic acid described above, a vector comprising the nucleic acid and a cell comprising the vector. The *pol*-expressing nucleic acid can also be present in an alphavirus replicon particle comprising the nucleic acid.

20

As noted above, the nucleic acid encoding the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in the inhibition of reverse transcriptase activity. In a preferred embodiment, a mutation is introduced at the active site motif that results in inhibition of reverse transcriptase activity. Such a mutation  
25 may remove the DNA binding domain of the enzyme, for example. A mutation from YMDD to YMAA or HMAA at this motif is an example of such a mutation.

The present invention additionally provides a method of making an alphavirus replicon particle comprising nucleic acid encoding a *pol* gene product or immunogenic  
30 fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or

immunogenic fragment thereof comprises a modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions from the *pol* gene product or immunogenic fragment thereof, comprising

A) providing a helper cell for producing an infectious, defective alphavirus particle, comprising in an alphavirus-permissive cell:

- (i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof is modified to delete or inactivate RNase H, integrase and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;
- (ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and
- (iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture;

- (B) producing the alphavirus particles in the helper cell; and
- (C) collecting the alphavirus particles from the helper cell.

In the method provided above, at least one of the replicon RNA, the first helper RNA, and the one or more additional helper RNA(s) can comprise one or more attenuating mutations, as described herein.

5           In a specific embodiment of this method, a mutation is introduced at the active site motif in the *pol* gene product or immunogenic fragment thereof that results in inhibition of reverse transcriptase activity. Such a mutation may remove the DNA binding domain of the enzyme, for example. A mutation from YMDD to YMAA or HMAA at this motif is an example of such a mutation.

10

Also provided herein is an alphavirus replicon particle expressing the *pol* gene product or immunogenic fragment thereof, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof, produced according to any of the above methods.

15

In a further embodiment, the present invention provides a method of inducing an immune response in a subject, comprising administering to the subject an immunogenic amount of a composition comprising an alphavirus particle comprising nucleic acid encoding a *pol* gene product or immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof, in a pharmaceutically acceptable carrier.

20

Furthermore, the present invention provides a method of treating or preventing infection by human immunodeficiency virus in a subject, comprising administering to the subject an effective amount of a composition comprising an alphavirus particle comprising nucleic acid encoding a *pol* gene product or immunogenic fragment thereof

30

of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof, in a pharmaceutically acceptable carrier.

5

In preferred embodiments of the methods of this invention, the subject is administered an effective amount of a population of alphavirus particles comprising particles expressing (1) nucleic acid encoding a *pol* gene product or immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in inactivation or deletion of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof, (2) nucleic acid encoding a *gag* gene product or immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit release of *gag* gene product or the immunogenic fragment thereof from a cell, and (3) nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus in a pharmaceutically acceptable carrier.

In further preferred embodiments, the population of alphavirus particles comprises particles expressing (1) nucleic acid encoding a *gag* gene sequence that has at least 92% identity with SEQ ID NO:4; (2) nucleic acid encoding a *pol* gene sequence that has at least 99% identity with SEQ ID NO:15; and (3) nucleic acid encoding an *env* gene sequence with at least 95% identity with SEQ ID NO:18. In a specific embodiment, the population of alphavirus particles comprises particles expressing (1) nucleic acid of SEQ ID NO:4, (2) nucleic acid of SEQ ID NO:15, and (3) nucleic acid of SEQ ID NO:18.

## EXAMPLES

30

The following examples are provided to illustrate the present invention, and

should not be construed as limiting thereof. In these examples, nm means nanometer, mL means milliliter, pfu/mL means plaque forming units/milliliter, VEE means Venezuelan Equine Encephalitis virus, EMC means encephalomyocarditis virus, BHK means baby hamster kidney cells, HA means hemagglutinin gene, N means  
5 nucleocapsid, FACS means fluorescence activated cell sorter, and IRES means internal ribosome entry site. The expression "E2 amino acid (e.g., lys, thr, etc.) number" indicates the designated amino acid at the designated residue of the E2 gene, and is also used to refer to amino acids at specific residues in the E1 protein and in the E3 protein, respectively.

10

### EXAMPLE 1

#### VEE Replicon Particles as Vaccines

Replicon particles for use as a vaccine are produced using the VEE-based vector  
15 system, originally developed from a full-length, infectious cDNA clone of the RNA genome of VEE (Figure 1 in Davis *et al.*, 1989). In this Example, one or more attenuating mutations (Johnston and Smith, 1988; Davis *et al.*, 1990) have been inserted into the clone to generate attenuated VEE vaccine vectors (Davis *et al.*, 1991; 1995; Grieder *et al.*, 1995).

20

As described herein, these constructs are genetically modified to create an RNA replicon (i.e., an RNA that self-amplifies and expresses), and one or more helper RNAs to allow packaging. The replicon RNA expresses an HIV gene, e.g., the Clade C HIV-1 *gag* gene. The replicon RNA is packaged into virus-like particles (herein referred to  
25 as "virus replicon particles" or "VRPs") that are infectious for only one cycle. During this cycle, the characteristics of the alphavirus-based vector result in very high levels of expression of the replicon RNA in cells to which the VRP is targeted, e.g., cells of the lymph node.

30

In the cytoplasm of the target cell, the replicon RNA is first translated to

produce the viral replicase proteins necessary to initiate self-amplification and expression. In this Example, the HIV-1 Clade C *gag* gene is encoded by a subgenomic mRNA, abundantly transcribed from a negative-sense replicon RNA intermediate, leading to high-level expression of the HIV-1 Clade C *gag* gene product. Since the  
5 VEE structural protein genes are not encoded by the replicon RNA, progeny virion particles are not assembled, thus limiting the replication to a single cycle within the infected target cell.

Importantly, only the replicon RNA is packaged into VRPs, as the helper RNAs  
10 lack the *cis*-acting packaging sequence required for encapsidation. The "split helper" or bipartite system (see Example 4) greatly reduces the chance for an intact genome being assembled by recombination, and as a back-up safety feature, one or more highly attenuating mutations, such as those contained in the glycoprotein genes in V3014 (Grieder *et al.*, 1995), are incorporated.

15 Overall, the design of the VRPs incorporates several layered and redundant safety features. In addition to the above-described split helper system and attenuating mutations, over one-third of the genome of the virus has been removed, creating a defective genome which prevents spread from the initially infected target cell.  
20 Nonetheless, if a statistically rare recombination event occurs to yield replication competent virus (RCV), the resulting virus would be a highly attenuated VEE strain.

## EXAMPLE 2

### Construction of VEE Replicon

25 The VEE structural protein genes (C-PE2-6K-E1) are removed from a cDNA clone (pV4031) which contained two attenuating mutations (E2 lys 209, E1 thr 272), and a duplication of the 26S subgenomic RNA promoter sequence immediately downstream from the 3'-end of the E1 glycoprotein gene, followed by a multiple  
30 cloning site as described in U.S. Pat. No. 5,505,947 to Johnston *et al.* The pV4031

plasmid DNA is digested to completion with *ApaI* restriction enzyme, which cuts the VEE genomic sequence at nucleotide 7505 (numbered from the 5'-end of the genome sequence). A second recognition site for this enzyme is found in the duplicate 26S subgenomic promoter. Therefore, digestion of pV4031 with *ApaI* produces two DNA fragments, one containing the VEE nonstructural genes (e.g. SEQ ID NO:2) and a single copy of the 26S subgenomic RNA promoter followed by a multiple cloning site, and a second smaller fragment containing a 26S subgenomic RNA promoter followed by the VEE structural genes. The large fragment is isolated and religated to produce the replicon, pVR2. In this example, as well as in the construction of the helper plasmids (Example 3), a kanamycin resistance gene (SEQ ID NO:6, encoding amino acid sequence as in SEQ ID NO:7) is present in the plasmids to aid in the cloning manipulations.

### EXAMPLE 3

#### Construction of Helper Plasmids

The starting materials for the helper plasmids are four full-length cDNA clones: V3000, the virulent Trinidad donkey strain of VEE, three clones with attenuating mutations, pV3014 (E2 lys 209, E1 thr 272), V3519 (E2 lys 76, E2 lys 209, E1 thr 272) and V3526 (deletion of E3 56-59, E1 ser 253), which are in the genetic background of Trinidad donkey strain VEE. Several different helper plasmids have been made by using unique or rare restriction sites in the full-length cDNA clone to delete portions of the nonstructural protein region. The full-length clone is digested with one or two restriction enzymes, the larger DNA fragment is isolated and then religated to form a functional plasmid. *In vitro* RNA transcripts from these plasmids upon transfection of tissue culture cells would not encode a functional RNA replication complex, and also would not include an encapsidation signal. The helper constructs differ in the size of the nonstructural gene deletion. The helper constructs are designated by the attenuated mutant clone used in their construction, and by the percentage of the nonstructural region deleted. The following helper constructs were generated:

	V3014Δ520-7507(93%)
	V3519Δ520-7507(93%)
	<del>V3526Δ520-7505(93%)</del>
	V3014Δ520-6965(87%)
5	V3519Δ1687-7507(78%)
	V3014Δ2311-7505(70%)
	V3519Δ3958-7507(47%)
	V3526Δ520-7505(93%)
	V3014Δ3958-7505(47%)
10	V3519Δ1955-3359(19%)
	V3014Δ520-3954(46%)
	V3014Δ1955-3359(19%)
	V3014Δ1951-3359(19%)
	V3014Δ2311-3055(10%)
15	V3014Δ2307-3055(10%)

#### EXAMPLE 4

##### Construction of Bipartite RNA Helper Plasmids

20 A bipartite helper system is constructed as described herein. The V3014Δ520-7505(93%) helper is used to construct an additional deletion of the E2 and E1 glycoprotein genes by digestion with HpaI restriction enzyme and ligation, resulting in deletion of the sequence between nucleotide 8494 (in the E3 gene) and nucleotide 11,299 (near the 3'-end of the E1 gene). *In vitro* RNA transcripts of this glycoprotein

25 helper plasmid (presented graphically in Figure 2; an exemplary nucleotide sequence for such a plasmid is SEQ ID NO:8, including the nucleotide sequence (SEQ ID NO:9 and the amino acid sequence (SEQ ID NO:10 of the VEE capsid), when electroporated into BHK cells with a replicon RNA, are replicated and transcribed to give a mRNA encoding only the capsid protein of VEE.

The second member of the bipartite helper is constructed from the same original helper plasmid 3014Δ5207505(93%) by cleavage with Tth111I restriction enzyme (at nucleotide 7544) and SpeI restriction enzyme (at nucleotide 8389), resulting in deletion of the capsid gene, followed by insertion of a synthetic double-stranded oligonucleotide with Tth111I and SpeI termini. The inserted sequence restored the downstream portion of the 26S promoter and an ATG initiation codon followed by a Ser codon, such that the first amino acid residue of E3 (Ser) is the first codon following the inserted AUG. The resulting glycoprotein helper plasmid is presented graphically in Figure 3, and an exemplary nucleic acid sequence for such a plasmid is SEQ ID NO:11, encoding the VEE glycoproteins (E3-E2-6kD-E1), SEQ ID NO:12. The *in vitro* transcript of this plasmid, when transfected into a cell with replicon RNA, will produce the VEE glycoproteins (SEQ ID NO:13). Co-electroporation of both of these helper RNAs into a cell with replicon RNA results in production of infectious particles containing only replicon RNA.

15

Other than the 5' and 3' ends and the 26S promoters (40 nucleotides) of these helper RNAs, the only sequence in common between the capsid and glycoprotein helpers is the sequence from 8389 to 8494 (106 nucleotides)

20

## EXAMPLE 5

### VEE REPLICON PARTICLES EXPRESSING HIV GENES

The vaccines of this invention are exemplified by the use of a propagation defective, replicon particle vector system derived from an attenuated strain of Venezuelan equine encephalitis virus (VEE) to create a mixture of VEE replicon particles individually expressing HIV-1 *gag*, *pol*, or *env* genes. The three genes used in this Example were selected based on homology to consensus sequences generated from primary isolates obtained from recent seroconverters in Kwazulu/Natal. Plasma samples from approximately 20 recent seroconverters in the Durban/Hlabisa cohort and a similar number of HIV-positive, asymptomatic individuals were collected. HIV viral

30

RNA was isolated from the plasma, and the sequences of the *gag*, *pol* and *env* genes were analyzed. Two regions from each gene were amplified, and the resulting PCR products were sequenced (see Figure 10 for regions analyzed). A consensus sequence was derived for each gene, and the sequences of each isolate were compared to the  
5 derived consensus. All isolates were found to be Subtype C of HIV, thus confirming the predominance of this subtype in South Africa.

#### A. CONSTRUCTION OF THE Gag-VRP VACCINE

10 Described herein is the design and manufacture of VEE replicon particles (VRPs) engineered to express the *gag* gene from a Subtype C isolate of HIV-1. The main purpose of this single antigen vaccine is to establish a safety profile for VRPs in healthy human subjects. Optimally, the HIV-Gag-VRPs will be formulated as a component of a trivalent vaccine, also containing HIV-Pol-VRP and HIV-gp160-VRP  
15 (*env*) made in analogous procedures to the one described herein for HIV-Gag-VRPs.

In this Example, the VEE particles are based on the V3014 glycoprotein helper plasmid (Figure 3, SEQ ID NO:12 and SEQ ID NO:13), which harbors two highly attenuating mutations, one in E2 and the other in E1 (Grieder *et al.*, 1995). The V3014  
20 glycoprotein helper RNA is able to package VRPs with significantly greater efficiency than the glycoprotein helper RNA derived from V3526 (Pushko *et al.*, 1997). Nonetheless, safety of the VRP vector system has not been compromised since detailed pathogenesis studies clearly have shown V3014 to be avirulent in adult mice by  
subcutaneous inoculation (Grieder *et al.*, 1995). V3014 was found to be significantly  
25 impaired in its ability to reach and spread beyond the draining lymph node following subcutaneous inoculation. Unlike wild-type V3000, V3014 does not establish a viremia and does not reach the brain. In addition, on rare occasions when found, histopathological lesions in the periphery were much less severe than those induced by  
wild-type V3000 (Grieder *et al.*, 1995). Following inoculation with V3014, adult mice  
30 are protected against lethal wild-type VEE infection.

The attenuated phenotype of V3014 also was observed in VEE challenge studies in horses. Animals inoculated subcutaneously with V3014 showed no significant leukopenia or febrile response compared to mock-vaccinated controls. In addition, results indicated that these animals were completely protected against virulent VEE (V3000) challenge.

Taken together, these data indicate that if the rare recombination event did occur during VRP assembly to yield RCV, the worst case scenario would be the generation of a highly attenuated strain of VEE.

## B. SELECTION AND CLONING OF THE HETEROLOGOUS ANTIGEN

The exemplary HIV genes used in this invention, *gag*, *pol* and *env*, are derived from Subtype C (Clade C) viruses isolated from likely Phase III clinical trial sites in South Africa. The HIV infection rate in South Africa and its long established virology and public health infrastructure make this country an attractive choice for clinical testing of HIV vaccines. Focused sequencing and phylogenetic analysis of the *gag*, *pol*, and *env* genes of these isolates has allowed the selection of genes representative of the Clade C isolates circulating in this region of Africa.

### 1. HIV-1 Clade C *gag* gene

Two 400 bp regions of the *gag* gene were sequenced from approximately 30 plasma samples collected from HIV seropositive individuals in South Africa. A South African consensus sequence was then determined for the *gag* gene as well as a consensus sequence from the Los Alamos database for Subtype C virus. In addition, approximately 20 comparable sequences from Malawi were used, generated as part of another study, to confirm conclusions about sequence variation. Several isolates that were close to the South African consensus sequence were compared to other isolates in distance measurements. Among these 30 isolates, one was chosen as the source for the *gag* gene (SEQ ID NO:4; corresponding to the amino acid sequence in SEQ ID NO:5)

for the following reasons.

This isolate had greater than 95% amino acid identity to the South African consensus sequence, representing the approximate middle of the sequence diversity of all isolates. This isolate, known as DU422, came from a recent seroconverter, reflecting currently circulating strains and the transmitted phenotype. The phenotype of DU422 is NS1, CCR5(+), and CXCR4(-).

Prior to the insertion of the *gag* gene into the VEE replicon plasmid vector, the amino terminal myristylation ("myr") site of *gag* was removed to prevent the formation of Gag-containing virus-like particles. Restriction enzyme digests of the *gag* gene plasmid, the capsid helper plasmid, and the glycoprotein helper plasmid were performed to confirm the identity of the three vectors when compared to published maps of the parental plasmid pBR322, with the kanamycin resistance gene substituted for the ampicillin resistance gene. The confirmed plasmid maps of the VEE replicon plasmid containing the DU422 *gag* gene (p3-40.1.6), the capsid helper plasmid (p3-13.2.2), and the glycoprotein helper plasmid (p3-13.4.6) are presented in Figures 1, 2, and 3, respectively. The full nucleotide sequence of each of these plasmids is presented herein as SEQ ID NO:1, SEQ ID NO:8, and SEQ ID NO:11, respectively.

20

In Figures 6 and 15, expression of this HIV-1 Gag protein in BHK cells infected with VRPs expressing such a *gag* construct is demonstrated (Figure 6: Western blot, lane 3; Figure 15, immunofluorescence detection). The cells were infected at a multiplicity of infection (m.o.i.) of 3.5 infectious units (i.u.) per cell, and expression was measured 18 hours post-infection (p.i.). Cell lysates (from approximately  $2 \times 10^3$  cells) were collected and fractionated either by a 4-12% gradient SDS-PAGE or by 10% SDS-PAGE. The fractionated polypeptides were transferred to PVDF membranes and probed with human HIV-1 positive serum.

30

### 2. HIV-1 Clade C *env* gene

A Clade C *env* gene (aka "gp160") from another HIV isolate, DU151, from a recent seroconverter was chosen based on its 92% amino acid identity to the South African consensus sequence for this gene, determined in an analogous method to the one described for the *gag* gene in Example 5.A.1. The phenotype of the DU151 isolate is NS1, CCR5(+), CXCR4(-). This gene was engineered into a VEE RNA replicon plasmid as shown in Figure 5, and the entire sequence of the plasmid is given at SEQ ID NO:17. The *env* gene construct used in this Example is SEQ ID NO:18.

In Figure 6, expression of this ENV protein (SEQ. ID. NO:19) in BHK cells infected with VRPs expressing this HIV *env* construct is demonstrated (Western blot, lane 2), showing that the protein expressed in the cells is of the correct size and is immunoreactive. In Figure 7, expression of this ENV protein in U87.CD4.CCR5 cells is shown. These cells process the ENV protein into two components, GP120 and GP41. In these cells, the expressed GP160 is fusogenic (see Figure 8).

### 3. HIV-1 Clade C *pol* gene

A Clade C *pol* gene from isolate DU151 was chosen based on its 99% amino acid identity with the South African consensus sequence. This gene was modified at the active site of the reverse transcriptase encoding sequence to inhibit its activity, and the p51 fragment of this modified gene (SEQ ID NO:15) was engineered into a VEE RNA replicon plasmid. The map of this *pol* plasmid is shown in Figure 4, and the nucleotide sequence of the plasmid is provided as SEQ ID NO:14. In Figure 6, expression of this POL p51 fragment (SEQ ID NO:16) in BHK cells is demonstrated (Western blot, lane 1), showing that the protein expressed in these cells is both the correct size and immunoreactive.

### C. IMMUNOLOGICAL RESPONSE TO VRP-GAG VACCINE

Mice were injected subcutaneously in two doses, with 8-9 mice in each group. The mice were immunized once, then immunized a second time, with the same dose, 28 days later. Serum was collected the day prior to the first immunization, then at day 27 ("after 1<sup>st</sup> immunization") and at day 35 (after 2<sup>nd</sup> immunization).

The vigorous, antigen-specific humoral response of mice to the HIV-1 Clade C VRP-gag vaccine described in Example 5.A.1. is presented in Table 1. Details of this assay are described in Example 7A.1.

TABLE 1. Humoral Response to VRP-gag Vaccine

Dose:	Total Ab Titer	
	(log <sub>10</sub> )	
10 <sup>3</sup> i.u. dose:		
after 1 <sup>st</sup> immunization	1.3 +/- 0.1	
after 2 <sup>nd</sup> immunization	2.8 +/- 1.1	
10 <sup>5</sup> i.u. dose		
after 1 <sup>st</sup> immunization	2.1 +/- 0.5	
after 2 <sup>nd</sup> immunization	4.1 +/- 0.6	

The vigorous, antigen-specific CTL response in mice to the HIV-1 Clade C VRP-gag vaccine (Example 5.A.1) is presented in Figure 9. Details of this assay are described in Example 7A.3.

## EXAMPLE 6

### MANUFACTURING PROCESS FOR HIV VRP VACCINES

#### A. Manufacturing Process

5

Disclosed herein is a manufacturing process for VRP vaccines that is suitable for large-scale preparation of GMP-compliant (GMP = Good Manufacturing Practices) material for use in human clinical trials or for commercial manufacture. The process includes several steps and after each step (as appropriate), a set of "in process control" (IPC) assays or Release Tests (RT) is performed to confirm the successful completion of the step. The process steps and the accompanying IPC assay(s) or RTs (described in more detail in Example 6D.1 and 6D.2) are as follows:

	Process Step	IPC/RT
15	Linearize 3 DNA plasmids	IPC: Check for linearity
	<i>In vitro</i> RNA transcription	IPC: Size, integrity and concentration
	Electroporation of certified Vero cell line	IPC:
	Harvest culture fluids	Titration/Identity
		Test for replication-competent virus (RCV)
	Pool the culture fluid	RT:
		Mycoplasma
		Adventitious virus
		PERT assay
20	Purification of bulk VRP by heparin affinity chromatography	IPCs:
		Heparin residual assay
		BSA assay
		Bovine IgG assay

Filtration of bulk VRP

RT:

Test for RCV

Titration/Identity

Contaminating protein/DNA

Sterility

Endotoxin

Formulate, Fill, Release

RT:

Titration/Identity

Sterility

General Safety

#### B. Preparation of plasmid DNAs

5 Stock solutions of replicon plasmid DNA, capsid helper plasmid DNA and glycoprotein helper plasmid DNA are produced in *Escherichia coli* XL2 Blue cells (Stratagene, cat# 200150). All plasmids harbor the kanamycin resistance gene marker. The three plasmid DNAs were manufactured and purified by PureSyn, Inc. (Malvern, PA) under appropriate GLP/GMP procedures, with a complete Batch Record with full  
10 traceability. Following fermentation and cell harvest, cell paste was lysed with base and plasmid DNAs were purified by ion pair chromatography on PolyFlo™ separation media.

Prior to release by appropriate quality assurance/quality control oversight, each  
15 lot of each plasmid DNA is analyzed to confirm identity, purity and quality (Table 2). An approved certificate of analysis for each DNA is then established for each plasmid DNA lot.

Table 2. Plasmid DNA Release Tests

	Test	Method	Specification
5	DNA homogeneity	Agarose gel electrophoresis	>90% supercoiled
	<i>E. coli</i> genomic DNA	Southern Blot	<50 µg/mg plasmid
10	<i>E. coli</i> RNA	Agarose gel electrophoresis	No detectable bands
	Endotoxin	Limulus Amoebocyte Lysate (LAL)	< 0.1 EU/mg
	Total protein	Abs 260/280	1.8-1.9
15	Sterility	Bioburden assay, USP23	< 1 CFU
	Identity	Restriction enzyme analysis	Matches map

20 To produce HIV-VRP vaccine for clinical use, both replicon and helper plasmids are linearized by digestion at the unique Not I site and used as templates for synthesis of run-off transcripts. The quality of the transcription products (i.e., the replicon and the two helper RNAs) is evaluated by agarose gel electrophoresis.

### 25 C. Characterization of the Vero cells

Vero cells are used in the production of HIV-VRPs (WHO Vero MCB P139, BioReliance Inc., Rockville, MD). Vials contained approximately  $1 \times 10^7$  cells/mL in a cryoprotectant solution of 90% fetal bovine serum and 10% dimethyl sulfoxide. A Cell  
 30 Certification Summary is provided with each lot. BioReliance Inc. has filed a Master File with the FDA regarding the WHO Vero MCB P139.

Vials of WHO Vero MCB P139 cells are expanded into flasks. Each of the flasks is then expanded again in order to prepare the Master Cell Bank (MCB). The Working Cell Bank (WCB) is prepared from the MCB. The MCB is tested for purity and identity. The WCB is tested for adventitious agents (detection of mycoplasma and viruses). Viability tests are performed on both the MCB and the WCB.

Tumorigenicity tests are performed once at the end of the production period.

#### **D. Electroporation**

10

Vero cells are cotransfected by electroporation with RNA mixtures comprising replicon RNA transcripts encoding HIV-gag, VEE capsid helper RNA transcripts, and VEE glycoprotein helper RNA transcripts. The transfected cells are transferred to tissue culture vessels and incubated in well-defined culture medium. Following harvest, the HIV-Gag-VRP is purified from pooled culture fluid supernatants by affinity column chromatography. Prior to formulation and filling, purified, bulk HIV-Gag-VRP is tested for the presence of RCV.

#### **E. Final formulated product**

20

The HIV-Gag-VRP vaccine is vialled at four different doses. The material is filtered (0.22  $\mu$ m) and added to vials at the appropriate concentration and volume, stoppered, quick-frozen and stored at  $-20^{\circ}$  C.

#### **F. Control tests of the Gag-VRP vaccine**

##### **1. In-Process Controls**

Table 3 below summarizes the In-Process Controls performed during the manufacturing process of the HIV-Gag-VRP Vaccine.

**Table 3. IPCs during the manufacture of HIV-Gag-VRP Vaccine**

5	<b>Test</b>	<b>Method</b>	<b>Target</b>
	Check for linearity	Agarose Gel electrophoresis	Report
10	Size, integrity and concentration of RNAs	Agarose Gel electrophoresis	Report
	Titration/Identity	Indirect immunofluorescence assay(IFA), using standardized Gag-specific antibody preparation	Report
	Test for RCV	CPE Assay	Report
15	Heparin Residual	Chromogenic Inhibitory Assay	Report
	BSA residual	ELISA	Report
20	Bovine IgG Residual	ELISA	Report

**2. Release tests**

Tables 4 and 5 below summarize the release tests performed on the HIV-Gag-VRP Vaccine.

**Table 4. Pool of the Culture Fluids**

5	<b>Test</b>	<b>Method</b>	<b>Target</b>
	Adventitious Virus ( <i>in vivo</i> )	European guidelines	Negative
	Adventitious Virus ( <i>in vitro</i> )	5 cell lines	No growth
10	Mycoplasma	21CFR 610.30	No Growth
	Reverse Transcriptase	PERT Assay	Negative

**Table 5. Bulk VRP and Final Vial testing**

20	<b>Test</b>	<b>Method</b>	<b>Target Result</b>
	Replication competent virus (RCV)	Cytopathic effect (CPE) assay	Absence (in BHK cells, sensitivity is 1-10 pfu V3014)
	VRP identity/ potency	Indirect immunofluorescence assay (IFA)	$10^6$ to $10^8$ i.u. per mL
25	Cellular Protein Contaminant	Bio-Rad® DC protein assay	Total protein content per dose
	Cellular DNA Contaminant	Southern Blot or PCR	< 10 ng per dose
	Sterility	21 CFR § 610.12	Pass

Endotoxin	LAL	< 5 EU/dose
General Safety	21 CFR § 610.11	Pass
Particulates	USP	Pass
Stability	IFA	$10^6$ to $10^8$ i.u. per mL

## EXAMPLE 7

### PRECLINICAL STUDIES

Pilot lots are manufactured following written procedures (SOPs and STMs) and according to the manufacturing scheme described in Example 6. These pilot lots are prepared and used for two major tasks. The first one is a preclinical immunogenicity evaluation, which includes studies to assess the immune response and the cell-mediated immune response in vaccinated animals. The second major task is a preclinical safety evaluation, which includes evaluations of system toxicity, hematopoietic and immune system toxicity, and local reactogenicity.

Finally, an *in situ* hybridization study is performed in mice in order to verify the *in vivo* expression of HIV-Gag-VRP gene product in lymphoid tissue.

#### A. Immunogenicity Studies

##### A.1 Humoral Immune Response in Mice

Three groups of five female BALB/c mice (4-6 weeks of age) are inoculated subcutaneously with  $10^5$ ,  $10^6$ , or  $10^7$  i.u. of the HIV-Gag-VRP at three time points: on day 0, and at weeks 4 and 8. The fourth group, Control Group, receives the vehicle only. Immediately prior to inoculation, and at weeks 3, 5, 8 and 10 post-inoculation,

blood samples are collected for humoral immune response evaluations. Gag protein-specific serum antibody titers and seroconversion rates are measured by ELISA (Caley *et al.*, 1997) against purified, recombinant Gag protein. The source of the antigen is the homologous Clade C gag gene expressed in insect or mammalian cells. Antigen  
5 specificity also is confirmed by immunoblot analysis. Anti-VEE responses are monitored by ELISA (Johnston and Smith, 1988).

#### A.2 Humoral Immune Response in Rabbits

10 Three groups of five female New Zealand white rabbits are inoculated subcutaneously with  $10^5$ ,  $10^6$ , or  $10^7$  i.u. of the HIV-Gag-VRP. The fourth group, Control Group, receives the vehicle only. Immediately prior to inoculation, and at weeks 3, 5, 8 and 10 post-inoculation, blood samples are collected for humoral immune response evaluations.

15 Humoral immune responses are evaluated as described in Section A.1.

#### A.3 Cell-Mediated Immune Response in Mice

20 Three groups of five female BALB/c mice are inoculated subcutaneously with  $10^5$ ,  $10^6$ , or  $10^7$  i.u. of the HIV-Gag-VRP at day 0 and day 28. The fourth group, Control Group, receives the vehicle only. Blood samples are collected at week 3 post-inoculation. Spleens are harvested for splenocyte collection on day 7 following the second inoculation for evaluation of cell-mediated immune responses.

25 The cell-mediated immune response is evaluated by determining the ability of splenic T cells from immunized mice to proliferate *ex vivo* in the presence of either Gag protein or Gag peptide(s). The ability of splenic T and CD4+ T cells to produce interferon- $\gamma$  and interleukin-4 respectively, is determined. Finally, the ability of  
30 cytotoxic T lymphocytes to lyse target cells that present murine major

histocompatibility complex class-I restricted epitopes for HIV-1 Clade C Gag protein is measured (see Betts *et al.*, 1997 for methods)

## B. Safety Study

5

Three groups of six male and six female New Zealand white rabbits are inoculated subcutaneously with  $10^4$ ,  $10^6$ , or  $3 \times 10^7$  i.u. of the HIV-Gag-VRP. The fourth group, Control Group, receives the vehicle only. Animals receive four injections at week 0, week 3, week 6 and Week 9. Half of the animals are sacrificed two days  
10 after the last injection (week 9) and the other half at three weeks after the last injection (week 12). Similar studies are performed in mice with a high dose at  $10^8$  i.u. This level is 100 times the likely primate dose, based on efficacy studies in rhesus macaques.

In addition to system toxicity (record of mortality/morbidity, body temperature,  
15 body weight, food consumption and ophthalmic examinations), hematopoietic toxicity is evaluated by quantitating cellular components of peripheral blood, and immune system toxicity is assessed by histopathologic evaluation of the lymphoid organs. Local reactogenicity is evaluated by examining the injection sites grossly and  
microscopically to determine irritation potential. Serum samples are also tested for the  
20 presence of replication competent virus by blind passage in cell culture.

## C. *In Situ* Hybridization Study in Mice

Three groups of five female BALB/c mice are inoculated subcutaneously with  
25  $10^5$ ,  $10^6$ , or  $10^7$  i.u. of the HIV-Gag-VRP. The fourth group, Control Group, receives the vehicle only. A single injection is performed in each group.

To verify expression of HIV-GAG-VRP in lymphoid tissue, the draining lymph nodes, spleen, and thymus of the mice are examined by *in situ* hybridization at 24 hours  
30 and 48 hours after the single inoculation.

**EXAMPLE 8****Heparin Affinity Chromatography of VRPs**

5           Generally, the majority of contaminating protein is non-VEE protein from the conditioned media. Heparin column capacity requirements for GMP manufacturing runs are therefore based on the volume of conditioned media, rather than the concentration of VRPs. Column parameters are optimized at room temperature, but variations in temperature do not greatly affect performance. The expected yields of  
10   VRPs can range from 50% to > 90%.

          While only minimal leaching of heparin from the columns has been detected, GMP requirements stipulate that a residual heparin assay be performed as an IPC test following the chromatography step.

15

**A.     Pharmacia HiTrap® Heparin**

          Five mL columns of Pharmacia HiTrap® Heparin (cat no. 17-0407-01, Amersham Pharmacia Biotech), pre-equilibrated with 25 mM HEPES/0.25 M NaCl, pH  
20   7.5, were loaded with HIV-Gag-VRPs produced in Vero cells. After column washing with the equilibration buffer, VRPs were eluted with a 15 column volume gradient from 0.25 – 1.0 M NaCl gradient in 25 mM HEPES, pH 7.5. The HIV-Gag-VRPs eluted at a conductivity of approximately 48 mS/cm. The wash step was optimized (based on the  $A_{230}$  peak) at a NaCl concentration between 0.25 M and 0.3 M.

25

**B.     Heparin Sepharose 6 Fast Flow® resin**

          Heparin Sepharose 6 Fast Flow® resin (catalog no. 90-1000-2; Amersham Pharmacia Biotech) is supplied as a bulk resin which allows various size columns to be  
30   packed as needed. Fast Flow® resins have the advantages of excellent flow

characteristics and ability to be sanitized with sodium hydroxide solutions, which are particularly useful in a GMP manufacturing process. A 6 mL column was prepared by packing the Heparin Sepharose 6 Fast Flow® bulk resin in a BioRad® Econo-Column chromatography column, which was then pre-equilibrated with 25 mM HEPES/0.12 M NaCl, pH 7.5. VRPs were loaded onto the column, which was then washed with the equilibration buffer. Initial experiments indicated that the VRPs eluted at a lower conductivity (36 mS/cm) with this resin as compared to the HiTrap® Heparin, so the wash conditions were modified accordingly. The VRPs were eluted from the Fast Flow® resin with a 15 column volume gradient from 0.12 M to 1 M NaCl in 25 mM HEPES, pH 7.5.

## EXAMPLE 9

### Virosome Formation

15

The feasibility of virosome formation is demonstrated in a series of experiments in which replicon RNA and RNA encoding the glycoprotein E1 and E2 genes (glycoprotein helper) were first transfected into BHK cells by electroporation. After 18-24 hours, cell supernatants were harvested and tested for the presence of virosomes as described briefly below.

20

### Cell Culture

BHK cells were used as a cell substrate and were maintained in growth medium (alpha-MEM (Life Technologies), supplemented with 10% Fetal Bovine Serum (HyClone), 1x Glutamine (Life-Technologies)), in an atmosphere of 5% CO<sub>2</sub> at 37°C. Prior to electroporation, cells were detached from the cell culture vessel using 0.05% trypsin-0.53 mM EDTA solution (Life Technologies). Trypsin was neutralized with growth medium, and cells were washed twice with cold Phosphate-Buffered Saline (PBS, BioWhittaker) and resuspended at a concentration of  $1.5 \times 10^7$  cells/ml.

30

### RNA Transcription, Electroporation and Virosome Harvest

Plasmid DNA pVR-GFP (green fluorescent protein) was linearized using restriction endonuclease NotI (New England Biolabs) as recommended by the manufacturer. DNA was extracted with phenol:chloroform:iso-amyl alcohol (25:24:1, Gibco BRL) and precipitated with ethanol, following the addition of  $\text{NH}_4\text{Ac}$  to 2.5 M final concentration. RNA was synthesized in an *in vitro* transcription reaction using an mMessage mMachine® kit (Ambion) as recommended by the manufacturer. This RNA, without further purification, was used to transfect BHK cells. Helper RNA was prepared in a similar fashion. A BHK cell suspension in PBS (0.8 mL,  $1.2 \times 10^7$  cells) was mixed with 10  $\mu\text{g}$  of each RNA, and the mixture was electroporated. Electroporation settings for Gene-Pulser® (Bio-Rad Laboratories) were: 850 V, 25  $\mu\text{F}$ , 3 pulses. Culture supernatant was collected at 18-24 hr post-electroporation and clarified by centrifugation for 10 min at 1000 rpm.

### Titration of Virosomes

The presence of infectious virosome particles was demonstrated using an immunofluorescence assay to titer the virosomes by detecting the fluorescence of the GFP encoded by the replicon RNA in the virosomes. Serial dilutions of the cell culture supernatant were added to 12-well plates of BHK cells. Following an 18-24 hour incubation in an atmosphere of 5%  $\text{CO}_2$  at 37°C, the medium was removed from each plate. Virosome infectious titer was then determined by counting the number of green-fluorescent single cells at a particular dilution, followed by a back-calculation to determine total infectious units (i.u.) per mL. A final titer of 440 i.u./mL was collected.

### Confirmation of virosome identity

Three independent experimental methods were used to determine that the infectious particles were in fact virosomes, rather than replication competent viral

particles or naked RNA being carried over from the electroporated cells.

- i) The virosome-containing supernatant was passaged a second time by removing the cell supernatant from the 12-well plate used for titration and placing this supernatant onto a fresh monolayer of BHK cells. At 18-24 hours post-passage, the monolayer was examined under U/V fluorescence and found to contain 0 (zero) GFP-positive cells, indicating the infectious particles produced using this method can undergo only a single round of replication, a critical characteristic of a virosome.
- ii) To establish that the infectious titer detected following virosome packaging was not due to carry-over of RNA used in the electroporation, the supernatant was treated with RNase A (Invitrogen) at a concentration of 100  $\mu\text{g}/\mu\text{L}$  for 15 minutes at 37°C. The treated and untreated control supernatants were titered according to the methods outlined above. The RNase-treated sample contained 400 i.u./mL and the control group had 440 i.u./mL, indicating that the RNase treatment had no significant effect on virosome titer.
- iii) To establish that the infectious particles were enveloped in the E1 and E2 glycoproteins, anti-VEE mouse serum was used to treat the cell supernatant in a neutralization assay. As a control, normal mouse serum was used to treat the virosome supernatant. In addition, VEE replicon particles expressing GFP were used in the assay, the infectivity of which is known to be inhibited by this serum.

	Anti-VEE serum	Particle Titer (i.u./mL)	
		Normal Mouse Serum	No serum
Virosome Supernatant	20	440	530
VRP-GFP	0	530	890

The infectivity of the virosomes was inhibited similar to that of VRP-GFP,

indicating that the virosome particles were enveloped by the E1 and E2 glycoproteins.

These examples clearly demonstrate the ability to produce infectious virosome particles comprising replicon RNA enveloped with only the alphavirus E1 and E2 glycoproteins. Testing confirmed that these virosomes are infectious agents, but that they undergo only a single round of replication, as indicated by the inability to passage the agent. In addition, the agents contained the E1 and E2 glycoproteins, as evidenced by the ability to block infection with only VEE specific serum. Finally, the infectious RNA is protected from RNase enzymatic digestion, indicating an enveloped particle.

The natural lipid content in BHK cells is primarily non-cationic. Virosomes made in a completely cell free system can be made by using one or more non-cationic lipids, such as lecithin (phosphatidylcholine).

#### EXAMPLE 10

##### PHASE I CLINICAL PROTOCOL

###### Phase I Safety and Immunogenicity Trial of an HIV Subtype C Gag-VEE

###### Replicon Particle Vaccine in HIV-1 Seronegative Human Subjects

A Phase I trial is conducted to evaluate the safety and immunogenicity of the HIV Gag-VRP prototype vaccine component in healthy seronegative adult volunteers. The doses are selected based on preclinical studies in rodents and nonhuman primates. The schedule mimics previous preclinical efficacy studies with the SIV model that demonstrated the capacity of SIV-VRP to induce SIV specific neutralizing antibodies and CTL.

**Purpose:** To evaluate the candidate vaccine component in an open-labeled, placebo-controlled study.

**Subjects:** Healthy adult volunteers without a history of identifiable high-risk behavior for HIV-1 infection as determined by a comprehensive screening questionnaire.

No. Subjects: 40

5

**Route:** Subcutaneous injection

**Scheme:** The volunteers are arranged in four groups, ten subjects per group. In each group, two subjects receive a placebo, while the other eight subjects receive either  $10^4$ ,  $10^6$ ,  $10^7$ , or  $10^8$  i.u. of HIV-Gag-VRPs. Subjects are vaccinated on day 0, day 30, and

10 day 120.

**Estimated Duration:** Forty weeks

#### A. SELECTION of SUBJECTS

15 Subjects are healthy HIV-1 seronegative adults who fully comprehend the purpose and details of the study as described in the informed consent. Subjects whom either themselves or whose sexual partners have identifiable higher risk behavior for HIV-1 infection are not eligible. Higher risk behavior is determined by a prescreen series of questions designed to identify risk factors for HIV-1 infection. An assessment

20 of absolute exclusion criteria using the self-administered and interview questions is conducted. Subsequently, investigators proceed with phlebotomy, history and physical examination, and final questions regarding sexual behavior and other practices. Eligibility determinations for the trial depend on results of laboratory tests and answers to these self-administered and interview questions.

25

The criteria used to define low risk behavior are as follows:

##### EITHER ALL OF THE FOLLOWING:

1. No newly acquired higher risk associated STD in the last six months
- 30 2. No possibly safe or unsafe sex with a known HIV+ individual or an active

injection drug user in the past six months

3. No unsafe sexual activity
4. Possibly safe sexual activity with two or fewer partners within the last six months
5. No injection drug use

OR BOTH OF THE FOLLOWING:

1. Mutually monogamous relationship with a known or presumed HIV seronegative partner for the last six months
- 10 2. No injection drug use

**A.1 Inclusion Criteria**

Age: 18-60

- 15 - Sex: Male or Female [*For females, negative pregnancy test at time of entry and assurance that adequate birth control measures will be used for one month prior to immunization and the duration of the study*]

Normal history and physical examination

Lower risk sexual behavior as defined above.

- 20 Normal complete blood count and differential defined as:

- Hematocrit 34% for women; 38% for men
- White count 3500 cells/mm<sup>3</sup> with normal differential
- Total lymphocyte count 800 cells/mm<sup>3</sup>
- Absolute CD4 count 400 cells/mm<sup>3</sup>

- 25 - Platelets (150,000-550,000)

Normal ALT (~ 1.5 x institutional upper normal limit) and creatinine (1.6 mg/dl)

Normal urine dipstick with esterase and nitrite

Negative for hepatitis B surface antigen

- 30 Negative ELISA for HIV within eight weeks of immunization

Availability for follow-up for planned duration of the study (68 weeks)

A viable EBV transformed autologous B cell line

## A.2 Exclusion Criteria

5

History of immunodeficiency, chronic illness, malignancy, autoimmune disease, or use of immunosuppressive medications

10 Medical or psychiatric condition or occupational responsibilities which preclude subject compliance with the protocol

Subjects with identifiable higher risk behavior for HIV infection as determined by screening questionnaire designed to identify risk factors for HIV infection; specific exclusions include:

15

History of injection drug use within the last 12 months prior to enrollment.

Higher risk sexual behavior defined as one or more of the following behaviors:

1. A newly acquired higher risk associated STD within the past six months
2. Possibly safe or unsafe sex with a known HIV+ individual in the past six months
- 20 3. Possibly safe sexual activity with twelve or more partners in the past six months
4. Unsafe sexual activity with four or more partners within the past six months.

25

Live attenuated vaccines within 60 days of study [NOTE: Medically indicated subunit or killed vaccines (e.g., influenza, pneumococcal) are not exclusionary, but should be given at least two weeks away from test article immunizations.]

Use of experimental agents within 30 days prior to study

Receipt of blood products or immunoglobulin in the past six months

30

Active syphilis [NOTE: If the serology is documented to be a false positive or

due to a remote (>six months) treated infection, the volunteer is eligible]

Active tuberculosis [NOTE: Volunteers with a positive PPD and a normal chest X-ray showing no evidence of TB and not requiring INH therapy are eligible.]

History of anaphylaxis or other serious adverse reactions to vaccines

5 Prior receipt of HIV vaccines or a placebo recipient in an HIV vaccine trial

Pregnant or lactating women

## **B. SAFETY and IMMUNOGENICITY MONITORING**

10 Safety is evaluated by monitoring volunteers for adverse reactions during the course of the trial. Volunteers are followed for a total of 26 weeks post-final inoculation. The main toxicity associated with the subcutaneous injection in this study is that associated with subcutaneous injection of any immunogen, i.e., pain, redness and swelling at the injection site, as well as the possibility of fever, chills, aches and pains  
15 and perhaps fatigue.

Safety monitoring includes periodic review of data from the trial with particular emphasis on monitoring for adverse reactions including the following evaluations:

Hematologic: CBC, differential, platelets

20 Hepatic/renal: ALT, creatinine, urinalysis

Neurologic: headache, paralysis, anxiety, confusion, weakness, tremors.

Systemic symptoms: fever, gastrointestinal complaints, myalgia, malaise, fatigue, headache, anaphylaxis, immune complex disease, and other hypersensitivity reactions

25 Local toxicity at the site of injection: e.g., pain, tenderness, erythema, regional lymphadenopathy, limitation of limb movement

The immunogenicity monitoring includes the following immunological assays, all utilizing HIV Subtype C based reagents:

Humoral responses:

HIV Subtype C Gag-specific ELISA

Anti-VEE ELISA

5 Cellular immune responses:

Standard cell-killing assay (i.e., chromium release) to measure CD8+ Gag-specific CTL activity

ELISPOT assay to measure IFN-?

10 Mucosal immune responses:

Standardized assay for assessment of Gag-specific IgA

Throughout this application, various publications are referenced. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains.

**REFERENCES**

- 20 Barany F. 1985. Single-stranded hexameric linkers: a system for in-phase insertion mutagenesis and protein engineering. *Gene* 37(1-3):111-23.

- 25 Betts, M. R., J. Krowka, C. Santamaria, K. Balsamo, F. Gao, G. Mulundu, C. Luo, N. N'Gandu, H. Sheppard, B. H. Hahn, S. Allen and J. A. Frelinger. 1997. Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected Zambians. *J. Virol.* 71:8908-8911.

- 30 Caley, I. J., M.R. Betts, D.M. Irlbeck, N. L. Davis, R. Swanstrom, J.A. Frelinger and R. E. Johnston. 1997. Humoral, mucosal and cellular immunity in response to an HIV-1 vaccine candidate. *J. Virol.* 71:3031-3038.

Davis *et al.* 1980. In: Microbiology, 3d ed., p. 132.

Davis, N.L., L.V. Willis, J.F. Smith and R.E. Johnston. 1989. *In vitro* synthesis of infectious Venezuelan equine encephalitis virus RNA from a cDNA clone: Analysis of  
5 a viable deletion mutant. *Virology* 171:189-204.

Davis, N. L., L. V. Willis, J. F. Smith, G. Greenwald and R. E. Johnston. 1990. *In vitro* synthesis of infectious VEE virus RNA from a cDNA clone: Analysis of a viable deletion mutant and mutations affecting virulence. In: Vaccines 90, Cold Spring Harbor  
10 Press, Cold Spring Harbor, NY. pp. 109-113.

Davis, N. L., N. Powell, G. F. Greenwald, L. V. Willis, B. J. Johnson, J. F. Smith and R. E. Johnston. 1991. Attenuating mutations in the E2 glycoprotein gene of Venezuelan equine encephalitis virus: Construction of single and multiple mutants in a  
15 full-length cDNA clone. *Virology* 183:20-31.

Davis, N. L., K. W. Brown, G. F. Greenwald, A. J. Zajac, V. L. Zacny, J. F. Smith and R. E. Johnston. 1995. Attenuated mutants of Venezuelan equine encephalitis virus containing lethal mutations in the PE2 cleavage signal combined with a second-site  
20 suppressor mutation in E1. *Virology* 212:102-110.

Davis, N. L., K. W. Brown and R. E. Johnston. 1996a. A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge. *J. Virol.* 70:3781-3787.  
25

Davis, N. L., P. Pushko, K. W. Brown, P. C. Charles, I. J. Caley, M. Parker, G. Ludwig, J. F. Smith and R. E. Johnston. 1996b. Immunization against influenza with attenuated Venezuelan equine encephalitis virus vectors. In: Options for the Control of Influenza, III, L. E. Brown and A. W. Hampson, eds. Elsevier, Amsterdam. pp.803-  
30 809.

Davis, N. L., I. J. Caley, K. W. Brown, M.R. Betts, D.L. Irlbeck, K.M. McGrath, M.J. Connell, D.C. Montefiori, J.A. Frelinger, R. Swanstrom, P.R. Johnson and R. E. Johnston. 2000. Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles. *J. Virol.* 74:371-378

5

Grieder, F. B., N. L. Davis, J. F. Aronson, P. C. Charles, D. C. Sellon, K. Suzuki and R. E. Johnston. 1995. Specific restrictions in the progression of Venezuelan equine encephalitis virus induced disease resulting from single amino acid changes in the glycoproteins. *Virology* 206:994-1006.

10

Hevey, M., D. Negley, P. Pushko, J. Smith and A. Schmaljohn. 1998. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. *Virology* 251:28-37.

15 Hirsch, V., T.R. Fuerst, G. Sutter, M.W. Carroll, L. C. Yang, S. Goldstein *et al.* 1996. Patterns of viral replication correlate with outcome in SIV-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. *J. Virol.* 70:3741-3752.

20 Johnston, Robert E. and Jonathan F. Smith. 1988. Selection for accelerated penetration in cell culture co-selects for attenuated mutants of Venezuelan equine encephalitis virus. *Virology* 162:437-443.

Johnston, R. E. and C. J. Peters. 1996. *Alphaviruses*. In: *Virology*, Third Edition, B. N.

25 Fields, D. M. Knipe and P. M. Howley, eds., Raven Press, New York. pp. 843-898.

Kinney, R.M., B.J.B. Johnson, J.B. Welch, K.R. Tsuchiya and D.W. Trent. 1989. The full-length nucleotide sequences of the virulent Trinidad donkey strain of Venezuelan equine encephalitis virus and its attenuated vaccine derivative, strain TC-83. *Virology*

30 170:19-30.

- Kinney, R.M., G-J. Chang, K. R. Tsuchiya, J. M. Sneider, J. T. Roehrig, T. M. Woodward and D. W. Trent. 1993. Attenuation of Venezuelan equine encephalitis virus strain TC-83 is encoded by the 5'-noncoding region and the E2 envelope glycoprotein. *J. Virol.* 67:1269-1277.
- 5 Kunkel. 1985. *Proc. Natl. Acad. Sci. USA* 82:488.
- Paredes, A.M., D.T. Brown, R. Rothnagel, W. Chiu, R.J. Schoepp, R.E. Johnston and B.V. Prasad. 1993. Three-dimensional structure of a membrane-containing virus. *Proc.*
- 10 *Natl. Acad. Sci., USA* 90:9095-9099.
- Pushko, P., M. Parker, G. V. Ludwig, N. L. Davis, R. E. Johnston and J. F. Smith. 1997. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes *in vitro* and immunization against heterologous
- 15 pathogens *in vivo*. *Virology* 239:389-401.
- Rosenberg, A.H., *et al.* 1987. Vectors for selective expression of cloned DNAs by T7 RNA polymerase. *Gene*. 56(1): p. 125-35.
- 20 Schlesinger, S. and M.J. Schlesinger. 1990. *Replication of Togaviridae and Flaviviridae*. In: *Virology*, Fields, B.N. and Knipe, D.M. (eds.) Raven Press. pp. 697-711.
- Strauss *et al.* 1990. *Seminars in Virology* 1:347.
- 25 Strauss, J.H. and E.G. Strauss. 1994. The alphaviruses: Gene expression, replication, and evolution. *Micro. Rev.* 58:491-562.
- Studier, F.W., *et al.* 1990. Use of T7 RNA polymerase to direct expression of cloned
- 30 genes. 1990. *Methods Enzymol.* 185:60-89.

What is claimed is:

1. A composition comprising two or more isolated nucleic acids selected from the group consisting of an isolated nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, an isolated nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and an isolated nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof is modified to inhibit reverse transcriptase activity.
2. A composition comprising a population of alphavirus replicon particles comprising two or more isolated nucleic acids selected from the group consisting of 1) an isolated nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, 2) an isolated nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and 3) an isolated nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof is modified to inhibit reverse transcriptase activity, and wherein the nucleic acids are each contained within a separate alphavirus replicon particle.
3. A composition comprising a population of alphavirus replicon particles comprising two or more isolated nucleic acids selected from the group consisting of 1) an isolated nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, 2) an isolated nucleic acid encoding a *gag*

gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and 3) an isolated nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof is modified to inhibit reverse transcriptase activity, and wherein the nucleic acids are each contained within a separate alphavirus replicon particle, and further wherein the alphavirus replicon particles comprise a replicon RNA or at least one structural protein which comprises one or more attenuating mutations.

4. A method of making the population of alphavirus replicon particles of claim 2 comprising:
    - A) (a) providing a first helper cell for producing a first population of infectious, replication defective alphavirus particles, comprising in an alphavirus-permissive cell:
      - (i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;
      - (ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and
      - (iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;
- and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the first population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture;

- (b) producing the alphavirus particles in the helper cell; and
- (c) collecting the alphavirus particles from the helper cells;

B) (a) providing a second helper cell for producing a second population of infectious, replication defective alphavirus particles, comprising in an alphavirus-permissive cell:

- (i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;
- (ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and
- (iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the

helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the second population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture;

- (b) producing the alphavirus particles in the helper cell; and
- (c) collecting the alphavirus particles from the helper cells;

C) (a) providing a third helper cell for producing a third population of infectious, replication defective alphavirus particles, comprising in an alphavirus-permissive cell:

- (i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof is modified to inhibit reverse transcriptase activity, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;
- (ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and
- (iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the third population contains

no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture;

- (b) producing the alphavirus particles in the helper cell; and
- (c) collecting the alphavirus particles from the helper cells; and

D) combining the first population of alphavirus particles produced from the first helper cell, the second population of alphavirus particles produced from the second helper cell and the third population of alphavirus particles produced from the third helper cell, thereby producing the population of alphavirus replicon particles of claim 2.

5. The method of claim 4, wherein the alphavirus replicon RNA of at least one of the first helper cell, the second helper cell and the third helper cell comprises sequence encoding at least one alphavirus structural protein and wherein the first helper RNA and the one or more additional helper RNA(s) in the at least one of the first helper cell, the second helper cell and the third helper cell, encodes at least one other alphavirus structural protein not encoded by said replicon RNA.

6. A method of making the population of alphavirus replicon particles of claim 3, comprising:

- A) (a) providing a first helper cell for producing a first population of infectious, replication defective alphavirus particles, comprising in an alphavirus-permissive cell:
  - (i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;
  - (ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein;

and

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the first population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture, and further wherein at least one of said replicon RNA, said first helper RNA, and said one or more additional helper RNA(s) comprises one or more attenuating mutations;

- (b) producing the alphavirus particles in the helper cell; and
- (c) collecting the alphavirus particles from the helper cells;

B) (a) providing a second helper cell for producing a second population of infectious, replication defective alphavirus particle, comprising in an alphavirus-permissive cell:

- (i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;
- (ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and

furthermore not encoding at least one other alphavirus structural protein;  
and

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the second population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture, and further wherein at least one of said replicon RNA, said first helper RNA, and said one or more additional helper RNA(s) comprises one or more attenuating mutations;

(b) producing the alphavirus particles in the helper cell; and

(c) collecting the alphavirus particles from the helper cells;

C) (a) providing a third helper cell for producing a third population of infectious, replication defective alphavirus particles, comprising in an alphavirus-permissive cell:

(i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof is modified to inhibit reverse transcriptase activity, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

(ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and

furthermore not encoding at least one other alphavirus structural protein;

and

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the third population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture, and further wherein at least one of said replicon RNA, said first helper RNA, and said one or more additional helper RNA(s) comprises one or more attenuating mutations;

(b) producing the alphavirus particles in the helper cell; and

(c) collecting the alphavirus particles from the helper cells; and

D) combining the first population of alphavirus particles produced from the first helper cell, the second population of alphavirus particles produced from the second helper cell and the third population of alphavirus particles produced from the third helper cell, thereby producing the population of alphavirus replicon particles of claim 3.

7. The method of claim 6, wherein the alphavirus replicon RNA of at least one of the first helper cell, the second helper cell and the third helper cell comprises sequence encoding at least one alphavirus structural protein and wherein the first helper RNA and the one or more additional helper RNA(s) in the at least one of the first helper cell, the second helper cell and the third helper cell, encodes at least one other alphavirus structural protein not encoded by said replicon RNA.

8. The method of claim 6, wherein only at least one of the first population of alphavirus particles, the second population of alphavirus particles and the third population of alphavirus particles comprises particles wherein at least one of said replicon RNA, said first helper RNA, and said one or more additional helper RNA(s) comprises one or more attenuating mutations.
9. A population of alphavirus replicon particles produced by the method of claim 4.
10. A population of alphavirus replicon particles produced by the method of claim 6.
11. A method of inducing an immune response to human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the composition of claim 1 in a pharmaceutically acceptable carrier.
12. A method of inducing an immune response to human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the composition of claim 2 in a pharmaceutically acceptable carrier.
13. A method of inducing an immune response to human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the composition of claim 3 in a pharmaceutically acceptable carrier.
14. A method of inducing an immune response to human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the population of claim 9 in a pharmaceutically acceptable carrier.
15. A method of inducing an immune response to human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the

population of claim 10 in a pharmaceutically acceptable carrier.

16. A method of treating or preventing infection by human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the composition of claim 1 in a pharmaceutically acceptable carrier.

17. A method of treating or preventing infection by human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the composition of claim 2 in a pharmaceutically acceptable carrier.

18. A method of treating or preventing infection by human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the composition of claim 3 in a pharmaceutically acceptable carrier.

19. A method of treating or preventing infection by human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the population of claim 9 in a pharmaceutically acceptable carrier.

20. A method of treating or preventing infection by human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the population of claim 10 in a pharmaceutically acceptable carrier.

21. A composition comprising two or more isolated nucleic acids selected from the group consisting of an isolated nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, an isolated nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and an isolated nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof

of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof.

22. A composition comprising a population of alphavirus replicon particles comprising two or more isolated nucleic acids selected from the group consisting of 1) an isolated nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, 2) an isolated nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and 3) an isolated nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof, and wherein the nucleic acids are each contained within a separate alphavirus replicon particle.

23. A composition comprising a population of alphavirus replicon particles comprising two or more isolated nucleic acids selected from the group consisting of 1) an isolated nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, 2) an isolated nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and 3) an isolated nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof comprises a

modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof, and wherein the nucleic acids are each contained within a separate alphavirus replicon particle, and further wherein the alphavirus replicon particles comprise a replicon RNA or at least one structural protein which comprises one or more attenuating mutations.

24. A method of making the population of alphavirus replicon particles of claim 22, comprising:

A) (a) providing a first helper cell for producing a first population of infectious, replication defective alphavirus particles, comprising in an alphavirus-permissive cell:

(i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

(ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the first population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture;

- (b) producing the alphavirus particles in the helper cell; and
- (c) collecting the alphavirus particles from the helper cells;

B) (a) providing a second helper cell for producing a second population of infectious, replication defective alphavirus particles, comprising in an alphavirus-permissive cell:

- (i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;
- (ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and
- (iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the second population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture;

- (b) producing the alphavirus particles in the helper cell; and

- (c) collecting the alphavirus particles from the helper cells;
- C) (a) providing a third helper cell for producing a third population of infectious, replication defective alphavirus particles, comprising in an alphavirus-permissive cell:
- (i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;
  - (ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and
  - (iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;
- and with at least one of said helper RNAs lacking an alphavirus packaging signal;
- wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the third population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture;
- (b) producing the alphavirus particles in the helper cell; and
  - (c) collecting the alphavirus particles from the helper cells; and

D) combining the first population of alphavirus particles produced from the first helper cell, the second population of alphavirus particles produced from the second helper cell and the third population of alphavirus particles produced from the third helper cell, thereby producing the population of alphavirus replicon particles of claim 22.

25. The method of claim 24, wherein the alphavirus replicon RNA of at least one of the first helper cell, the second helper cell and the third helper cell comprises sequence encoding at least one alphavirus structural protein and wherein the first helper RNA and the one or more additional helper RNA(s) in the at least one of the first helper cell, the second helper cell and the third helper cell, encodes at least one other alphavirus structural protein not encoded by said replicon RNA.

26. A method of making the population of alphavirus replicon particles of claim 23, comprising:

- A) (a) providing a first helper cell for producing a first population of infectious, replication defective alphavirus particles, comprising in an alphavirus-permissive cell:
- (i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;
  - (ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and
  - (iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the first population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture, and further wherein at least one of said replicon RNA, said first helper RNA, and said one or more additional helper RNA(s) comprises one or more attenuating mutations;

- (b) producing the alphavirus particles in the helper cell; and
- (c) collecting the alphavirus particles from the helper cells;

B) (a) providing a second helper cell for producing a second population of infectious, replication defective alphavirus particle, comprising in an alphavirus-permissive cell:

- (i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;
- (ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and
- (iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein

not encoded by said first helper RNA;  
and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the second population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture, and further wherein at least one of said replicon RNA, said first helper RNA, and said one or more additional helper RNA(s) comprises one or more attenuating mutations;

- (b) producing the alphavirus particles in the helper cell; and
  - (c) collecting the alphavirus particles from the helper cells;
- C) (a) providing a third helper cell for producing a third population of infectious, replication defective alphavirus particles, comprising in an alphavirus-permissive cell:
- (i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;
  - (ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and
  - (iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional

helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;  
and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication, and further wherein the third population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture, and further wherein at least one of said replicon RNA, said first helper RNA, and said one or more additional helper RNA(s) comprises one or more attenuating mutations;

- (b) producing the alphavirus particles in the helper cell; and
- (c) collecting the alphavirus particles from the helper cells; and

D) combining the first population of alphavirus particles produced from the first helper cell, the second population of alphavirus particles produced from the second helper cell and the third population of alphavirus particles produced from the third helper cell, thereby producing the population of alphavirus replicon particles of claim 23.

27. The method of claim 26, wherein the alphavirus replicon RNA of at least one of the first helper cell, the second helper cell and the third helper cell comprises sequence encoding at least one alphavirus structural protein and wherein the first helper RNA and the one or more additional helper RNA(s) in the at least one of the first helper cell, the second helper cell and the third helper cell, encodes at least one other alphavirus structural protein not encoded by said replicon RNA.

28. The method of claim 26, wherein only at least one of the first population of alphavirus particles, the second population of alphavirus particles and the third population of alphavirus particles comprises particles wherein at least one of said

, said first helper RNA, and said one or more additional helper RNA(s)  
or more attenuating mutations.

ulation of alphavirus replicon particles produced by the method of claim

ulation of alphavirus replicon particles produced by the method of claim

thod of inducing an immune response to human immunodeficiency virus  
omprising administering to the subject an immunogenic amount of the  
of claim 21 in a pharmaceutically acceptable carrier.

thod of inducing an immune response to human immunodeficiency virus  
omprising administering to the subject an immunogenic amount of the  
of claim 22 in a pharmaceutically acceptable carrier.

thod of inducing an immune response to human immunodeficiency virus  
omprising administering to the subject an immunogenic amount of the  
of claim 23 in a pharmaceutically acceptable carrier.

thod of inducing an immune response to human immunodeficiency virus  
omprising administering to the subject an immunogenic amount of the  
claim 29 in a pharmaceutically acceptable carrier.

thod of inducing an immune response to human immunodeficiency virus  
omprising administering to the subject an immunogenic amount of the  
claim 30 in a pharmaceutically acceptable carrier.

thod of treating or preventing infection by human immunodeficiency

virus in a subject, comprising administering to the subject an immunogenic amount of the composition of claim 21 in a pharmaceutically acceptable carrier.

37. A method of treating or preventing infection by human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the composition of claim 22 in a pharmaceutically acceptable carrier.

38. A method of treating or preventing infection by human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the composition of claim 23 in a pharmaceutically acceptable carrier.

39. A method of treating or preventing infection by human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the population of claim 29 in a pharmaceutically acceptable carrier.

40. A method of treating or preventing infection by human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the population of claim 30 in a pharmaceutically acceptable carrier.

41. An alphavirus replicon virosome comprising an alphavirus replicon RNA encapsidated by a lipid bilayer comprising alphavirus glycoproteins, E1 and E2.

42. The virosome of claim 41, wherein the alphavirus glycoproteins are Venezuelan Equine Encephalitis glycoproteins E1 and E2.

43. A method of producing the alphavirus replicon virosome of claim 41, comprising:

a) combining alphavirus replicon RNA, alphavirus glycoproteins E1 and E2, non-cationic lipids and detergent; and

b) gradually removing detergent, whereby alphavirus replicon virosomes are produced.

44. An alphavirus replicon virosome produced from the method of claim 43.

45. A method of eliciting an immune response in a subject, comprising administering to the subject an immunogenic amount of the alphavirus replicon virosome of claim 41 in a pharmaceutically acceptable carrier.

46. A method of treating or preventing infection by human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the alphavirus replicon virosome of claim 41, wherein the virosome comprises alphavirus replicon RNA encoding one or more HIV immunogens.

47. A composition comprising a population of alphavirus replicon virosomes comprising two or more isolated nucleic acids selected from the group consisting of 1) an isolated nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, 2) an isolated nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and 3) an isolated nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof, and wherein the nucleic acids are each contained within a separate alphavirus replicon virosome.

48. A composition comprising a population of alphavirus replicon virosomes

comprising two or more isolated nucleic acids selected from the group consisting of 1) an isolated nucleic acid encoding an *env* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, 2) an isolated nucleic acid encoding a *gag* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, and 3) an isolated nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in inactivation of reverse transcriptase activity in the *pol* gene product or immunogenic fragment thereof, and wherein the nucleic acids are each contained within a separate alphavirus replicon virosome.

49. A method of producing the population of alphavirus replicon virosomes of claim 47, comprising:

A) (a) producing a first population of alphavirus replicon virosomes by combining alphavirus replicon RNA comprising nucleic acid encoding and *env* gene product or immunogenic fragment thereof, alphavirus glycoproteins E1 and E2, non-cationic lipids and detergent; and

b) gradually removing detergent, whereby alphavirus replicon virosomes are produced;

B) (a) producing a second population of alphavirus replicon virosomes by combining alphavirus replicon RNA comprising nucleic acid encoding and *gag* gene product or immunogenic fragment thereof, wherein the *gag* gene product or immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, alphavirus glycoproteins E1 and E2, non-cationic lipids and detergent; and

b) gradually removing detergent, whereby alphavirus replicon virosomes

producing a third population of alphavirus replicon virosomes by  
havirus replicon RNA comprising nucleic acid encoding the *pol* gene  
nonogenic fragment thereof, wherein the *pol* gene product or  
fragment thereof comprises a modification resulting in deletion or  
integrase, RNase H and reverse transcriptase functions in the *pol* gene  
nonogenic fragment thereof, alphavirus glycoproteins E1 and E2, non-  
and detergent; and

gradually removing detergent, whereby alphavirus replicon virosomes  
and

ing the first population of alphavirus replicon virosomes, the second  
alphavirus replicon virosomes and the third population of alphavirus  
omes to produce the population of alphavirus replicon virosomes of claim

od of producing the population of alphavirus replicon virosomes of  
prising:

producing a first population of alphavirus replicon virosomes by  
havirus replicon RNA comprising nucleic acid encoding and *env* gene  
nonogenic fragment thereof, alphavirus glycoproteins E1 and E2, non-  
and detergent; and

gradually removing detergent, whereby alphavirus replicon virosomes

producing a second population of alphavirus replicon virosomes by  
havirus replicon RNA comprising nucleic acid encoding and *gag* gene  
nonogenic fragment thereof, wherein the *gag* gene product or

immunogenic fragment thereof is modified to inhibit formation of virus-like particles containing the *gag* gene product or the immunogenic fragment thereof and their release from a cell, alphavirus glycoproteins E1 and E2, non-cationic lipids and detergent; and

b) gradually removing detergent, whereby alphavirus replicon virosomes are produced;

C) (a) producing a third population of alphavirus replicon virosomes by combining alphavirus replicon RNA comprising nucleic acid encoding the *pol* gene product or immunogenic fragment thereof, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in inactivation of reverse transcriptase activity in the *pol* gene product or immunogenic fragment thereof, alphavirus glycoproteins E1 and E2, non-cationic lipids and detergent; and

b) gradually removing detergent, whereby alphavirus replicon virosomes are produced; and

D) combining the first population of alphavirus replicon virosomes, the second population of alphavirus replicon virosomes and the third population of alphavirus replicon virosomes to produce the population of alphavirus replicon virosomes of claim 48.

51. A method of eliciting an immune response in a subject, comprising administering to the subject an immunogenic amount of the composition of claim 47, in a pharmaceutically acceptable carrier.

52. A method of eliciting an immune response in a subject, comprising administering to the subject an immunogenic amount of the composition of claim 48, in a pharmaceutically acceptable carrier.

53. A method of treating or preventing infection by human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the composition of claim 47, in a pharmaceutically acceptable carrier.

A method of treating or preventing infection by human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the composition of claim 47, in a pharmaceutically acceptable carrier.

A composition comprising heparin affinity-purified alphavirus replicon particles, wherein the alphavirus replicon particles comprise at least one structural protein which comprises one or more attenuating mutations.

A method of preparing the heparin affinity-purified alphavirus particles of claim 55, comprising:

- a) producing alphavirus replicon particles, wherein the alphavirus replicon particles comprise at least one structural protein which comprises one or more attenuating mutations;
- b) loading the alphavirus replicon particles of step (a) in a heparin affinity chromatography column; and
- c) collecting the fraction from the column which contains the heparin affinity-purified alphavirus replicon particles.

A composition produced by the method of claim 56.

A method of producing VRP for use in a vaccine comprising:

- a) producing a plasmid encoding the nucleotide sequence of an alphavirus replicon RNA;
- b) producing a plasmid encoding the nucleotide sequence of one or more other RNAs;
- c) transcribing the plasmids of steps (a) and (b) into RNA *in vitro*;
- d) electroporating the RNA of step (c) into a Vero cell line; and
- e) purifying VRP from the Vero cell line of step (d) by heparin affinity chromatography.

59. The method of claim 58, wherein the VRP is produced in large-scale.
60. VRP produced by the method of claim 59.
61. An isolated nucleic acid encoding a *pol* gene product or immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof.
62. A composition comprising the nucleic acid of claim 61.
63. A vector comprising the nucleic acid of claim 61.
64. A cell comprising the vector of claim 63.
65. An alphavirus replicon particle comprising the nucleic acid of claim 61.
66. A method of making the alphavirus replicon particle of claim 65, comprising
- a) providing a helper cell for producing an infectious, defective alphavirus particle, comprising in an alphavirus-permissive cell:
    - (i) an alphavirus replicon RNA, wherein the replicon RNA comprises an alphavirus packaging signal and a nucleic acid encoding a *pol* gene product or an immunogenic fragment thereof of a human immunodeficiency virus, wherein the *pol* gene product or immunogenic fragment thereof comprises a modification resulting in deletion or inactivation of integrase, RNase H and reverse transcriptase functions in the *pol* gene product or immunogenic fragment thereof, and wherein the replicon RNA lacks sequences encoding alphavirus structural proteins;

(ii) a first helper RNA separate from said replicon RNA, said first helper RNA encoding at least one alphavirus structural protein and furthermore not encoding at least one other alphavirus structural protein; and

(iii) one or more additional helper RNA(s) separate from said replicon RNA and separate from said first helper RNA, said additional helper RNA(s) encoding at least one other alphavirus structural protein not encoded by said first helper RNA;

and with at least one of said helper RNAs lacking an alphavirus packaging signal;

wherein the combined expression of the alphavirus replicon RNA and the helper RNAs produces an assembled alphavirus particle which is able to infect a cell, and is unable to complete viral replication; and further wherein the population contains no detectable replication-competent alphavirus particles as determined by passage on permissive cells in culture;

- (b) producing the alphavirus particles in the helper cell; and
- (c) collecting the alphavirus particles from the helper cell.


67. The method of claim 66, wherein at least one of said replicon RNA, said first helper RNA, and said one or more additional helper RNA(s) comprises one or more attenuating mutations.

68. An alphavirus replicon particle produced according to the method of claim 66.

69. An alphavirus replicon particle produced according to the method of claim 67.


70. A method of inducing an immune response in a subject, comprising administering to the subject an immunogenic amount of the composition of claim 62 in a pharmaceutically acceptable carrier.

71. A method of inducing an immune response in a subject, comprising administering to the subject an immunogenic amount of the alphavirus replicon particle of claim 65 in a pharmaceutically acceptable carrier.
72. A method of treating or preventing infection by human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the composition of claim 62 in a pharmaceutically acceptable carrier.
73. A method of treating or preventing infection by human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of the alphavirus replicon particle of claim 65 in a pharmaceutically acceptable carrier.
74. A method of inducing an immune response in a subject, comprising administering to the subject an immunogenic amount of a composition comprising the alphavirus replicon particles of claim 65 in a pharmaceutically acceptable carrier.
75. A method of treating or preventing infection by human immunodeficiency virus in a subject, comprising administering to the subject an immunogenic amount of a composition comprising the alphavirus replicon particles of claim 65 in a pharmaceutically acceptable carrier.


**FIG. 1**

**THIS PAGE BLANK (USPTO)**


2/15

**FIG. 2**


**THIS PAGE BLANK (USPTO)**

**FIG. 3**

THIS PAGE BLANK (USPTO)

**FIG. 4**

**NO PAGE BLANK (USPTO)**

**FIG. 5**

**THIS PAGE BLANK (USP 10)**

6/15




FIG. 6

**THIS PAGE BLANK (USPTO)**

7/15




FIG. 7

**THIS PAGE BLANK (USPTO)**







FIG. 8

**THIS PAGE BLANK (USPTO)**

9/15

**FIG. 9A****FIG. 9B****FIG. 9C**

**THIS PAGE BLANK (USPTO)**




FIG. 10

**THIS PAGE BLANK (USPTO)**




FIG. 11

**THIS PAGE BLANK (USPTO)**




FIG. 12

**REAL BLANK (USPTO)**






FIG. 13

**THIS PAGE BLANK (USPTO)**



**FIG. 14**

**THIS PAGE BLANK (USPTO)**



**FIG. 15**

**THIS PAGE BLANK (USPTO)**

## SEQUENCE LISTING

<110> AlphaVax, Inc. and University of North Carolina

Olmsted, Robert  
 Keith, Paula  
 Drygan, Sergey  
 Daley, Ian  
 Maughan, Maureen  
 Johnston, Robert  
 Davis, Nancy  
 Swanstrom, Ronald

<120> ALPHAVIRUS VECTORS AND VIROSOMES WITH MODIFIED HIV GENES FOR USE AS VACCINES

<130> 01113.0001P1

<150> 60/216,995

<151> 2000-07-07

<160> 19

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 12523

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence; Note =  
 synthetic construct

<400>..1

atgggcgggcg catgagagaa gcccagacca attacctacc caaaatggag aaagttcacg	60
ttgacatcga ggaagacagc ccattcctca gagctttgca gggagcttc ccgagtttg	120
aggtagaagc caagcaggtc actgataatg accatgctaa tgccagagcg ttttcgcac	180
tggcttcaaa actgatcgaa acggaggtgg acccatccga cagatcctt gacattggaa	240
gtgcgcccgc cgcagaatg tattctaagc acaagtatca ttgtatctgt ccgatgagat	300
gtgcggaaga tccggacaga ttgtataagt atgcaactaa gctgaagaaa aactgtaagg	360
aaataactga taaggaattg gacaagaaa tgaaggagct cgcgcgcgtc atgagcgacc	420
ctgacctgga aactgagact atgtgcctcc acgacgacga gtcgtgtcgc tacgaagggc	480
aagtcgctgt ttaccaggat gtatacgogg ttgacggacc gacaagtctc tatcaccaag	540
ccaataaggg agttagagtc gcctactgga taggctttga caccaccctt tttatgttta	600
agaacttggc tggagcatat ccatacact ctaccaactg ggccgacgaa accgtgttaa	660
cggctcgtaa cataggccta tgcagctctg acgttatgga gcggtcacgt agagggatgt	720
ccattcttag aaagaagtat ttgaaaccat ccaacaatgt tctattctct gttggctcga	780
ccatctacca cgagaagagg gacttactga ggagctggca cctgccgtct gtatttcact	840
tacgtggcaa gcaaaattac acatgtcggg gtgagactat agttagttgc gacgggtacg	900
tcgttaaaag aatagctatc agtccaggcc tgtatgggaa gccttcaggc tatgctgcta	960
cgatgcaccg cgagggattc ttgtgctgca aagtgcagca cacattaaac ggggagaggg	1020
tctcttttcc cgtgtgcacg tatgtgccag ctacattgtg tgaccaaag actggcatac	1080
tggcaacaga tgtcagtgcg gacgacgcgc aaaaactgct ggttgggctc aaccagcgta	1140

**THIS PAGE BLANK (USPIC,**

tagtcgtcaa	cggtcgcacc	cagagaaaca	ccaataccat	gaaaaattac	cttttgcccg	1200
tagtggccca	ggcatttgct	aggtgggcaa	aggaatataa	ggaagatcaa	gaagatgaaa	1260
ggccactagg	actacgagat	agacagttag	tcattggggtg	ttgttgggct	tttagaaggc	1320
acaagataac	atctatttat	aagcgcccg	atacccaaac	catcatcaaa	gtgaacagcg	1380
atttccactc	attcgtgctg	cccaggatag	gcagtaacac	attggagatc	gggctgagaa	1440
caagaatcag	gaaaatgtta	gaggagcaca	aggagccgtc	acctctcatt	accgccgagg	1500
acgtacaaga	agctaagtgc	gcagccgatg	aggctaagga	ggtgcgtgaa	gccgaggagt	1560
tgcgcgcagc	tctaccacct	ttggcagctg	atggttagga	gccactctg	gaagccgatg	1620
tgcacttgat	gttacaagag	gctggggccg	gctcagtggg	gacacctcgt	ggcttgataa	1680
aggttaccag	ctacgctggc	gaggacaaga	tcggctctta	cgctgtgctt	tctccgcagg	1740
ctgtactcaa	gagtgaaaaa	ttatcttgca	tccacctct	cgctgaacaa	gtcatagtga	1800
taacacactc	tggccgaaaa	gggcgttatg	ccgtggaacc	ataccatggg	aaagtagtgg	1860
tgccagaggg	acatgcaata	cccgctccagg	actttcaagc	tctgagtga	agtgccacca	1920
ttgtgtacaa	cgaacgtgag	ttcgtaaaaca	ggtacctgca	ccatattgcc	acacatggag	1980
gagcgctgaa	cactgatgaa	gaatattaca	aaactgtcaa	gccagcgag	cacgacggcg	2040
aatacctgta	cgacatcgac	aggaaacagt	gcgtcaagaa	agaactagtc	actgggctag	2100
ggctcacagg	cgagctgggtg	gatcctccct	tccatgaatt	cgctacgag	agtctgagaa	2160
cacgaccagc	cgctccttac	caagtaccaa	ccataggggt	gtatggcggtg	ccaggatcag	2220
gcaagtctgg	catcattaaa	agcgagtc	ccaaaaaaga	tctagtgggtg	agcgccaaga	2280
aagaaaactg	tgcaaaaatt	ataagggacg	tcaagaaaat	gaaagggctg	gacgtcaatg	2340
ccagaactgt	ggactcagtg	ctcttgaatg	gatgcaacaa	cccgtagag	accctgtata	2400
ttgacgaagc	ttttgcttgt	catgcaggta	ctctcagagc	gctcatagcc	attataagac	2460
ctaaaaaggc	agtgtctctg	ggggatccca	aacagtgcgg	tttttttaac	attagtgtgc	2520
tgaagtgca	ttttaaccac	gagatttgca	cacaagctct	ccacaaaagc	atctctcgcc	2580
gttgactact	atctgtgact	tcggctcgtct	caaccttggt	ttacgacaaa	aaaatgagaa	2640
cgacgaatcc	gaaagagact	aagatttgtga	ttgacactac	cggcagtacc	aaacctaaagc	2700
aggacgatct	cattctcact	tggttcagag	gggtgggtgaa	gcagttgcaa	atagattaca	2760
aaggcaacga	aataatgacg	gcagctgcct	ctcaagggct	gacccgtaaa	ggtgtgtatg	2820
ccgttcggta	caaggtgaat	gaaaatcctc	tgtacgcacc	cacctcagaa	catgtgaacg	2880
tcctactgac	ccgcacggag	gaccgcacg	tgtggaaaac	actagccggc	gacccatgga	2940
taaaaacact	gactgccaa	tacctggga	atttcaactgc	cacgatagag	gagtggcaag	3000
cagagcatga	tgccatcatg	aggcacatct	tggagagacc	ggacctacc	gacgtcttcc	3060
agaataaggc	aaacgtgtgt	tgggccaagg	ctttagtgc	ggtgctgaag	accgctggca	3120
tagacatgac	cactgaacaa	tggaaactg	tggattatgt	tgaacggac	aaagctcact	3180
cagcagagat	agtattgaac	caactatgcg	tgaggttctt	tggactcgat	ctggactccg	3240
gtctattttc	tgcacccact	gttccgttat	ccattaggaa	taatcactgg	gataactccc	3300
cgctgcctaa	catgtacggg	ctgaataaag	aagtgggtccg	tcagctctct	cgcaggtacc	3360
cacaactgcc	tcgggcagtt	gccactggaa	gagtcctatga	catgaacact	ggtacactgc	3420
gcaattatga	tcgcgcgata	aacctagtag	ctgtaaacag	aagactgcct	catgctttag	3480
tcctocacca	taatgaacac	ccacagagtg	acttttcttc	attcgtcagc	aaattgaagg	3540
gcagaactgt	cctggtggtc	ggggaaaagt	tgtccgtccc	aggcaaaatg	gttgactggg	3600
tgtcagaccg	gcctgaggct	accttcagag	ctcggttgga	tttaggcac	ccaggtgatg	3660
tgcccaata	tgacataata	tttggttaatg	tgaggacccc	atataaatac	catcactatc	3720
agcagtgtga	agaccatgcc	attaagctta	gcattgtgac	caagaaagct	tgtctgcac	3780
tgaatcccgg	cggaacctgt	gtcagcatag	gttatgggtta	cgctgacagg	gccagcgaaa	3840
gcacattgg	tgctatagcg	cggcagttca	agttttcccg	ggtagcaaa	ccgaaatcct	3900
cacttgaaga	gacggaagtt	ctgtttgtat	tcattgggtta	cgatcgcaag	gcccgtagcg	3960
acaatcctta	caagctttca	tcaaccttga	ccaacattta	tacaggttcc	agactccacg	4020
aagccggatg	tgcacctca	tatcatgtgg	tgcgagggga	tattgccacg	gccaccgaag	4080
gagtgattat	aaatgctgct	aacagcaaag	gacaacctgg	cggaggggtg	tgcggagcgc	4140
tgtataagaa	gttcccggaa	agcttcgatt	tacagccgat	cgaagtagga	aaagcgcgac	4200
tggtcaaaag	tgcagctaaa	catatcattc	atgccgtagg	accaaacttc	aaacaaagttt	4260
cggaggggtg	aggtgacaaa	cagttggcag	aggtctatga	gtccatcgct	aagattgtca	4320
acgataacaa	ttacaagtca	gtagcgattc	cactgttgtc	caccggcatc	ttttccggga	4380
acaaagatcg	actaacccaa	tcattgaacc	atttgcgtgac	agcttttagac	accactgatg	4440

**THIS PAGE BLANK (USMC)**

cagatgtagc	catatactgc	agggacaaga	aatgggaaat	gactctcaag	gaagcagtg	4500
ctaggagaga	agcagtgag	gagatatgca	tatccgacga	ctcttcagtg	acagaacctg	4560
atgcagagct	ggtgagggg	catccgaaga	gttctttggc	tggaaggaag	ggctacagca	4620
caagcgatgg	caaaactttc	tcatatttgg	aagggaacca	gtttcaccag	gcggccaagg	4680
atatagcaga	aattaatgcc	atgtggcccg	ttgcaacgga	ggccaatgag	caggtatgca	4740
tgtatatcct	cggagaaagc	atgagcagta	ttaggtcgaa	atgccccgct	gaagagtcgg	4800
aagcctccac	accacctagc	acgctgcctt	gcttgtgcat	ccatgccatg	actccagaaa	4860
gagtacagcg	cctaaaagcc	tcacgtccag	aacaaattac	tgtgtgctca	tcctttccat	4920
tgccgaagta	tagaatcact	ggtgtgcaga	agatccaatg	ctcccagcct	atattgttct	4980
caccgaaagt	gcttgcgtat	attcatccaa	ggaagtatct	cgtggaaaca	ccaccggtag	5040
acgagactcc	ggagccatcg	gcagagaacc	aatccacaga	ggggacacct	gaacaaccac	5100
cacttataac	cgaggatgag	accaggacta	gaacgcctga	gccgatcatc	atcgaagagg	5160
aagaagagga	tagcataagt	ttgtgtgcag	atggcccagc	ccaccaggtg	ctgcaagtcg	5220
aggcagacat	tcacggggcg	ccctctgtat	ctagctcatc	ctgggtccatt	cctcatgcat	5280
ccgactttga	tgtggacagt	ttatccatac	ttgacaccct	ggagggagct	agcgtgacca	5340
gcggggcaac	gtcagccgag	actaactctt	acttcgcaaa	gagtatggag	tttctggcgc	5400
gaccggtgcc	tgccgctcga	acagtattca	ggaaccctcc	acatcccgtc	ccgcgcacaa	5460
gaacaccgtc	acttgcaacc	agcagggcct	gctcgagaac	cagcctagtt	tcacccccgc	5520
caggcgtgaa	tagggtgatc	actagagagg	agctcgaggc	gcttaccctg	tcacgcactc	5580
ctagcaggtc	ggtctcgaga	accagcctgg	tctccaaccc	gccaggcgta	aataggggtga	5640
ttacaagaga	ggagtttgag	gcgttcgtag	cacaacaaca	atgacggttt	gatgcgggtg	5700
catacatctt	ttcctccgac	accggccaag	ggcatttaca	acaaaaatca	gtaaggcaaa	5760
cgggtgcttc	cgaagtgggtg	ttggagagga	cgaatttga	gatttcgtat	gccccgcgc	5820
tcgaccaaga	aaaagaagaa	ttactacgca	agaaattaca	gttaaatccc	acacctgcta	5880
acagaagcag	ataccagtc	aggaaggtgg	agaacatgaa	agccataaca	gctagacgta	5940
ttctgcaagg	cctagggcat	tatttgaagg	cagaaggaaa	agtggagtgc	taccgaaccc	6000
tgcactcctg	tcctttgtat	tcactagtgt	tgaaccgtgc	cttttcaagc	cccaaggctg	6060
cagtggaaagc	ctgtaacgcc	atggtgaaag	agaactttcc	gactgtgggt	tcttactgta	6120
ttattccaga	gtacgatgcc	tatttggaca	tggttgacgg	agcttcatgc	tgcttagaca	6180
ctgccagttt	ttgccctgca	aagctgcgca	gctttccaaa	gaaacactcc	tatttggaac	6240
ccacaatacg	atcggcagtg	ccttcagcga	tccagaacac	gctccagaac	gtcctggcag	6300
ctgccacaaa	aagaaattgc	aatgtcacgc	aaatgagaga	attgcccgta	ttggattcgg	6360
cggcctttaa	tgtggaatgc	ttcaagaaat	atgcgtgtaa	taatgaatat	tgggaaacgt	6420
ttaaagaaaa	ccccatcagg	cttactgaag	aaaacgtggg	aaattacatt	accaaattaa	6480
aaggacccaaa	agctgctgct	ctttttgcga	agacacataa	tttgaatatg	ttgcaggaca	6540
taccaatgga	caggtttgta	atggacttaa	agagagacgt	gaaagtgact	ccaggaacaa	6600
aacatactga	agaacggccc	aaggtacagg	tgatccaggc	tgccgatccg	ctagcaacag	6660
cgtatctgtg	cggaatccac	cgagagctgg	ttaggagatt	aaatgcgggtc	ctgcttccga	6720
acattcatac	actgtttgat	atgtcggctg	aagactttga	cgctattata	gccgagcact	6780
tccagcctgg	ggattgtggt	ctggaaactg	acatcgcgct	gtttgataaa	agtgaggacg	6840
acgccatggc	tctgaccgcg	ttaatgatcc	tggaagactt	aggtgtggac	gcagagctgt	6900
tgacgctgat	tgaggcggtc	ttcggcgaaa	tttcatcaat	acatttgccc	actaaaacta	6960
aatttaaatt	cggagccatg	atgaaatctg	gaatgttcc	cacactgttt	gtgaacacag	7020
tcattaacat	tgtaatcgca	agcagagtgt	tgagagaacg	gctaaccgga	tcaccatgtg	7080
cagcattcat	tggagatgac	aatatcgtga	aaggagtcaa	atcggacaaa	ttaatggcag	7140
acaggtgcgc	cacctggttg	aatatggaag	tcaagattat	agatgctgtg	gtgggcgaga	7200
aagcgcccta	tttctgtgga	gggtttat	tgtgtgactc	cgtgaccggc	acagcgtgcc	7260
gtgtggcaga	ccccctaaaa	aggctgttta	agcttggcaa	acctctggca	gcagacgatg	7320
aacatgatga	tgacaggaga	agggcattgc	atgaagagtc	aacacgctgg	aaccgagtgg	7380
gtattctttc	agagctgtgc	aaggcagtag	aatcaaggta	tgaaccgta	ggaacttcca	7440
tcatagttat	ggccatgact	actctagcta	gcagtgttaa	atcattcagc	tccttgagag	7500
gggcccctat	aactctctac	ggctaacctg	aatggactac	gacatagtct	agtccgcaaa	7560
gatggctgcg	agagcgtcaa	tattaagagg	ggaaaaatta	gataaatggg	aaaagattag	7620
gttaaggcca	gggggaaaga	aacattatat	gttaaaacac	atagtatggg	cgagcagggg	7680
gctggaaaga	tttgcaacta	accctggcct	tttagaaaca	tcagaaggat	gtaaacaaat	7740

PAGE BLANK (USPTO)

aatgaaacag	ctacaaccag	ctctccagac	aggaacagag	gaacttaaat	cattatacaa	7800
cacagtagca	actctctatt	gtgtacatga	aaagatagaa	gtacgagaca	ccaaggaagc	7860
cttagataag	atagaggaag	aacaaaacaa	atgtcagcaa	aaaacgcagc	aggcaaaagc	7920
ggctgacggg	aaagtcagtc	aaaattatcc	tatagtgcag	aatctccaag	ggcaaatggt	7980
acatcaagcc	atatcaccta	gaaccttgaa	tgcattgggt	aaagtaatag	aagaaaaggc	8040
tttttagccca	gaggtaatac	ccatgtttac	agcattatca	gaaggagcca	ccccacaaga	8100
tttaaacacc	atgttaaata	cagtgggggg	acaccaagca	gccatgcaaa	tgtaaaaaga	8160
tactattaat	gaagaggctg	cagaatggga	tagattacat	ccagtccatg	cggggcctat	8220
tgcaccaggc	cagatgagag	aaccaagggg	aagtgcacata	gcaggaacta	ctagtaccct	8280
tcaggaacaa	atagcatgga	tgacaagtaa	cccacctatt	ccagtgggag	acatctataa	8340
aagatggata	attctggggg	taaaataaaat	agtgagaatg	tatagcccgg	tcagcatttt	8400
ggacataaga	caagggccaa	aggaaccctt	tcgagactat	gtagatcggg	tcttttaaac	8460
tttaagagct	gaacaagcta	cacaagaagt	aaaaaattgg	atgacagaca	ccttggttagt	8520
ccaaaatgcg	aaccagatt	gtaagaccat	tttgagagca	ttaggaccag	gggctacatt	8580
agaagaaatg	atgacagcat	gtcaaggggt	gggaggacct	ggccacaaag	caagagtatt	8640
ggctgaggca	atgagtcaaa	caaacagtgg	aaacataatg	atgcagagaa	gcaattttta	8700
aggccctaga	agaattgtta	aatgttttaa	ctgtggcaag	gaagggcaca	tagccagaaa	8760
ttgcagagcc	cctaggaaaa	aaggctgttg	gaaatgtgga	aaagaaggac	accaaataaa	8820
agactgcact	gagaggcagg	ctaatttttt	agggaaaatt	tggccttccc	acaaggggag	8880
gccaggggaat	ttccttcaga	acagaccaga	gccaacagcc	ccaccagcag	agagcttcag	8940
gttcgaagag	acaacccccg	ctccgaaaca	ggagccgata	gaaagggaac	ccttaacttc	9000
cctcaaatca	ctctttggca	gcgaccctt	gtctcaataa	gagtttaatt	aagtaacgat	9060
acagcagcaa	ttggcaagct	gcttacatag	aactcgcgcc	gattggcatg	ccgcttttaa	9120
atttttat	tatttttctt	ttcttttccg	aatcggat	tgttttta	atttcaaaaa	9180
aaaaaaaa	aaaaaaaa	aaaaaaaa	aaaaaaaa	gggaagagcg	cggccgcgcg	9240
ctgggctacg	ttttgctggc	gttcgcgacg	cgaggctgga	tggccttccc	cattatgatt	9300
cttctcgctt	ccggcgcat	cgggatgcc	gcgttgacag	ccatgctgtc	caggcaggta	9360
gatgacgacc	atcagggaca	gcttcaagga	tcgctcgcg	ctcttaccag	cctaacttcg	9420
atcattggac	cgctgatcgt	cacggcgatt	tatgccgcct	cggcgagcac	atggaacggg	9480
ttggcatgga	ttgtaggcgc	cgccctatac	cttgtctgcc	tccccgcgtt	gcgtcgcggt	9540
gcattggagcc	gggccacctc	gacctgaatg	gaagccggcg	gcacctcgct	aacggattca	9600
ccactccaag	aattggagcc	aatcaattct	tgcggagaac	tgtgaatgcg	caaaccaacc	9660
cttggcagaa	catatccatc	gcgtccgcca	tctccagcag	ccgcacgcgg	cgcattctcg	9720
gcagcggttg	gtcctggcca	cgggtgcgca	tgatcggtgt	cctgtcggtg	aggaccgcgg	9780
taggctggcg	gggttgctt	actggttagc	agaatgaatc	accgatacgc	gagcgaaagt	9840
gaagcgactg	ctgctgcaaa	acgtctgcga	cctgagcaac	aacatgaatg	gtcttcgggt	9900
tccgtgtttc	gtaaagtctg	gaaacgcgga	agtcagcgcc	ctgcaccatt	atgttcggga	9960
tctgcatcgc	aggatgctgc	tggctaccct	gtggaacacc	tacatctgta	ttaacgaagc	10020
gctggcattg	accctgagtg	atttttctct	ggtcccgcgc	catccatacc	gccagttggt	10080
taccttcaca	acgttccagt	aaccgggcat	gttcatcatc	agtaaccctg	atcgtgagca	10140
tcctctctcg	tttcatcggt	atcattaccc	ccatgaacag	aaatccccct	tacacggagg	10200
catcagtgac	caaacaggaa	aaaaccgccc	ttaacatggc	ccgctttatc	agaagccaga	10260
cattaacgct	tctggagaaa	ctcaacgagc	tggacgcgga	tgaacaggca	gacatctgtg	10320
aatcgcttca	cgaccagcgt	gatgagcttt	acgcgagctg	cctcgcgcg	ttcgggtgat	10380
acggtgaaaa	cctctgacac	atgcagctcc	cggagacggg	cacagcttgt	ctgtaagcgg	10440
atgccgggag	cagacaagcc	cgtcaggggc	cgtcagcggg	tggtggcggg	tgctggggcg	10500
cagccatgac	ccagtcacgt	agcgatagcg	gagtggtatac	tggcttaact	atgcggcatc	10560
agagcagatt	gtactgagag	tgcaccattg	cgggtgtgaaa	taccgcacag	atgcgtaagg	10620
agaaaatacc	gcatcaggcg	ctcttcgcgt	tctctgcgtc	ctgactcgct	gcgctcggtc	10680
gttcggctgc	ggcgagcggt	atcagctcac	tcaaaggcgg	taatacgggt	atccacagaa	10740
tcaggggata	acgcaggaaa	gaacatgtga	gcaaaaggcc	agcaaaaggc	caggaaacct	10800
aaaaaggccg	cgttgctggc	gtttttccat	aggctccgcc	cccctgacga	gcatcacaaa	10860
aatcagcgct	caagtcaagag	gtggcgaaac	ccgacaggac	tataaagata	ccaggcggtt	10920
ccccctggaa	gctccctcgt	gcgctctcct	gttccgaccc	tgccgcttac	ccgataacct	10980
tccgcctttc	tcccttcggg	aagcgtggcg	ctttctcata	gctcacgctg	taggtatctc	11040

**THIS PAGE BLANK (USPTO)**

```

agttcgggtgt aggtcgttcg ctccaagctg ggctgtgtgc acgaaccccc cgttcagccc 11100
gaccgctgcg ccttatccgg taactatcgt cttgagtcca acccggttaag acacgactta 11160
tcgccactgg cagcagccac tggtaacagg attagcagag cgaggatatgt aggcggtgct 11220
acagagttct tgaagtgggtg gcctaactac ggctacacta gaaggacagt atttggttatc 11280
tgcgctctgc tgaagccagt taccttcgga aaaagagttg gtagctcttg atccggcaaa 11340
caaaccaccg ctggtagcgg tggttttttt gtttgcaagc agcagattac gcgcagaaaa 11400
aaaggatctc aagaagatcc tttgatctt tctacggggt ctgacgctca gtggaacgaa 11460
aactcacgtt aagggatttt ggtcatgaac aataaaactg tctgcttaca taaacagtaa 11520
tacaaggggt gttatgagcc atattcaacg ggaaacgtct tgctcgaggc cgcgattaaa 11580
ttccaacatg gatgctgatt tatatgggta taaatgggct cgcgataatg tcgggcaatc 11640
aggtgcgaca atctatcgat tgtatgggaa gcccgatgcg ccagagttgt ttctgaaaca 11700
tggcaaaggt agcgttgcca atgatgttac agatgagatg gtcagactaa actggctgac 11760
ggaatttatg cctcttccga ccatcaagca ttttatccgt actcctgatg atgcatgggt 11820
actcaccact gcgatccccg ggaaaacagc attccaggta ttagaagaat atcctgattc 11880
aggtgaaaat attgttgatg cgctggcagt gttcctgcgc cggttgcatt cgattcctgt 11940
ttgtaattgt ctttttaaca gcgatcgctg atttcgtctc gctcaggcgc aatcacgaat 12000
gaataacggt ttggttgatg cgagtgatgt tgatgacgag cgtaatggct ggcctgttga 12060
acaagtctgg aaagaaatgc ataagctttt gccattctca ccggaattcag tcgtcactca 12120
tgggtatttc tcaattgata accttatttt tgacgagggg aaattaatag gttgtattga 12180
tgttggacga gtcggaatcg cagaccgata ccaggatctt gccatcctat ggaactgcct 12240
cggtagttt tctccttcat tacagaaacg gctttttcaa aaatatggta ttgataatcc 12300
tgatatgaat aaattgcagt ttcatttgat gctcgatgag tttttctaag aattctcatg 12360
tttgacagct tatcatcgat aagctttaat gcggtagttt atcacagtta aattgctaac 12420
gcagtcaggc accgtgtatg aaatctaaca atgcgctcat cgtcatcctc ggcaccgtca 12480
ccctggatgc tgtctagagg atccctaata cgactcacta tag 12523

```

&lt;210&gt; 2

&lt;211&gt; 7479

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence; Note =  
synthetic construct

&lt;221&gt; CDS

&lt;222&gt; (1)...(7479)

&lt;400&gt; 2

```

atg gag aaa gtt cac gtt gac atc gag gaa gac agc cca ttc ctc aga 48
Met Glu Lys Val His Val Asp Ile Glu Glu Asp Ser Pro Phe Leu Arg
1 5 10 15

```

```

gct ttg cag cgg agc ttc ccg cag ttt gag gta gaa gcc aag cag gtc 96
Ala Leu Gln Arg Ser Phe Pro Gln Phe Glu Val Glu Ala Lys Gln Val
20 25 30

```

```

act gat aat gac cat gct aat gcc aga gcg ttt tcg cat ctg gct tca 144
Thr Asp Asn Asp His Ala Asn Ala Arg Ala Phe Ser His Leu Ala Ser
35 40 45

```

```

aaa ctg atc gaa acg gag gtg gac cca tcc gac acg atc ctt gac att 192
Lys Leu Ile Glu Thr Glu Val Asp Pro Ser Asp Thr Ile Leu Asp Ile
50 55 60

```

**THIS PAGE BLANK (USPTO)**

gga agt gcg ccc gcc cgc aga atg tat tct aag cac aag tat cat tgt	240
Gly Ser Ala Pro Ala Arg Arg Met Tyr Ser Lys His Lys Tyr His Cys	
65 70 75 80	
atc tgt ccg atg aga tgt gcg gaa gat ccg gac aga ttg tat aag tat	288
Ile Cys Pro Met Arg Cys Ala Glu Asp Pro Asp Arg Leu Tyr Lys Tyr	
85 90 95	
gca act aag ctg aag aaa aac tgt aag gaa ata act gat aag gaa ttg	336
Ala Thr Lys Leu Lys Lys Asn Cys Lys Glu Ile Thr Asp Lys Glu Leu	
100 105 110	
gac aag aaa atg aag gag ctc gcc gcc gtc atg agc gac cct gac ctg	384
Asp Lys Lys Met Lys Glu Leu Ala Ala Val Met Ser Asp Pro Asp Leu	
115 120 125	
gaa act gag act atg tgc ctc cac gac gac gag tgc tgt cgc tac gaa	432
Glu Thr Glu Thr Met Cys Leu His Asp Asp Glu Ser Cys Arg Tyr Glu	
130 135 140	
ggg caa gtc gct gtt tac cag gat gta tac gcg gtt gac gga ccg aca	480
Gly Gln Val Ala Val Tyr Gln Asp Val Tyr Ala Val Asp Gly Pro Thr	
145 150 155 160	
agt ctc tat cac caa gcc aat aag gga gtt aga gtc gcc tac tgg ata	528
Ser Leu Tyr His Gln Ala Asn Lys Gly Val Arg Val Ala Tyr Trp Ile	
165 170 175	
ggc ttt gac acc acc cct ttt atg ttt aag aac ttg gct gga gca tat	576
Gly Phe Asp Thr Thr Pro Phe Met Phe Lys Asn Leu Ala Gly Ala Tyr	
180 185 190	
cca tca tac tct acc aac tgg gcc gac gaa acc gtg tta acg gct cgt	624
Pro Ser Tyr Ser Thr Asn Trp Ala Asp Glu Thr Val Leu Thr Ala Arg	
195 200 205	
aac ata ggc cta tgc agc tct gac gtt atg gag cgg tca cgt aga ggg	672
Asn Ile Gly Leu Cys Ser Ser Asp Val Met Glu Arg Ser Arg Arg Gly	
210 215 220	
atg tcc att ctt aga aag aag tat ttg aaa cca tcc aac aat gtt cta	720
Met Ser Ile Leu Arg Lys Lys Tyr Leu Lys Pro Ser Asn Asn Val Leu	
225 230 235 240	
ttc tct gtt ggc tgc acc atc tac cac gag aag agg gac tta ctg agg	768
Phe Ser Val Gly Ser Thr Ile Tyr His Glu Lys Arg Asp Leu Leu Arg	
245 250 255	
agc tgg cac ctg ccg tct gta ttt cac tta cgt ggc aag caa aat tac	816
Ser Trp His Leu Pro Ser Val Phe His Leu Arg Gly Lys Gln Asn Tyr	
260 265 270	
aca tgt ccg tgt gag act ata gtt agt tgc gac ggg tac gtc gtt aaa	864
Thr Cys Arg Cys Glu Thr Ile Val Ser Cys Asp Gly Tyr Val Val Lys	
275 280 285	

**PAGE BLANK (USPTO)**

aga ata gct atc agt cca ggc ctg tat ggg aag cct tca ggc tat gct Arg Ile Ala Ile Ser Pro Gly Leu Tyr Gly Lys Pro Ser Gly Tyr Ala 290 295 300	912
gct acg atg cac cgc gag gga ttc ttg tgc tgc aaa gtg aca gac aca Ala Thr Met His Arg Glu Gly Phe Leu Cys Cys Lys Val Thr Asp Thr 305 310 315 320	960
tta aac ggg gag agg gtc tct ttt ccc gtg tgc acg tat gtg cca gct Leu Asn Gly Glu Arg Val Ser Phe Pro Val Cys Thr Tyr Val Pro Ala 325 330 335	1008
aca ttg tgt gac caa atg act ggc ata ctg gca aca gat gtc agt gcg Thr Leu Cys Asp Gln Met Thr Gly Ile Leu Ala Thr Asp Val Ser Ala 340 345 350	1056
gac gac gcg caa aaa ctg ctg gtt ggg ctc aac cag cgt ata gtc gtc Asp Asp Ala Gln Lys Leu Leu Val Gly Leu Asn Gln Arg Ile Val Val 355 360 365	1104
aac ggt cgc acc cag aga aac acc aat acc atg aaa aat tac ctt ttg Asn Gly Arg Thr Gln Arg Asn Thr Asn Thr Met Lys Asn Tyr Leu Leu 370 375 380	1152
ccc gta gtg gcc cag gca ttt gct agg tgg gca aag gaa tat aag gaa Pro Val Val Ala Gln Ala Phe Ala Arg Trp Ala Lys Glu Tyr Lys Glu 385 390 395 400	1200
gat caa gaa gat gaa agg cca cta gga cta cga gat aga cag tta gtc Asp Gln Glu Asp Glu Arg Pro Leu Gly Leu Arg Asp Arg Gln Leu Val 405 410 415	1248
atg ggg tgt tgt tgg gct ttt aga agg cac aag ata aca tct att tat Met Gly Cys Cys Trp Ala Phe Arg Arg His Lys Ile Thr Ser Ile Tyr 420 425 430	1296
aag cgc ccg gat acc caa acc atc atc aaa gtg aac agc gat ttc cac Lys Arg Pro Asp Thr Gln Thr Ile Ile Lys Val Asn Ser Asp Phe His 435 440 445	1344
tca ttc gtg ctg ccc agg ata ggc agt aac aca ttg gag atc ggg ctg Ser Phe Val Leu Pro Arg Ile Gly Ser Asn Thr Leu Glu Ile Gly Leu 450 455 460	1392
aga aca aga atc agg aaa atg tta gag gag cac aag gag ccg tca cct Arg Thr Arg Ile Arg Lys Met Leu Glu Glu His Lys Glu Pro Ser Pro 465 470 475 480	1440
ctc att acc gcc gag gac gta caa gaa gct aag tgc gca gcc gat gag Leu Ile Thr Ala Glu Asp Val Gln Glu Ala Lys Cys Ala Ala Asp Glu 485 490 495	1488
gct aag gag gtg cgt gaa gcc gag gag ttg cgc gca gct cta cca cct Ala Lys Glu Val Arg Glu Ala Glu Glu Leu Arg Ala Ala Leu Pro Pro 500 505 510	1536

**THIS PAGE BLANK (USPTO)**

ttg gca gct gat gtt gag gag ccc act ctg gaa gcc gat gtc gac ttg	1584
Leu Ala Ala Asp Val Glu Glu Pro Thr Leu Glu Ala Asp Val Asp Leu	
515 520 525	
atg tta caa gag gct ggg gcc ggc tca gtg gag aca cct cgt ggc ttg	1632
Met Leu Gln Glu Ala Gly Ala Gly Ser Val Glu Thr Pro Arg Gly Leu	
530 535 540	
ata aag gtt acc agc tac gct ggc gag gac aag atc ggc tct tac gct	1680
Ile Lys Val Thr Ser Tyr Ala Gly Glu Asp Lys Ile Gly Ser Tyr Ala	
545 550 555 560	
gtg ctt tct ccg cag gct gta ctc aag agt gaa aaa tta tct tgc atc	1728
Val Leu Ser Pro Gln Ala Val Leu Lys Ser Glu Lys Leu Ser Cys Ile	
565 570 575	
cac cct ctc gct gaa caa gtc ata gtg ata aca cac tct ggc cga aaa	1776
His Pro Leu Ala Glu Gln Val Ile Val Ile Thr His Ser Gly Arg Lys	
580 585 590	
ggg cgt tat gcc gtg gaa cca tac cat ggt aaa gta gtg gtg cca gag	1824
Gly Arg Tyr Ala Val Glu Pro Tyr His Gly Lys Val Val Val Pro Glu	
595 600 605	
gga cat gca ata ccc gtc cag gac ttt caa gct ctg agt gaa agt gcc	1872
Gly His Ala Ile Pro Val Gln Asp Phe Gln Ala Leu Ser Glu Ser Ala	
610 615 620	
acc att gtg tac aac gaa cgt gag ttc gta aac agg tac ctg cac cat	1920
Thr Ile Val Tyr Asn Glu Arg Glu Phe Val Asn Arg Tyr Leu His His	
625 630 635 640	
att gcc aca cat gga gga gcg ctg aac act gat gaa gaa tat tac aaa	1968
Ile Ala Thr His Gly Gly Ala Leu Asn Thr Asp Glu Glu Tyr Tyr Lys	
645 650 655	
act gtc aag ccc agc gag cac gac ggc gaa tac ctg tac gac atc gac	2016
Thr Val Lys Pro Ser Glu His Asp Gly Glu Tyr Leu Tyr Asp Ile Asp	
660 665 670	
agg aaa cag tgc gtc aag aaa gaa cta gtc act ggg cta ggg ctc aca	2064
Arg Lys Gln Cys Val Lys Lys Glu Leu Val Thr Gly Leu Gly Leu Thr	
675 680 685	
ggc gag ctg gtg gat cct ccc ttc cat gaa ttc gcc tac gag agt ctg	2112
Gly Glu Leu Val Asp Pro Pro Phe His Glu Phe Ala Tyr Glu Ser Leu	
690 695 700	
aga aca cga cca gcc gct cct tac caa gta cca acc ata ggg gtg tat	2160
Arg Thr Arg Pro Ala Ala Pro Tyr Gln Val Pro Thr Ile Gly Val Tyr	
705 710 715 720	
ggc gtg cca gga tca ggc aag tct ggc atc att aaa agc gca gtc acc	2208
Gly Val Pro Gly Ser Gly Lys Ser Gly Ile Ile Lys Ser Ala Val Thr	
725 730 735	

**THIS PAGE BLANK (USPTO)**

aaa aaa gat cta gtg gtg agc gcc aag aaa gaa aac tgt gca gaa att	2256
Lys Lys Asp Leu Val Val Ser Ala Lys Lys Glu Asn Cys Ala Glu Ile	
740 745 750	
ata agg gac gtc aag aaa atg aaa ggg ctg gac gtc aat gcc aga act	2304
Ile Arg Asp Val Lys Lys Met Lys Gly Leu Asp Val Asn Ala Arg Thr	
755 760 765	
gtg gac tca gtg ctc ttg aat gga tgc aaa cac ccc gta gag acc ctg	2352
Val Asp Ser Val Leu Leu Asn Gly Cys Lys His Pro Val Glu Thr Leu	
770 775 780	
tat att gac gaa gct ttt gct tgt cat gca ggt act ctc aga gcg ctc	2400
Tyr Ile Asp Glu Ala Phe Ala Cys His Ala Gly Thr Leu Arg Ala Leu	
785 790 795 800	
ata gcc att ata aga cct aaa aag gca gtg ctc tgc ggg gat ccc aaa	2448
Ile Ala Ile Ile Arg Pro Lys Lys Ala Val Leu Cys Gly Asp Pro Lys	
805 810 815	
cag tgc ggt ttt ttt aac atg atg tgc ctg aaa gtg cat ttt aac cac	2496
Gln Cys Gly Phe Phe Asn Met Met Cys Leu Lys Val His Phe Asn His	
820 825 830	
gag att tgc aca caa gtc ttc cac aaa agc atc tct cgc cgt tgc act	2544
Glu Ile Cys Thr Gln Val Phe His Lys Ser Ile Ser Arg Arg Cys Thr	
835 840 845	
aaa tct gtg act tcg gtc gtc tca acc ttg ttt tac gac aaa aaa atg	2592
Lys Ser Val Thr Ser Val Val Ser Thr Leu Phe Tyr Asp Lys Lys Met	
850 855 860	
aga acg acg aat ccg aaa gag act aag att gtg att gac act acc ggc	2640
Arg Thr Thr Asn Pro Lys Glu Thr Lys Ile Val Ile Asp Thr Thr Gly	
865 870 875 880	
agt acc aaa cct aag cag gac gat ctc att ctc act tgt ttc aga ggg	2688
Ser Thr Lys Pro Lys Gln Asp Asp Leu Ile Leu Thr Cys Phe Arg Gly	
885 890 895	
tgg gtg aag cag ttg caa ata gat tac aaa ggc aac gaa ata atg acg	2736
Trp Val Lys Gln Leu Gln Ile Asp Tyr Lys Gly Asn Glu Ile Met Thr	
900 905 910	
gca gct gcc tct caa ggg ctg acc cgt aaa ggt gtg tat gcc gtt cgg	2784
Ala Ala Ala Ser Gln Gly Leu Thr Arg Lys Gly Val Tyr Ala Val Arg	
915 920 925	
tac aag gtg aat gaa aat cct ctg tac gca ccc acc tca gaa cat gtg	2832
Tyr Lys Val Asn Glu Asn Pro Leu Tyr Ala Pro Thr Ser Glu His Val	
930 935 940	
aac gtc cta ctg acc cgc gag gac cgc atc gtg tgg aaa aca cta	2880
Asn Val Leu Leu Thr Arg Thr Glu Asp Arg Ile Val Trp Lys Thr Leu	
945 950 955 960	

**THIS PAGE BLANK (USP)**

gcc ggc gac cca tgg ata aaa aca ctg act gcc aag tac cct ggg aat	2928
Ala Gly Asp Pro Trp Ile Lys Thr Leu Thr Ala Lys Tyr Pro Gly Asn	
965 970 975	
ttc act gcc acg ata gag gag tgg caa gca gag cat gat gcc atc atg	2976
Phe Thr Ala Thr Ile Glu Glu Trp Gln Ala Glu His Asp Ala Ile Met	
980 985 990	
agg cac atc ttg gag aga ccg gac cct acc gac gtc ttc cag aat aag	3024
Arg His Ile Leu Glu Arg Pro Asp Pro Thr Asp Val Phe Gln Asn Lys	
995 1000 1005	
gca aac gtg tgt tgg gcc aag gct tta gtg ccg gtg ctg aag acc gct	3072
Ala Asn Val Cys Trp Ala Lys Ala Leu Val Pro Val Leu Lys Thr Ala	
1010 1015 1020	
ggc ata gac atg acc act gaa caa tgg aac act gtg gat tat ttt gaa	3120
Gly Ile Asp Met Thr Thr Glu Gln Trp Asn Thr Val Asp Tyr Phe Glu	
1025 1030 1035 1040	
acg gac aaa gct cac tca gca gag ata gta ttg aac caa cta tgc gtg	3168
Thr Asp Lys Ala His Ser Ala Glu Ile Val Leu Asn Gln Leu Cys Val	
1045 1050 1055	
agg ttc ttt gga ctc gat ctg gac tcc ggt cta ttt tct gca ccc act	3216
Arg Phe Phe Gly Leu Asp Leu Asp Ser Gly Leu Phe Ser Ala Pro Thr	
1060 1065 1070	
gtt ccg tta tcc att agg aat aat cac tgg gat aac tcc ccg tgc cct	3264
Val Pro Leu Ser Ile Arg Asn Asn His Trp Asp Asn Ser Pro Ser Pro	
1075 1080 1085	
aac atg tac ggg ctg aat aaa gaa gtg gtc cgt cag ctc tct cgc agg	3312
Asn Met Tyr Gly Leu Asn Lys Glu Val Val Arg Gln Leu Ser Arg Arg	
1090 1095 1100	
tac cca caa ctg cct cgg gca gtt gcc act gga aga gtc tat gac atg	3360
Tyr Pro Gln Leu Pro Arg Ala Val Ala Thr Gly Arg Val Tyr Asp Met	
1105 1110 1115 1120	
aac act ggt aca ctg cgc aat tat gat ccg cgc ata aac cta gta cct	3408
Asn Thr Gly Thr Leu Arg Asn Tyr Asp Pro Arg Ile Asn Leu Val Pro	
1125 1130 1135	
gta aac aga aga ctg cct cat gct tta gtc ctc cac cat aat gaa cac	3456
Val Asn Arg Arg Leu Pro His Ala Leu Val Leu His His Asn Glu His	
1140 1145 1150	
cca cag agt gac ttt tct tca ttc gtc agc aaa ttg aag ggc aga act	3504
Pro Gln Ser Asp Phe Ser Ser Phe Val Ser Lys Leu Lys Gly Arg Thr	
1155 1160 1165	
gtc ctg gtg gtc ggg gaa aag ttg tcc gtc cca ggc aaa atg gtt gac	3552
Val Leu Val Val Gly Glu Lys Leu Ser Val Pro Gly Lys Met Val Asp	
1170 1175 1180	

**THIS PAGE BLANK (USPTO)**

11

tg tca gac cgg cct gag gct acc ttc aga gct cgg ctg gat tta	3600
eu Ser Asp Arg Pro Glu Ala Thr Phe Arg Ala Arg Leu Asp Leu	
1190 1195 1200	
tc cca ggt gat gtg ccc aaa tat gac ata ata ttt gtt aat gtg	3648
le Pro Gly Asp Val Pro Lys Tyr Asp Ile Ile Phe Val Asn Val	
1205 1210 1215	
cc cca tat aaa tac cat cac tat cag cag tgt gaa gac cat gcc	3696
hr Pro Tyr Lys Tyr His His Tyr Gln Gln Cys Glu Asp His Ala	
1220 1225 1230	
ag ctt agc atg ttg acc aag aaa gct tgt ctg cat ctg aat ccc	3744
ys Leu Ser Met Leu Thr Lys Lys Ala Cys Leu His Leu Asn Pro	
1235 1240 1245	
ga acc tgt gtc agc ata ggt tat ggt tac gct gac agg gcc agc	3792
ly Thr Cys Val Ser Ile Gly Tyr Gly Tyr Ala Asp Arg Ala Ser	
250 1255 1260	
gc atc att ggt gct ata gcg cgg cag ttc aag ttt tcc cgg gta	3840
er Ile Ile Gly Ala Ile Ala Arg Gln Phe Lys Phe Ser Arg Val	
1270 1275 1280	
aa ccg aaa tcc tca ctt gaa gag acg gaa gtt ctg ttt gta ttc	3888
ys Pro Lys Ser Ser Leu Glu Glu Thr Glu Val Leu Phe Val Phe	
1285 1290 1295	
gg tac gat cgc aag gcc cgt acg cac aat cct tac aag ctt tca	3936
ly Tyr Asp Arg Lys Ala Arg Thr His Asn Pro Tyr Lys Leu Ser	
1300 1305 1310	
cc ttg acc aac att tat aca ggt tcc aga ctc cac gaa gcc gga	3984
hr Leu Thr Asn Ile Tyr Thr Gly Ser Arg Leu His Glu Ala Gly	
1315 1320 1325	
ca ccc tca tat cat gtg gtg cga ggg gat att gcc acg gcc acc	4032
la Pro Ser Tyr His Val Val Arg Gly Asp Ile Ala Thr Ala Thr	
330 1335 1340	
ga gtg att ata aat gct gct aac agc aaa gga caa cct ggc gga	4080
ly Val Ile Ile Asn Ala Ala Asn Ser Lys Gly Gln Pro Gly Gly	
1350 1355 1360	
tg tgc gga gcg ctg tat aag aag ttc ccg gaa agc ttc gat tta	4128
al Cys Gly Ala Leu Tyr Lys Lys Phe Pro Glu Ser Phe Asp Leu	
1365 1370 1375	
cg atc gaa gta gga aaa gcg cga ctg gtc aaa ggt gca gct aaa	4176
ro Ile Glu Val Gly Lys Ala Arg Leu Val Lys Gly Ala Ala Lys	
1380 1385 1390	
tc att cat gcc gta gga cca aac ttc aac aaa gtt tcg gag gtt	4224
le Ile His Ala Val Gly Pro Asn Phe Asn Lys Val Ser Glu Val	
1395 1400 1405	

**THIS PAGE BLANK (USPTO)**

gaa ggt gac aaa cag ttg gca gag gct tat gag tcc atc gct aag att Glu Gly Asp Lys Gln Leu Ala Glu Ala Tyr Glu Ser Ile Ala Lys Ile 1410 1415 1420	4272
gtc aac gat aac aat tac aag tca gta gcg att cca ctg ttg tcc acc Val Asn Asp Asn Asn Tyr Lys Ser Val Ala Ile Pro Leu Leu Ser Thr 1425 1430 1435 1440	4320
ggc atc ttt tcc ggg aac aaa gat cga cta acc caa tca ttg aac cat Gly Ile Phe Ser Gly Asn Lys Asp Arg Leu Thr Gln Ser Leu Asn His 1445 1450 1455	4368
ttg ctg aca gct tta gac acc act gat gca gat gta gcc ata tac tgc Leu Leu Thr Ala Leu Asp Thr Thr Asp Ala Asp Val Ala Ile Tyr Cys 1460 1465 1470	4416
agg gac aag aaa tgg gaa atg act ctc aag gaa gca gtg gct agg aga Arg Asp Lys Lys Trp Glu Met Thr Leu Lys Glu Ala Val Ala Arg Arg 1475 1480 1485	4464
gaa gca gtg gag gag ata tgc ata tcc gac gac tct tca gtg aca gaa Glu Ala Val Glu Glu Ile Cys Ile Ser Asp Asp Ser Ser Val Thr Glu 1490 1495 1500	4512
cct gat gca gag ctg gtg agg gtg cat ccg aag agt tct ttg gct gga Pro Asp Ala Glu Leu Val Arg Val His Pro Lys Ser Ser Leu Ala Gly 1505 1510 1515 1520	4560
agg aag ggc tac agc aca agc gat ggc aaa act ttc tca tat ttg gaa Arg Lys Gly Tyr Ser Thr Ser Asp Gly Lys Thr Phe Ser Tyr Leu Glu 1525 1530 1535	4608
ggg acc aag ttt cac cag gcg gcc aag gat ata gca gaa att aat gcc Gly Thr Lys Phe His Gln Ala Ala Lys Asp Ile Ala Glu Ile Asn Ala 1540 1545 1550	4656
atg tgg ccc gtt gca acg gag gcc aat gag cag gta tgc atg tat atc Met Trp Pro Val Ala Thr Glu Ala Asn Glu Gln Val Cys Met Tyr Ile 1555 1560 1565	4704
ctc gga gaa agc atg agc agt att agg tcg aaa tgc ccc gtc gaa gag Leu Gly Glu Ser Met Ser Ser Ile Arg Ser Lys Cys Pro Val Glu Glu 1570 1575 1580	4752
tcg gaa gcc tcc aca cca cct agc acg ctg cct tgc ttg tgc atc cat Ser Glu Ala Ser Thr Pro Pro Ser Thr Leu Pro Cys Leu Cys Ile His 1585 1590 1595 1600	4800
gcc atg act cca gaa aga gta cag cgc cta aaa gcc tca cgt cca gaa Ala Met Thr Pro Glu Arg Val Gln Arg Leu Lys Ala Ser Arg Pro Glu 1605 1610 1615	4848
caa att act gtg tgc tca tcc ttt cca ttg ccg aag tat aga atc act Gln Ile Thr Val Cys Ser Ser Phe Pro Leu Pro Lys Tyr Arg Ile Thr 1620 1625 1630	4896

**THIS PAGE BLANK (USPTO)**

ggc gtc cag aag atc caa tgc tcc cag cct ata ttg ttc tca ccg aaa	4944
Gly Val Gln Lys Ile Gln Cys Ser Gln Pro Ile Leu Phe Ser Pro Lys	
1635 1640 1645	
gtg cct gcg tat att cat cca agg aag tat ctc gtg gaa aca cca ccg	4992
Val Pro Ala Tyr Ile His Pro Arg Lys Tyr Leu Val Glu Thr Pro Pro	
1650 1655 1660	
gta gac gag act ccg gag cca tcg gca gag aac caa tcc aca gag ggg	5040
Val Asp Glu Thr Pro Glu Pro Ser Ala Glu Asn Gln Ser Thr Glu Gly	
1665 1670 1675 1680	
aca cct gaa caa cca cca ctt ata acc gag gat gag acc agg act aga	5088
Thr Pro Glu Gln Pro Pro Leu Ile Thr Glu Asp Glu Thr Arg Thr Arg	
1685 1690 1695	
acg cct gag ccg atc atc atc gaa gag gaa gaa gag gat agc ata agt	5136
Thr Pro Glu Pro Ile Ile Ile Glu Glu Glu Glu Glu Asp Ser Ile Ser	
1700 1705 1710	
ttg ctg tca gat ggc ccg acc cac cag gtg ctg caa gtc gag gca gac	5184
Leu Leu Ser Asp Gly Pro Thr His Gln Val Leu Gln Val Glu Ala Asp	
1715 1720 1725	
att cac ggg ccg ccc tct gta tct agc tca tcc tgg tcc att cct cat	5232
Ile His Gly Pro Pro Ser Val Ser Ser Ser Trp Ser Ile Pro His	
1730 1735 1740	
gca tcc gac ttt gat gtg gac agt tta tcc ata ctt gac acc ctg gag	5280
Ala Ser Asp Phe Asp Val Asp Ser Leu Ser Ile Leu Asp Thr Leu Glu	
1745 1750 1755 1760	
gga gct agc gtg acc agc ggg gca acg tca gcc gag act aac tct tac	5328
Gly Ala Ser Val Thr Ser Gly Ala Thr Ser Ala Glu Thr Asn Ser Tyr	
1765 1770 1775	
ttc gca aag agt atg gag ttt ctg gcg cga ccg gtg cct gcg cct cga	5376
Phe Ala Lys Ser Met Glu Phe Leu Ala Arg Pro Val Pro Ala Pro Arg	
1780 1785 1790	
aca gta ttc agg aac cct cca cat ccc gct ccg cgc aca aga aca ccg	5424
Thr Val Phe Arg Asn Pro Pro His Pro Ala Pro Arg Thr Arg Thr Pro	
1795 1800 1805	
tca ctt gca ccc agc agg gcc tgc tcg aga acc agc cta gtt tcc acc	5472
Ser Leu Ala Pro Ser Arg Ala Cys Ser Arg Thr Ser Leu Val Ser Thr	
1810 1815 1820	
ccg cca ggc gtg aat agg gtg atc act aga gag gag ctc gag gcg ctt	5520
Pro Pro Gly Val Asn Arg Val Ile Thr Arg Glu Glu Leu Glu Ala Leu	
1825 1830 1835 1840	
acc ccg tca cgc act cct agc agg tcg gtc tcg aga acc agc ctg gtc	5568
Thr Pro Ser Arg Thr Pro Ser Arg Ser Val Ser Arg Thr Ser Leu Val	
1845 1850 1855	

**THIS PAGE BLANK (USPTO)**

tcc aac ccg cca ggc gta aat agg gtg att aca aga gag gag ttt gag	5616
Ser Asn Pro Pro Gly Val Asn Arg Val Ile Thr Arg Glu Glu Phe Glu	
1860 1865 1870	
gcg ttc gta gca caa caa caa tga cgg ttt gat gcg ggt gca tac atc	5664
Ala Phe Val Ala Gln Gln Gln * Arg Phe Asp Ala Gly Ala Tyr Ile	
1875 1880 1885	
ttt tcc tcc gac acc ggt caa ggg cat tta caa caa aaa tca gta agg	5712
Phe Ser Ser Asp Thr Gly Gln Gly His Leu Gln Gln Lys Ser Val Arg	
1890 1895 1900	
caa acg gtg cta tcc gaa gtg gtg ttg gag agg acc gaa ttg gag att	5760
Gln Thr Val Leu Ser Glu Val Val Leu Glu Arg Thr Glu Leu Glu Ile	
1905 1910 1915	
tcg tat gcc ccg cgc ctc gac caa gaa aaa gaa gaa tta cta cgc aag	5808
Ser Tyr Ala Pro Arg Leu Asp Gln Glu Lys Glu Glu Leu Leu Arg Lys	
1920 1925 1930 1935	
aaa tta cag tta aat ccc aca cct gct aac aga agc aga tac cag tcc	5856
Lys Leu Gln Leu Asn Pro Thr Pro Ala Asn Arg Ser Arg Tyr Gln Ser	
1940 1945 1950	
agg aag gtg gag aac atg aaa gcc ata aca gct aga cgt att ctg caa	5904
Arg Lys Val Glu Asn Met Lys Ala Ile Thr Ala Arg Arg Ile Leu Gln	
1955 1960 1965	
ggc cta ggg cat tat ttg aag gca gaa gga aaa gtg gag tgc tac cga	5952
Gly Leu Gly His Tyr Leu Lys Ala Glu Gly Lys Val Glu Cys Tyr Arg	
1970 1975 1980	
acc ctg cat cct gtt cct ttg tat tca tct agt gtg aac cgt gcc ttt	6000
Thr Leu His Pro Val Pro Leu Tyr Ser Ser Ser Val Asn Arg Ala Phe	
1985 1990 1995	
tca agc ccc aag gtc gca gtg gaa gcc tgt aac gcc atg ttg aaa gag	6048
Ser Ser Pro Lys Val Ala Val Glu Ala Cys Asn Ala Met Leu Lys Glu	
2000 2005 2010 2015	
aac ttt ccg act gtg gct tct tac tgt att att cca gag tac gat gcc	6096
Asn Phe Pro Thr Val Ala Ser Tyr Cys Ile Ile Pro Glu Tyr Asp Ala	
2020 2025 2030	
tat ttg gac atg gtt gac gga gct tca tgc tgc tta gac act gcc agt	6144
Tyr Leu Asp Met Val Asp Gly Ala Ser Cys Cys Leu Asp Thr Ala Ser	
2035 2040 2045	
ttt tgc cct gca aag ctg cgc agc ttt cca aag aaa cac tcc tat ttg	6192
Phe Cys Pro Ala Lys Leu Arg Ser Phe Pro Lys Lys His Ser Tyr Leu	
2050 2055 2060	
gaa ccc aca ata cga tcg gca gtg cct tca gcg atc cag aac acg ctc	6240
Glu Pro Thr Ile Arg Ser Ala Val Pro Ser Ala Ile Gln Asn Thr Leu	
2065 2070 2075	

**THIS PAGE BLANK (USPTO)**

cag aac gtc ctg gca gct gcc aca aaa aga aat tgc aat gtc acg caa	6288
Gln Asn Val Leu Ala Ala Ala Thr Lys Arg Asn Cys Asn Val Thr Gln	
2080 2085 2090 2095	
atg aga gaa ttg ccc gta ttg gat tcg gcg gcc ttt aat gtg gaa tgc	6336
Met Arg Glu Leu Pro Val Leu Asp Ser Ala Ala Phe Asn Val Glu Cys	
2100 2105 2110	
ttc aag aaa tat gcg tgt aat aat gaa tat tgg gaa acg ttt aaa gaa	6384
Phe Lys Lys Tyr Ala Cys Asn Asn Glu Tyr Trp Glu Thr Phe Lys Glu	
2115 2120 2125	
aac ccc atc agg ctt act gaa gaa aac gtg gta aat tac att acc aaa	6432
Asn Pro Ile Arg Leu Thr Glu Glu Asn Val Val Asn Tyr Ile Thr Lys	
2130 2135 2140	
tta aaa gga cca aaa gct gct gct ctt ttt gcg aag aca cat aat ttg	6480
Leu Lys Gly Pro Lys Ala Ala Ala Leu Phe Ala Lys Thr His Asn Leu	
2145 2150 2155	
aat atg ttg cag gac ata cca atg gac agg ttt gta atg gac tta aag	6528
Asn Met Leu Gln Asp Ile Pro Met Asp Arg Phe Val Met Asp Leu Lys	
2160 2165 2170 2175	
aga gac gtg aaa gtg act cca gga aca aaa cat act gaa gaa cgg ccc	6576
Arg Asp Val Lys Val Thr Pro Gly Thr Lys His Thr Glu Glu Arg Pro	
2180 2185 2190	
aag gta cag gtg atc cag gct gcc gat ccg cta gca aca gcg tat ctg	6624
Lys Val Gln Val Ile Gln Ala Ala Asp Pro Leu Ala Thr Ala Tyr Leu	
2195 2200 2205	
tgc gga atc cac cga gag ctg gtt agg aga tta aat gcg gtc ctg ctt	6672
Cys Gly Ile His Arg Glu Leu Val Arg Arg Leu Asn Ala Val Leu Leu	
2210 2215 2220	
ccg aac att cat aca ctg ttt gat atg tcg gct gaa gac ttt gac gct	6720
Pro Asn Ile His Thr Leu Phe Asp Met Ser Ala Glu Asp Phe Asp Ala	
2225 2230 2235	
att ata gcc gag cac ttc cag cct ggg gat tgt gtt ctg gaa act gac	6768
Ile Ile Ala Glu His Phe Gln Pro Gly Asp Cys Val Leu Glu Thr Asp	
2240 2245 2250 2255	
atc gcg tcg ttt gat aaa agt gag gac gac gcc atg gct ctg acc gcg	6816
Ile Ala Ser Phe Asp Lys Ser Glu Asp Asp Ala Met Ala Leu Thr Ala	
2260 2265 2270	
tta atg att ctg gaa gac tta ggt gtg gac gca gag ctg ttg acg ctg	6864
Leu Met Ile Leu Glu Asp Leu Gly Val Asp Ala Glu Leu Leu Thr Leu	
2275 2280 2285	
att gag gcg gct ttc ggc gaa att tca tca cat ttg ccc act aaa	6912
Ile Glu Ala Ala Phe Gly Glu Ile Ser Ser Ile His Leu Pro Thr Lys	
2290 2295 2300	

**THIS PAGE BLANK (USPTO)**

```

act aaa ttt aaa ttc gga gcc atg atg aaa tct gga atg ttc ctc aca      6960
Thr Lys Phe Lys Phe Gly Ala Met Met Lys Ser Gly Met Phe Leu Thr
2305      2310      2315

ctg ttt gtg aac aca gtc att aac att gta atc gca agc aga gtg ttg      7008
Leu Phe Val Asn Thr Val Ile Asn Ile Val Ile Ala Ser Arg Val Leu
2320      2325      2330      2335

aga gaa cgg cta acc gga tca cca tgt gca gca ttc att gga gat gac      7056
Arg Glu Arg Leu Thr Gly Ser Pro Cys Ala Ala Phe Ile Gly Asp Asp
      2340      2345      2350

aat atc gtg aaa gga gtc aaa tcg gac aaa tta atg gca gac agg tgc      7104
Asn Ile Val Lys Gly Val Lys Ser Asp Lys Leu Met Ala Asp Arg Cys
      2355      2360      2365

gcc acc tgg ttg aat atg gaa gtc aag att ata gat gct gtg gtg ggc      7152
Ala Thr Trp Leu Asn Met Glu Val Lys Ile Ile Asp Ala Val Val Gly
      2370      2375      2380

gag aaa gcg ccc tat ttc tgt gga ggg ttt att ttg tgt gac tcc gtg      7200
Glu Lys Ala Pro Tyr Phe Cys Gly Gly Phe Ile Leu Cys Asp Ser Val
      2385      2390      2395

acc ggc aca gcg tgc cgt gtg gca gac ccc cta aaa agg ctg ttt aag      7248
Thr Gly Thr Ala Cys Arg Val Ala Asp Pro Leu Lys Arg Leu Phe Lys
2400      2405      2410      2415

ctt ggc aaa cct ctg gca gca gac gat gaa cat gat gat gac agg aga      7296
Leu Gly Lys Pro Leu Ala Ala Asp Asp Glu His Asp Asp Asp Arg Arg
      2420      2425      2430

agg gca ttg cat gaa gag tca aca cgc tgg aac cga gtg ggt att ctt      7344
Arg Ala Leu His Glu Glu Ser Thr Arg Trp Asn Arg Val Gly Ile Leu
      2435      2440      2445

tca gag ctg tgc aag gca gta gaa tca agg tat gaa acc gta gga act      7392
Ser Glu Leu Cys Lys Ala Val Glu Ser Arg Tyr Glu Thr Val Gly Thr
      2450      2455      2460

tcc atc ata gtt atg gcc atg act act cta gct agc agt gtt aaa tca      7440
Ser Ile Ile Val Met Ala Met Thr Thr Leu Ala Ser Ser Val Lys Ser
      2465      2470      2475

ttc agc tac ctg aga ggg gcc cct ata act ctc tac ggc      7479
Phe Ser Tyr Leu Arg Gly Ala Pro Ile Thr Leu Tyr Gly
2480      2485      2490

```

&lt;210&gt; 3

&lt;211&gt; 2492

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

**THIS PAGE BLANK (USE)**

&lt;220&gt;

<223> Description of Artificial Sequence; Note =  
synthetic construct

&lt;400&gt; 3

```

Met Glu Lys Val His Val Asp Ile Glu Glu Asp Ser Pro Phe Leu Arg
 1           5           10           15
Ala Leu Gln Arg Ser Phe Pro Gln Phe Glu Val Glu Ala Lys Gln Val
 20           25           30
Thr Asp Asn Asp His Ala Asn Ala Arg Ala Phe Ser His Leu Ala Ser
 35           40           45
Lys Leu Ile Glu Thr Glu Val Asp Pro Ser Asp Thr Ile Leu Asp Ile
 50           55           60
Gly Ser Ala Pro Ala Arg Arg Met Tyr Ser Lys His Lys Tyr His Cys
 65           70           75           80
Ile Cys Pro Met Arg Cys Ala Glu Asp Pro Asp Arg Leu Tyr Lys Tyr
 85           90           95
Ala Thr Lys Leu Lys Lys Asn Cys Lys Glu Ile Thr Asp Lys Glu Leu
 100          105          110
Asp Lys Lys Met Lys Glu Leu Ala Val Met Ser Asp Pro Asp Leu
 115          120          125
Glu Thr Glu Thr Met Cys Leu His Asp Asp Glu Ser Cys Arg Tyr Glu
 130          135          140
Gly Gln Val Ala Val Tyr Gln Asp Val Tyr Ala Val Asp Gly Pro Thr
 145          150          155          160
Ser Leu Tyr His Gln Ala Asn Lys Gly Val Arg Val Ala Tyr Trp Ile
 165          170          175
Gly Phe Asp Thr Thr Pro Phe Met Phe Lys Asn Leu Ala Gly Ala Tyr
 180          185          190
Pro Ser Tyr Ser Thr Asn Trp Ala Asp Glu Thr Val Leu Thr Ala Arg
 195          200          205
Asn Ile Gly Leu Cys Ser Ser Asp Val Met Glu Arg Ser Arg Arg Gly
 210          215          220
Met Ser Ile Leu Arg Lys Lys Tyr Leu Lys Pro Ser Asn Asn Val Leu
 225          230          235          240
Phe Ser Val Gly Ser Thr Ile Tyr His Glu Lys Arg Asp Leu Leu Arg
 245          250          255
Ser Trp His Leu Pro Ser Val Phe His Leu Arg Gly Lys Gln Asn Tyr
 260          265          270
Thr Cys Arg Cys Glu Thr Ile Val Ser Cys Asp Gly Tyr Val Val Lys
 275          280          285
Arg Ile Ala Ile Ser Pro Gly Leu Tyr Gly Lys Pro Ser Gly Tyr Ala
 290          295          300
Ala Thr Met His Arg Glu Gly Phe Leu Cys Cys Lys Val Thr Asp Thr
 305          310          315          320
Leu Asn Gly Glu Arg Val Ser Phe Pro Val Cys Thr Tyr Val Pro Ala
 325          330          335
Thr Leu Cys Asp Gln Met Thr Gly Ile Leu Ala Thr Asp Val Ser Ala
 340          345          350
Asp Asp Ala Gln Lys Leu Leu Val Gly Leu Asn Gln Arg Ile Val Val
 355          360          365
Asn Gly Arg Thr Gln Arg Asn Thr Asn Thr Met Lys Asn Tyr Leu Leu
 370          375          380
Pro Val Val Ala Gln Ala Phe Ala Arg Trp Ala Lys Glu Tyr Lys Glu
 385          390          395          400

```

**THIS PAGE BLANK (USPTO)**

Asp	Gln	Glu	Asp	Glu	Arg	Pro	Leu	Gly	Leu	Arg	Asp	Arg	Gln	Leu	Val	405	410	415
Met	Gly	Cys	Cys	Trp	Ala	Phe	Arg	Arg	His	Lys	Ile	Thr	Ser	Ile	Tyr	420	425	430
Lys	Arg	Pro	Asp	Thr	Gln	Thr	Ile	Ile	Lys	Val	Asn	Ser	Asp	Phe	His	435	440	445
Ser	Phe	Val	Leu	Pro	Arg	Ile	Gly	Ser	Asn	Thr	Leu	Glu	Ile	Gly	Leu	450	455	460
Arg	Thr	Arg	Ile	Arg	Lys	Met	Leu	Glu	Glu	His	Lys	Glu	Pro	Ser	Pro	465	470	475
Leu	Ile	Thr	Ala	Glu	Asp	Val	Gln	Glu	Ala	Lys	Cys	Ala	Ala	Asp	Glu	485	490	495
Ala	Lys	Glu	Val	Arg	Glu	Ala	Glu	Glu	Leu	Arg	Ala	Ala	Leu	Pro	Pro	500	505	510
Leu	Ala	Ala	Asp	Val	Glu	Glu	Pro	Thr	Leu	Glu	Ala	Asp	Val	Asp	Leu	515	520	525
Met	Leu	Gln	Glu	Ala	Gly	Ala	Gly	Ser	Val	Glu	Thr	Pro	Arg	Gly	Leu	530	535	540
Ile	Lys	Val	Thr	Ser	Tyr	Ala	Gly	Glu	Asp	Lys	Ile	Gly	Ser	Tyr	Ala	545	550	555
Val	Leu	Ser	Pro	Gln	Ala	Val	Leu	Lys	Ser	Glu	Lys	Leu	Ser	Cys	Ile	565	570	575
His	Pro	Leu	Ala	Glu	Gln	Val	Ile	Val	Ile	Thr	His	Ser	Gly	Arg	Lys	580	585	590
Gly	Arg	Tyr	Ala	Val	Glu	Pro	Tyr	His	Gly	Lys	Val	Val	Val	Pro	Glu	595	600	605
Gly	His	Ala	Ile	Pro	Val	Gln	Asp	Phe	Gln	Ala	Leu	Ser	Glu	Ser	Ala	610	615	620
Thr	Ile	Val	Tyr	Asn	Glu	Arg	Glu	Phe	Val	Asn	Arg	Tyr	Leu	His	His	625	630	635
Ile	Ala	Thr	His	Gly	Gly	Ala	Leu	Asn	Thr	Asp	Glu	Glu	Tyr	Tyr	Lys	645	650	655
Thr	Val	Lys	Pro	Ser	Glu	His	Asp	Gly	Glu	Tyr	Leu	Tyr	Asp	Ile	Asp	660	665	670
Arg	Lys	Gln	Cys	Val	Lys	Lys	Glu	Leu	Val	Thr	Gly	Leu	Gly	Leu	Thr	675	680	685
Gly	Glu	Leu	Val	Asp	Pro	Pro	Phe	His	Glu	Phe	Ala	Tyr	Glu	Ser	Leu	690	695	700
Arg	Thr	Arg	Pro	Ala	Ala	Pro	Tyr	Gln	Val	Pro	Thr	Ile	Gly	Val	Tyr	705	710	715
Gly	Val	Pro	Gly	Ser	Gly	Lys	Ser	Gly	Ile	Ile	Lys	Ser	Ala	Val	Thr	725	730	735
Lys	Lys	Asp	Leu	Val	Val	Ser	Ala	Lys	Lys	Glu	Asn	Cys	Ala	Glu	Ile	740	745	750
Ile	Arg	Asp	Val	Lys	Lys	Met	Lys	Gly	Leu	Asp	Val	Asn	Ala	Arg	Thr	755	760	765
Val	Asp	Ser	Val	Leu	Leu	Asn	Gly	Cys	Lys	His	Pro	Val	Glu	Thr	Leu	770	775	780
Tyr	Ile	Asp	Glu	Ala	Phe	Ala	Cys	His	Ala	Gly	Thr	Leu	Arg	Ala	Leu	785	790	795
Ile	Ala	Ile	Ile	Arg	Pro	Lys	Lys	Ala	Val	Leu	Cys	Gly	Asp	Pro	Lys	805	810	815
Gln	Cys	Gly	Phe	Phe	Asn	Met	Met	Cys	Leu	Lys	Val	His	Phe	Asn	His	820	825	830

**THIS PAGE BLANK (USPIC,**

Glu Ile Cys Thr Gln Val Phe His Lys Ser Ile Ser Arg Arg Cys Thr  
 835 840 845  
 Lys Ser Val Thr Ser Val Val Ser Thr Leu Phe Tyr Asp Lys Lys Met  
 850 855 860  
 Arg Thr Thr Asn Pro Lys Glu Thr Lys Ile Val Ile Asp Thr Thr Gly  
 865 870 875 880  
 Ser Thr Lys Pro Lys Gln Asp Asp Leu Ile Leu Thr Cys Phe Arg Gly  
 885 890 895  
 Trp Val Lys Gln Leu Gln Ile Asp Tyr Lys Gly Asn Glu Ile Met Thr  
 900 905 910  
 Ala Ala Ala Ser Gln Gly Leu Thr Arg Lys Gly Val Tyr Ala Val Arg  
 915 920 925  
 Tyr Lys Val Asn Glu Asn Pro Leu Tyr Ala Pro Thr Ser Glu His Val  
 930 935 940  
 Asn Val Leu Leu Thr Arg Thr Glu Asp Arg Ile Val Trp Lys Thr Leu  
 945 950 955 960  
 Ala Gly Asp Pro Trp Ile Lys Thr Leu Thr Ala Lys Tyr Pro Gly Asn  
 965 970 975  
 Phe Thr Ala Thr Ile Glu Glu Trp Gln Ala Glu His Asp Ala Ile Met  
 980 985 990  
 Arg His Ile Leu Glu Arg Pro Asp Pro Thr Asp Val Phe Gln Asn Lys  
 995 1000 1005  
 Ala Asn Val Cys Trp Ala Lys Ala Leu Val Pro Val Leu Lys Thr Ala  
 1010 1015 1020  
 Gly Ile Asp Met Thr Thr Glu Gln Trp Asn Thr Val Asp Tyr Phe Glu  
 1025 1030 1035 1040  
 Thr Asp Lys Ala His Ser Ala Glu Ile Val Leu Asn Gln Leu Cys Val  
 1045 1050 1055  
 Arg Phe Phe Gly Leu Asp Leu Asp Ser Gly Leu Phe Ser Ala Pro Thr  
 1060 1065 1070  
 Val Pro Leu Ser Ile Arg Asn Asn His Trp Asp Asn Ser Pro Ser Pro  
 1075 1080 1085  
 Asn Met Tyr Gly Leu Asn Lys Glu Val Val Arg Gln Leu Ser Arg Arg  
 1090 1095 1100  
 Tyr Pro Gln Leu Pro Arg Ala Val Ala Thr Gly Arg Val Tyr Asp Met  
 1105 1110 1115 1120  
 Asn Thr Gly Thr Leu Arg Asn Tyr Asp Pro Arg Ile Asn Leu Val Pro  
 1125 1130 1135  
 Val Asn Arg Arg Leu Pro His Ala Leu Val Leu His His Asn Glu His  
 1140 1145 1150  
 Pro Gln Ser Asp Phe Ser Ser Phe Val Ser Lys Leu Lys Gly Arg Thr  
 1155 1160 1165  
 Val Leu Val Val Gly Glu Lys Leu Ser Val Pro Gly Lys Met Val Asp  
 1170 1175 1180  
 Trp Leu Ser Asp Arg Pro Glu Ala Thr Phe Arg Ala Arg Leu Asp Leu  
 1185 1190 1195 1200  
 Gly Ile Pro Gly Asp Val Pro Lys Tyr Asp Ile Ile Phe Val Asn Val  
 1205 1210 1215  
 Arg Thr Pro Tyr Lys Tyr His His Tyr Gln Gln Cys Glu Asp His Ala  
 1220 1225 1230  
 Ile Lys Leu Ser Met Leu Thr Lys Lys Ala Cys Leu His Leu Asn Pro  
 1235 1240 1245  
 Gly Gly Thr Cys Val Ser Ile Gly Tyr Gly Tyr Ala Asp Arg Ala Ser  
 1250 1255 1260

**THIS PAGE BLANK (USPTO)**

Glu Ser Ile Ile Gly Ala Ile Ala Arg Gln Phe Lys Phe Ser Arg Val  
 1265 1270 1275 1280  
 Cys Lys Pro Lys Ser Ser Leu Glu Glu Thr Glu Val Leu Phe Val Phe  
 1285 1290 1295  
 Ile Gly Tyr Asp Arg Lys Ala Arg Thr His Asn Pro Tyr Lys Leu Ser  
 1300 1305 1310  
 Ser Thr Leu Thr Asn Ile Tyr Thr Gly Ser Arg Leu His Glu Ala Gly  
 1315 1320 1325  
 Cys Ala Pro Ser Tyr His Val Val Arg Gly Asp Ile Ala Thr Ala Thr  
 1330 1335 1340  
 Glu Gly Val Ile Ile Asn Ala Ala Asn Ser Lys Gly Gln Pro Gly Gly  
 1345 1350 1355 1360  
 Gly Val Cys Gly Ala Leu Tyr Lys Lys Phe Pro Glu Ser Phe Asp Leu  
 1365 1370 1375  
 Gln Pro Ile Glu Val Gly Lys Ala Arg Leu Val Lys Gly Ala Ala Lys  
 1380 1385 1390  
 His Ile Ile His Ala Val Gly Pro Asn Phe Asn Lys Val Ser Glu Val  
 1395 1400 1405  
 Glu Gly Asp Lys Gln Leu Ala Glu Ala Tyr Glu Ser Ile Ala Lys Ile  
 1410 1415 1420  
 Val Asn Asp Asn Asn Tyr Lys Ser Val Ala Ile Pro Leu Leu Ser Thr  
 1425 1430 1435 1440  
 Gly Ile Phe Ser Gly Asn Lys Asp Arg Leu Thr Gln Ser Leu Asn His  
 1445 1450 1455  
 Leu Leu Thr Ala Leu Asp Thr Thr Asp Ala Asp Val Ala Ile Tyr Cys  
 1460 1465 1470  
 Arg Asp Lys Lys Trp Glu Met Thr Leu Lys Glu Ala Val Ala Arg Arg  
 1475 1480 1485  
 Glu Ala Val Glu Glu Ile Cys Ile Ser Asp Asp Ser Ser Val Thr Glu  
 1490 1495 1500  
 Pro Asp Ala Glu Leu Val Arg Val His Pro Lys Ser Ser Leu Ala Gly  
 1505 1510 1515 1520  
 Arg Lys Gly Tyr Ser Thr Ser Asp Gly Lys Thr Phe Ser Tyr Leu Glu  
 1525 1530 1535  
 Gly Thr Lys Phe His Gln Ala Ala Lys Asp Ile Ala Glu Ile Asn Ala  
 1540 1545 1550  
 Met Trp Pro Val Ala Thr Glu Ala Asn Glu Gln Val Cys Met Tyr Ile  
 1555 1560 1565  
 Leu Gly Glu Ser Met Ser Ser Ile Arg Ser Lys Cys Pro Val Glu Glu  
 1570 1575 1580  
 Ser Glu Ala Ser Thr Pro Pro Ser Thr Leu Pro Cys Leu Cys Ile His  
 1585 1590 1595 1600  
 Ala Met Thr Pro Glu Arg Val Gln Arg Leu Lys Ala Ser Arg Pro Glu  
 1605 1610 1615  
 Gln Ile Thr Val Cys Ser Ser Phe Pro Leu Pro Lys Tyr Arg Ile Thr  
 1620 1625 1630  
 Gly Val Gln Lys Ile Gln Cys Ser Gln Pro Ile Leu Phe Ser Pro Lys  
 1635 1640 1645  
 Val Pro Ala Tyr Ile His Pro Arg Lys Tyr Leu Val Glu Thr Pro Pro  
 1650 1655 1660  
 Val Asp Glu Thr Pro Glu Pro Ser Ala Glu Asn Gln Ser Thr Glu Gly  
 1665 1670 1675 1680  
 Thr Pro Glu Gln Pro Pro Leu Ile Thr Glu Asp Glu Thr Arg Thr Arg  
 1685 1690 1695

**THIS PAGE BLANK (USPTO)**

Thr	Pro	Glu	Pro	Ile	Ile	Ile	Glu	Glu	Glu	Glu	Glu	Asp	Ser	Ile	Ser	1700	1705	1710
Leu	Leu	Ser	Asp	Gly	Pro	Thr	His	Gln	Val	Leu	Gln	Val	Glu	Ala	Asp	1715	1720	1725
Ile	His	Gly	Pro	Pro	Ser	Val	Ser	Ser	Ser	Ser	Trp	Ser	Ile	Pro	His	1730	1735	1740
Ala	Ser	Asp	Phe	Asp	Val	Asp	Ser	Leu	Ser	Ile	Leu	Asp	Thr	Leu	Glu	1745	1750	1755
Gly	Ala	Ser	Val	Thr	Ser	Gly	Ala	Thr	Ser	Ala	Glu	Thr	Asn	Ser	Tyr	1765	1770	1775
Phe	Ala	Lys	Ser	Met	Glu	Phe	Leu	Ala	Arg	Pro	Val	Pro	Ala	Pro	Arg	1780	1785	1790
Thr	Val	Phe	Arg	Asn	Pro	Pro	His	Pro	Ala	Pro	Arg	Thr	Arg	Thr	Pro	1795	1800	1805
Ser	Leu	Ala	Pro	Ser	Arg	Ala	Cys	Ser	Arg	Thr	Ser	Leu	Val	Ser	Thr	1810	1815	1820
Pro	Pro	Gly	Val	Asn	Arg	Val	Ile	Thr	Arg	Glu	Glu	Leu	Glu	Ala	Leu	1825	1830	1835
Thr	Pro	Ser	Arg	Thr	Pro	Ser	Arg	Ser	Val	Ser	Arg	Thr	Ser	Leu	Val	1845	1850	1855
Ser	Asn	Pro	Pro	Gly	Val	Asn	Arg	Val	Ile	Thr	Arg	Glu	Glu	Phe	Glu	1860	1865	1870
Ala	Phe	Val	Ala	Gln	Gln	Gln	Arg	Phe	Asp	Ala	Gly	Ala	Tyr	Ile	Phe	1875	1880	1885
Ser	Ser	Asp	Thr	Gly	Gln	Gly	His	Leu	Gln	Gln	Lys	Ser	Val	Arg	Gln	1890	1895	1900
Thr	Val	Leu	Ser	Glu	Val	Val	Leu	Glu	Arg	Thr	Glu	Leu	Glu	Ile	Ser	1905	1910	1915
Tyr	Ala	Pro	Arg	Leu	Asp	Gln	Glu	Lys	Glu	Glu	Leu	Leu	Arg	Lys	Lys	1925	1930	1935
Leu	Gln	Leu	Asn	Pro	Thr	Pro	Ala	Asn	Arg	Ser	Arg	Tyr	Gln	Ser	Arg	1940	1945	1950
Lys	Val	Glu	Asn	Met	Lys	Ala	Ile	Thr	Ala	Arg	Arg	Ile	Leu	Gln	Gly	1955	1960	1965
Leu	Gly	His	Tyr	Leu	Lys	Ala	Glu	Gly	Lys	Val	Glu	Cys	Tyr	Arg	Thr	1970	1975	1980
Leu	His	Pro	Val	Pro	Leu	Tyr	Ser	Ser	Ser	Val	Asn	Arg	Ala	Phe	Ser	1985	1990	1995
Ser	Pro	Lys	Val	Ala	Val	Glu	Ala	Cys	Asn	Ala	Met	Leu	Lys	Glu	Asn	2005	2010	2015
Phe	Pro	Thr	Val	Ala	Ser	Tyr	Cys	Ile	Ile	Pro	Glu	Tyr	Asp	Ala	Tyr	2020	2025	2030
Leu	Asp	Met	Val	Asp	Gly	Ala	Ser	Cys	Cys	Leu	Asp	Thr	Ala	Ser	Phe	2035	2040	2045
Cys	Pro	Ala	Lys	Leu	Arg	Ser	Phe	Pro	Lys	Lys	His	Ser	Tyr	Leu	Glu	2050	2055	2060
Pro	Thr	Ile	Arg	Ser	Ala	Val	Pro	Ser	Ala	Ile	Gln	Asn	Thr	Leu	Gln	2065	2070	2075
Asn	Val	Leu	Ala	Ala	Ala	Thr	Lys	Arg	Asn	Cys	Asn	Val	Thr	Gln	Met	2085	2090	2095
Arg	Glu	Leu	Pro	Val	Leu	Asp	Ser	Ala	Ala	Phe	Asn	Val	Glu	Cys	Phe	2100	2105	2110
Lys	Lys	Tyr	Ala	Cys	Asn	Asn	Glu	Tyr	Trp	Glu	Thr	Phe	Lys	Glu	Asn	2115	2120	2125

**THIS PAGE BLANK (USPIC,**

22

Pro Ile Arg Leu Thr Glu Glu Asn Val Val Asn Tyr Ile Thr Lys Leu  
 2130 2135 2140  
 Lys Gly Pro Lys Ala Ala Ala Leu Phe Ala Lys Thr His Asn Leu Asn  
 2145 2150 2155 2160  
 Met Leu Gln Asp Ile Pro Met Asp Arg Phe Val Met Asp Leu Lys Arg  
 2165 2170 2175  
 Asp Val Lys Val Thr Pro Gly Thr Lys His Thr Glu Glu Arg Pro Lys  
 2180 2185 2190  
 Val Gln Val Ile Gln Ala Ala Asp Pro Leu Ala Thr Ala Tyr Leu Cys  
 2195 2200 2205  
 Gly Ile His Arg Glu Leu Val Arg Arg Leu Asn Ala Val Leu Leu Pro  
 2210 2215 2220  
 Asn Ile His Thr Leu Phe Asp Met Ser Ala Glu Asp Phe Asp Ala Ile  
 2225 2230 2235 2240  
 Ile Ala Glu His Phe Gln Pro Gly Asp Cys Val Leu Glu Thr Asp Ile  
 2245 2250 2255  
 Ala Ser Phe Asp Lys Ser Glu Asp Asp Ala Met Ala Leu Thr Ala Leu  
 2260 2265 2270  
 Met Ile Leu Glu Asp Leu Gly Val Asp Ala Glu Leu Leu Thr Leu Ile  
 2275 2280 2285  
 Glu Ala Ala Phe Gly Glu Ile Ser Ser Ile His Leu Pro Thr Lys Thr  
 2290 2295 2300  
 Lys Phe Lys Phe Gly Ala Met Met Lys Ser Gly Met Phe Leu Thr Leu  
 2305 2310 2315 2320  
 Phe Val Asn Thr Val Ile Asn Ile Val Ile Ala Ser Arg Val Leu Arg  
 2325 2330 2335  
 Glu Arg Leu Thr Gly Ser Pro Cys Ala Ala Phe Ile Gly Asp Asp Asn  
 2340 2345 2350  
 Ile Val Lys Gly Val Lys Ser Asp Lys Leu Met Ala Asp Arg Cys Ala  
 2355 2360 2365  
 Thr Trp Leu Asn Met Glu Val Lys Ile Ile Asp Ala Val Val Gly Glu  
 2370 2375 2380  
 Lys Ala Pro Tyr Phe Cys Gly Gly Phe Ile Leu Cys Asp Ser Val Thr  
 2385 2390 2395 2400  
 Gly Thr Ala Cys Arg Val Ala Asp Pro Leu Lys Arg Leu Phe Lys Leu  
 2405 2410 2415  
 Gly Lys Pro Leu Ala Ala Asp Asp Glu His Asp Asp Asp Arg Arg Arg  
 2420 2425 2430  
 Ala Leu His Glu Glu Ser Thr Arg Trp Asn Arg Val Gly Ile Leu Ser  
 2435 2440 2445  
 Glu Leu Cys Lys Ala Val Glu Ser Arg Tyr Glu Thr Val Gly Thr Ser  
 2450 2455 2460  
 Ile Ile Val Met Ala Met Thr Thr Leu Ala Ser Ser Val Lys Ser Phe  
 2465 2470 2475 2480  
 Ser Tyr Leu Arg Gly Ala Pro Ile Thr Leu Tyr Gly  
 2485 2490

&lt;210&gt; 4

&lt;211&gt; 1476

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

 <223> Description of Artificial Sequence; Note =  
 synthetic construct

**THIS PAGE BLANK (USPTO)**

&lt;221&gt; CDS

&lt;222&gt; (1)...(1476)

&lt;400&gt; 4

atg gct gcg aga gcg tca ata tta aga ggg gaa aaa tta gat aaa tgg	48
Met Ala Ala Arg Ala Ser Ile Leu Arg Gly Glu Lys Leu Asp Lys Trp	
1 5 10 15	
 gaa aag att agg tta agg cca ggg gga aag aaa cat tat atg tta aaa	96
Glu Lys Ile Arg Leu Arg Pro Gly Gly Lys Lys His Tyr Met Leu Lys	
20 25 30	
 cac ata gta tgg gcg agc agg gag ctg gaa aga ttt gca ctt aac cct	144
His Ile Val Trp Ala Ser Arg Glu Leu Glu Arg Phe Ala Leu Asn Pro	
35 40 45	
 ggc ctt tta gaa aca tca gaa gga tgt aaa caa ata atg aaa cag cta	192
Gly Leu Leu Glu Thr Ser Glu Gly Cys Lys Gln Ile Met Lys Gln Leu	
50 55 60	
 caa cca gct ctg cag aca gga aca gag gaa ctt aaa tca tta tac aac	240
Gln Pro Ala Leu Gln Thr Gly Thr Glu Glu Leu Lys Ser Leu Tyr Asn	
65 70 75 80	
 aca gta gca act ctg tat tgt gta cat gaa aag ata gaa gta cga gac	288
Thr Val Ala Thr Leu Tyr Cys Val His Glu Lys Ile Glu Val Arg Asp	
85 90 95	
 acc aag gaa gcc tta gat aag ata gag gaa gaa caa aac aaa tgt cag	336
Thr Lys Glu Ala Leu Asp Lys Ile Glu Glu Glu Gln Asn Lys Cys Gln	
100 105 110	
 caa aaa acg cag cag gca aaa gcg gct gac ggg aaa gtc agt caa aat	384
Gln Lys Thr Gln Gln Ala Lys Ala Ala Asp Gly Lys Val Ser Gln Asn	
115 120 125	
 tat cct ata gtg cag aat ctg caa ggg caa atg gta cat caa gcc ata	432
Tyr Pro Ile Val Gln Asn Leu Gln Gly Gln Met Val His Gln Ala Ile	
130 135 140	
 tca cct aga acc ttg aat gca tgg gta aaa gta ata gaa gaa aag gct	480
Ser Pro Arg Thr Leu Asn Ala Trp Val Lys Val Ile Glu Glu Lys Ala	
145 150 155 160	
 ttt agc cca gag gta ata ccc atg ttt aca gca tta tca gaa gga gcc	528
Phe Ser Pro Glu Val Ile Pro Met Phe Thr Ala Leu Ser Glu Gly Ala	
165 170 175	
 acc cca caa gat tta aac acc atg tta aat aca gtg ggg gga cac caa	576
Thr Pro Gln Asp Leu Asn Thr Met Leu Asn Thr Val Gly Gly His Gln	
180 185 190	
 gca gcc atg caa atg tta aaa gat act att aat gaa gag gct gca gaa	624
Ala Ala Met Gln Met Leu Lys Asp Thr Ile Asn Glu Glu Ala Ala Glu	
195 200 205	

**THIS PAGE BLANK (USPTO**

tgg gat aga tta cat cca gtc cat gcg ggg cct att gca cca ggc cag	672
Trp Asp Arg Leu His Pro Val His Ala Gly Pro Ile Ala Pro Gly Gln	
210 215 220	
atg aga gaa cca agg gga agt gac ata gca gga act act agt acc ctt	720
Met Arg Glu Pro Arg Gly Ser Asp Ile Ala Gly Thr Thr Ser Thr Leu	
225 230 235 240	
cag gaa caa ata gca tgg atg aca agt aac cca cct att cca gtg gga	768
Gln Glu Gln Ile Ala Trp Met Thr Ser Asn Pro Pro Ile Pro Val Gly	
245 250 255	
gac atc tat aaa aga tgg ata att ctg ggg tta aat aaa ata gtg aga	816
Asp Ile Tyr Lys Arg Trp Ile Ile Leu Gly Leu Asn Lys Ile Val Arg	
260 265 270	
atg tat agc ccg gtc agc att ttg gac ata aga caa ggg cca aag gaa	864
Met Tyr Ser Pro Val Ser Ile Leu Asp Ile Arg Gln Gly Pro Lys Glu	
275 280 285	
ccc ttt cga gac tat gta gat cgg ttc ttt aaa act tta aga gct gaa	912
Pro Phe Arg Asp Tyr Val Asp Arg Phe Phe Lys Thr Leu Arg Ala Glu	
290 295 300	
caa gct aca caa gaa gta aaa aat tgg atg aca gac acc ttg tta gtc	960
Gln Ala Thr Gln Glu Val Lys Asn Trp Met Thr Asp Thr Leu Leu Val	
305 310 315 320	
caa aat gcg aac cca gat tgt aag acc att ttg aga gca tta gga cca	1008
Gln Asn Ala Asn Pro Asp Cys Lys Thr Ile Leu Arg Ala Leu Gly Pro	
325 330 335	
ggg gct aca tta gaa gaa atg atg aca gca tgt caa ggg gtg gga gga	1056
Gly Ala Thr Leu Glu Glu Met Met Thr Ala Cys Gln Gly Val Gly Gly	
340 345 350	
cct ggc cac aaa gca aga gta ttg gct gag gca atg agt caa aca aac	1104
Pro Gly His Lys Ala Arg Val Leu Ala Glu Ala Met Ser Gln Thr Asn	
355 360 365	
agt gga aac ata atg atg cag aga agc aat ttt aaa ggc cct aga aga	1152
Ser Gly Asn Ile Met Met Gln Arg Ser Asn Phe Lys Gly Pro Arg Arg	
370 375 380	
att gtt aaa tgt ttt aac tgt ggc aag gaa ggg cac ata gcc aga aat	1200
Ile Val Lys Cys Phe Asn Cys Gly Lys Glu Gly His Ile Ala Arg Asn	
385 390 395 400	
tgc aga gcc cct agg aaa aaa ggc tgt tgg aaa tgt gga aaa gaa gga	1248
Cys Arg Ala Pro Arg Lys Lys Gly Cys Trp Lys Cys Gly Lys Glu Gly	
405 410 415	
cac caa atg aaa gac tgc act gag agg cag gct aat ttt tta ggg aaa	1296
His Gln Met Lys Asp Cys Thr Glu Arg Gln Ala Asn Phe Leu Gly Lys	
420 425 430	

**THIS PAGE BLANK (USPTO)**

25

att tgg cct tcc cac aag ggg agg cca ggg aat ttc ctt cag aac aga 1344  
 Ile Trp Pro Ser His Lys Gly Arg Pro Gly Asn Phe Leu Gln Asn Arg  
 435 440 445

cca gag cca aca gcc cca cca gca gag agc ttc agg ttc gaa gag aca 1392  
 Pro Glu Pro Thr Ala Pro Pro Ala Glu Ser Phe Arg Phe Glu Glu Thr  
 450 455 460

acc ccc gct ccg aaa cag gag ccg ata gaa agg gaa ccc tta act tcc 1440  
 Thr Pro Ala Pro Lys Gln Glu Pro Ile Glu Arg Glu Pro Leu Thr Ser  
 465 470 475 480

ctc aaa tca ctc ttt ggc agc gac ccc ttg tct caa 1476  
 Leu Lys Ser Leu Phe Gly Ser Asp Pro Leu Ser Gln  
 485 490

&lt;210&gt; 5

&lt;211&gt; 492

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence; Note =  
 synthetic construct

&lt;400&gt; 5

Met Ala Ala Arg Ala Ser Ile Leu Arg Gly Glu Lys Leu Asp Lys Trp  
 1 5 10 15  
 Glu Lys Ile Arg Leu Arg Pro Gly Gly Lys Lys His Tyr Met Leu Lys  
 20 25 30  
 His Ile Val Trp Ala Ser Arg Glu Leu Glu Arg Phe Ala Leu Asn Pro  
 35 40 45  
 Gly Leu Leu Glu Thr Ser Glu Gly Cys Lys Gln Ile Met Lys Gln Leu  
 50 55 60  
 Gln Pro Ala Leu Gln Thr Gly Thr Glu Glu Leu Lys Ser Leu Tyr Asn  
 65 70 75 80  
 Thr Val Ala Thr Leu Tyr Cys Val His Glu Lys Ile Glu Val Arg Asp  
 85 90 95  
 Thr Lys Glu Ala Leu Asp Lys Ile Glu Glu Glu Gln Asn Lys Cys Gln  
 100 105 110  
 Gln Lys Thr Gln Gln Ala Lys Ala Ala Asp Gly Lys Val Ser Gln Asn  
 115 120 125  
 Tyr Pro Ile Val Gln Asn Leu Gln Gly Gln Met Val His Gln Ala Ile  
 130 135 140  
 Ser Pro Arg Thr Leu Asn Ala Trp Val Lys Val Ile Glu Glu Lys Ala  
 145 150 155 160  
 Phe Ser Pro Glu Val Ile Pro Met Phe Thr Ala Leu Ser Glu Gly Ala  
 165 170 175  
 Thr Pro Gln Asp Leu Asn Thr Met Leu Asn Thr Val Gly Gly His Gln  
 180 185 190  
 Ala Ala Met Gln Met Leu Lys Asp Thr Ile Asn Glu Glu Ala Ala Glu  
 195 200 205

**THIS PAGE BLANK (USPTO)**

26

```

Trp Asp Arg Leu His Pro Val His Ala Gly Pro Ile Ala Pro Gly Gln
  210                215                220
Met Arg Glu Pro Arg Gly Ser Asp Ile Ala Gly Thr Thr Ser Thr Leu
  225                230                235                240
Gln Glu Gln Ile Ala Trp Met Thr Ser Asn Pro Pro Ile Pro Val Gly
                245                250                255
Asp Ile Tyr Lys Arg Trp Ile Ile Leu Gly Leu Asn Lys Ile Val Arg
                260                265                270
Met Tyr Ser Pro Val Ser Ile Leu Asp Ile Arg Gln Gly Pro Lys Glu
                275                280                285
Pro Phe Arg Asp Tyr Val Asp Arg Phe Phe Lys Thr Leu Arg Ala Glu
                290                295                300
Gln Ala Thr Gln Glu Val Lys Asn Trp Met Thr Asp Thr Leu Leu Val
  305                310                315                320
Gln Asn Ala Asn Pro Asp Cys Lys Thr Ile Leu Arg Ala Leu Gly Pro
                325                330                335
Gly Ala Thr Leu Glu Glu Met Met Thr Ala Cys Gln Gly Val Gly Gly
                340                345                350
Pro Gly His Lys Ala Arg Val Leu Ala Glu Ala Met Ser Gln Thr Asn
                355                360                365
Ser Gly Asn Ile Met Met Gln Arg Ser Asn Phe Lys Gly Pro Arg Arg
                370                375                380
Ile Val Lys Cys Phe Asn Cys Gly Lys Glu Gly His Ile Ala Arg Asn
  385                390                395                400
Cys Arg Ala Pro Arg Lys Lys Gly Cys Trp Lys Cys Gly Lys Glu Gly
                405                410                415
His Gln Met Lys Asp Cys Thr Glu Arg Gln Ala Asn Phe Leu Gly Lys
                420                425                430
Ile Trp Pro Ser His Lys Gly Arg Pro Gly Asn Phe Leu Gln Asn Arg
                435                440                445
Pro Glu Pro Thr Ala Pro Pro Ala Glu Ser Phe Arg Phe Glu Glu Thr
                450                455                460
Thr Pro Ala Pro Lys Gln Glu Pro Ile Glu Arg Glu Pro Leu Thr Ser
  465                470                475                480
Leu Lys Ser Leu Phe Gly Ser Asp Pro Leu Ser Gln
                485                490

```

&lt;210&gt; 6

&lt;211&gt; 813

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence; Note =  
synthetic construct

&lt;221&gt; CDS

&lt;222&gt; (1)...(813)

&lt;400&gt; 6

```

atg agc cat att caa cgg gaa acg tct tgc tcg agg ccg cga tta aat
Met Ser His Ile Gln Arg Glu Thr Ser Cys Ser Arg Pro Arg Leu Asn
  1              5              10              15

```

48

**THIS PAGE BLANK (USPTO)**

27

tcc aac atg gat gct gat tta tat ggg tat aaa tgg gct cgc gat aat	96
Ser Asn Met Asp Ala Asp Leu Tyr Gly Tyr Lys Trp Ala Arg Asp Asn	
20 25 30	
gtc ggg caa tca ggt gcg aca atc tat cga ttg tat ggg aag ccc gat	144
Val Gly Gln Ser Gly Ala Thr Ile Tyr Arg Leu Tyr Gly Lys Pro Asp	
35 40 45	
gcg cca gag ttg ttt ctg aaa cat ggc aaa ggt agc gtt gcc aat gat	192
Ala Pro Glu Leu Phe Leu Lys His Gly Lys Gly Ser Val Ala Asn Asp	
50 55 60	
gtt aca gat gag atg gtc aga cta aac tgg ctg acg gaa ttt atg cct	240
Val Thr Asp Glu Met Val Arg Leu Asn Trp Leu Thr Glu Phe Met Pro	
65 70 75 80	
ctt ccg acc atc aag cat ttt atc cgt act cct gat gat gca tgg tta	288
Leu Pro Thr Ile Lys His Phe Ile Arg Thr Pro Asp Asp Ala Trp Leu	
85 90 95	
ctc acc act gcg atc ccc ggg aaa aca gca ttc cag gta tta gaa gaa	336
Leu Thr Thr Ala Ile Pro Gly Lys Thr Ala Phe Gln Val Leu Glu Glu	
100 105 110	
tat cct gat tca ggt gaa aat att gtt gat gcg ctg gca gtg ttc ctg	384
Tyr Pro Asp Ser Gly Glu Asn Ile Val Asp Ala Leu Ala Val Phe Leu	
115 120 125	
cgc cgg ttg cat tcg att cct gtt tgt aat tgt cct ttt aac agc gat	432
Arg Arg Leu His Ser Ile Pro Val Cys Asn Cys Pro Phe Asn Ser Asp	
130 135 140	
cgc gta ttt cgt ctc gct cag gcg caa tca cga atg aat aac ggt ttg	480
Arg Val Phe Arg Leu Ala Gln Ala Gln Ser Arg Met Asn Asn Gly Leu	
145 150 155 160	
gtt gat gcg agt gat ttt gat gac gag cgt aat ggc tgg cct gtt gaa	528
Val Asp Ala Ser Asp Phe Asp Asp Glu Arg Asn Gly Trp Pro Val Glu	
165 170 175	
caa gtc tgg aaa gaa atg cat aag ctt ttg cca ttc tca ccg gat tca	576
Gln Val Trp Lys Glu Met His Lys Leu Leu Pro Phe Ser Pro Asp Ser	
180 185 190	
gtc gtc act cat ggt gat ttc tca ctt gat aac ctt att ttt gac gag	624
Val Val Thr His Gly Asp Phe Ser Leu Asp Asn Leu Ile Phe Asp Glu	
195 200 205	
ggg aaa tta ata ggt tgt att gat gtt gga cga gtc gga atc gca gac	672
Gly Lys Leu Ile Gly Cys Ile Asp Val Gly Arg Val Gly Ile Ala Asp	
210 215 220	
cga tac cag gat ctt gcc atc cta tgg aac tgc ctc ggt gag ttt tct	720
Arg Tyr Gln Asp Leu Ala Ile Leu Trp Asn Cys Leu Gly Glu Phe Ser	
225 230 235 240	

**THIS PAGE BLANK (USPTO)**

28

cct tca tta cag aaa cgg ctt ttt caa aaa tat ggt att gat aat cct 768  
 Pro Ser Leu Gln Lys Arg Leu Phe Gln Lys Tyr Gly Ile Asp Asn Pro  
                   245                  250                  255

gat atg aat aaa ttg cag ttt cat ttg atg ctc gat gag ttt ttc 813  
 Asp Met Asn Lys Leu Gln Phe His Leu Met Leu Asp Glu Phe Phe  
                   260                  265                  270

&lt;210&gt; 7

&lt;211&gt; 271

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence; Note =  
 synthetic construct

&lt;400&gt; 7

Met Ser His Ile Gln Arg Glu Thr Ser Cys Ser Arg Pro Arg Leu Asn  
 1                  5                  10                  15  
 Ser Asn Met Asp Ala Asp Leu Tyr Gly Tyr Lys Trp Ala Arg Asp Asn  
                   20                  25                  30  
 Val Gly Gln Ser Gly Ala Thr Ile Tyr Arg Leu Tyr Gly Lys Pro Asp  
                   35                  40                  45  
 Ala Pro Glu Leu Phe Leu Lys His Gly Lys Gly Ser Val Ala Asn Asp  
                   50                  55                  60  
 Val Thr Asp Glu Met Val Arg Leu Asn Trp Leu Thr Glu Phe Met Pro  
 65                  70                  75                  80  
 Leu Pro Thr Ile Lys His Phe Ile Arg Thr Pro Asp Asp Ala Trp Leu  
                   85                  90                  95  
 Leu Thr Thr Ala Ile Pro Gly Lys Thr Ala Phe Gln Val Leu Glu Glu  
                   100                  105                  110  
 Tyr Pro Asp Ser Gly Glu Asn Ile Val Asp Ala Leu Ala Val Phe Leu  
                   115                  120                  125  
 Arg Arg Leu His Ser Ile Pro Val Cys Asn Cys Pro Phe Asn Ser Asp  
                   130                  135                  140  
 Arg Val Phe Arg Leu Ala Gln Ala Gln Ser Arg Met Asn Asn Gly Leu  
 145                  150                  155                  160  
 Val Asp Ala Ser Asp Phe Asp Asp Glu Arg Asn Gly Trp Pro Val Glu  
                   165                  170                  175  
 Gln Val Trp Lys Glu Met His Lys Leu Leu Pro Phe Ser Pro Asp Ser  
                   180                  185                  190  
 Val Val Thr His Gly Asp Phe Ser Leu Asp Asn Leu Ile Phe Asp Glu  
                   195                  200                  205  
 Gly Lys Leu Ile Gly Cys Ile Asp Val Gly Arg Val Gly Ile Ala Asp  
                   210                  215                  220  
 Arg Tyr Gln Asp Leu Ala Ile Leu Trp Asn Cys Leu Gly Glu Phe Ser  
 225                  230                  235                  240  
 Pro Ser Leu Gln Lys Arg Leu Phe Gln Lys Tyr Gly Ile Asp Asn Pro  
                   245                  250                  255  
 Asp Met Asn Lys Leu Gln Phe His Leu Met Leu Asp Glu Phe Phe  
                   260                  265                  270

**THIS PAGE BLANK (USPTO)**

<210> 8  
 <211> 5076  
 <212> DNA  
 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence; Note =  
 synthetic construct

<400> 8

ataggcggcg	catgagagaa	gccagacca	attacctacc	caaaatggag	aaagttcacg	60
ttgacatcga	ggaagacagc	ccattcctca	gagctttgca	gcggagcttc	ccgcagtttg	120
aggtagaagc	caagcaggtc	actgataatg	accatgctaa	tgccagagcg	ttttcgcctc	180
tggcttcaaa	actgatcgaa	acggaggtgg	acccatccga	cacgatcctt	gacattggaa	240
gtgcgcccgc	ccgcagaatg	tattctaagc	acaagtatca	ttgtatctgt	ccgatgagat	300
gtgcggaaga	tccggacaga	ttgtataagt	atgcaactaa	gctgaagaaa	aactgtaagg	360
aaataactga	taaggaattg	gacaagaaaa	tgaaggagct	cgccgccgtc	atgagcgacc	420
ctgacctgga	aactgagact	atgtgcctcc	acgacgacga	gtcgtgtcgc	tacgaagggc	480
aagtgcgtgt	ttaccaggat	gtatacgcg	ttgacggacc	ctataactct	ctacggctaa	540
cctgaatgga	ctacgacata	gtctagtccg	ccaagatgtt	cccgttccag	ccaatgtatc	600
cgatgcagcc	aatgccctat	cgcaaccctg	tgcgggcccc	gcgcaggccc	tggttccccca	660
gaaccgaccc	ttttctggcg	atgcaggtgc	aggaattaac	ccgctcgatg	gctaacctga	720
cgttcaagca	acgcggggac	gcgccacctg	agggggccatc	cgctaagaaa	ccgaagaagg	780
aggcctcgca	aaaacagaaa	gggggaggcc	aagggaagaa	gaagaagaac	caaggggaaga	840
agaaggctaa	gacagggccg	cctaataccga	aggcacagaa	tggaaacaag	aagaagacca	900
acaagaaaac	aggcaagaga	cagcgcatgg	tcatgaaatt	ggaatctgac	aagacgttcc	960
caatcatggt	ggaaggggaag	ataaacggct	acgcttgtgt	ggcggagggg	aagttattca	1020
ggccgatgca	tgtggaaggc	aagatcgaca	acgacgttct	ggccgcgctt	aagacgaaga	1080
aagcatccaa	atacgatctt	gagtatgcag	atgtgccaca	gaacatgcgg	gccgatacat	1140
tcaaatcac	ccatgagaaa	cccgaaggct	attacagctg	gcatcatgga	gcagtccaat	1200
atgaaaatgg	gcgtttcacg	gtgccgaaag	gagttggggc	caaggagagac	agcggacgac	1260
ccattctgga	taaccagggg	cgggtggtcg	ctattgtgct	gggaggtgtg	aatgaaggat	1320
ctaggacagc	cctttcagtc	gtcatgtgga	acgagaaggg	agttaccgtg	aagtatactc	1380
cggagaactg	cgagcaatgg	tcactagtga	ccaccatgtg	tctgctcgcc	aatgtgacgt	1440
tcccatgtgc	tcaaccacca	atttgctacg	acagaaaacc	agcagagact	ttggccatgc	1500
tcagcggttaa	catccctgct	gggaggatca	gccgtaatta	ttataattgg	cttgggtgctg	1560
gctactattg	tggccatgta	cgtgctgacc	aaccagaaac	ataattgaat	acagcagcaa	1620
ttggcaagct	gcttacatag	aactcgcggc	gattggcatg	ccgctttaa	atttttat	1680
tatttttctt	ttcttttccg	aatcggat	tgttttta	atttcaaaaa	aaaaaaaaa	1740
aaaaaaaaa	aaaaaaaaa	aaaaaaaaa	gggaagagcg	cgccgcgcgc	ctgggctacg	1800
tcttgctggc	gttcgcgacg	cgaggctgga	tggccttccc	cattatgatt	cttctcgctt	1860
ccggcggcat	cgggatgccc	gcgttgccag	ccatgctgtc	caggcaggta	gatgacgacc	1920
atcagggaca	gcttcaagga	tcgctcgccg	ctcttaccag	cctaacttcg	atcactggac	1980
cgctgatcgt	cacggcgatt	tatgccgcct	cggcagacac	atggaaacggg	ttggcatgga	2040
ttgtaggcgc	cgccctatac	cttgtctgcc	tcccgcgctt	gcgtcgcggt	gcattggagcc	2100
gggccacctc	gacctgaatg	gaagccggcg	gcacctcgct	aacggattca	ccactccaag	2160
aattggagcc	aatcaattct	tgcggagaac	tgtgaatgcg	caaaccaacc	cttggcagaa	2220
catatccatc	gcgtccgcca	tctccagcag	ccgcacgcgg	cgcactctcg	gcagcgttgg	2280
gtcctggcca	cgggtgcgca	tgatcgtgct	cctgtcgttg	aggaccggc	taggctggcg	2340
gggttgccct	actggttagc	agaatgaatc	accgatacgc	gagcgaacgt	gaagcgactg	2400
ctgctgcaaa	acgtctgcga	cctgagcaac	aacatgaatg	gtcttcgggt	tccgtgttcc	2460
gtaaagtctg	gaaacgcgga	agtcagcgcc	ctgcaccatt	atgttccgga	tctgcatcgc	2520
aggatgctgc	tggctaccct	gtggaacacc	tacatctgta	ttaacgaagc	gctggcattg	2580
accctgagtg	atttttctct	ggtcccgcgc	catccatacc	gccagttgtt	taccctcaca	2640
acgttccagt	aaccgggcat	gttcatcatc	agtaaccctg	atcgtgagca	tcctctctcg	2700

**THIS PAGE BLANK (USPTO)**

tttcatcggt	atcattaccc	ccatgaacag	aaatccccct	tacacggagg	catcagtgac	2760
caaacaggaa	aaaaccgccc	ttaacatggc	ccgctttatc	agaagccaga	cattaacgct	2820
tctggagaaa	ctcaacgagc	tggaacggga	tgaacaggca	gacatctgtg	aatcgcttca	2880
cgaccacgct	gatgagcttt	accgcagctg	cctcgcgctg	ttcggtgatg	acggtgaaaa	2940
cctctgacac	atgcagctcc	cggagacggt	cacagcttgt	ctgtaagcgg	atgccgggag	3000
cagacaagcc	cgtcagggcg	cgtcagcggg	tgttgggcgg	tgtcggggcg	cagccatgac	3060
ccagtcacgt	agcgatagcg	gagtgatatac	tggtttaact	atgcggcatc	agagcagatt	3120
gtactgagag	tgcaccatat	atgcggtgtg	aaataccgca	cagatgcgta	aggagaaaat	3180
accgcatcag	gcgctcttcc	gcttcctcgc	tactgactc	gctgcgctcg	gtcggttcggc	3240
tgcggcgagc	gggtatcagct	cactcaaagg	cggtaatatc	gttatccaca	gaatcagggg	3300
ataacgcagg	aaagaacatg	tgagcaaaa	gccagcaaaa	ggccagggaac	cgtaaaaagg	3360
ccgcgttgct	ggcggttttc	cataggctcc	gccccctga	cgagcatcac	aaaaatcgac	3420
gctcaagtca	gaggtggcga	aaccgcagag	gactataaag	ataccaggcg	tttccccctg	3480
gaagctccct	cgtgcgctct	cctgttccga	ccctgcgct	taccggatac	ctgtccgcct	3540
ttctcccttc	gggaagcggtg	gcgctttctc	atagctcacg	ctgtagggtat	ctcagttcgg	3600
tgtaggctcg	tcgctccaag	ctgggctgtg	tgcacgaacc	ccccgttcag	cccgaaccgt	3660
gcgccttatc	cggtaactat	cgtcttgagt	ccaaccgggt	aagacacgac	ttatcgccac	3720
tggcagcagc	cactggtaac	aggattagca	gagcgaggta	tgtaggcggt	gctacagagt	3780
tcttgaagtg	gtggcctaac	tacggctaca	ctagaaggac	agtatttggt	atctgcgctc	3840
tgctgaagcc	agttaccttc	ggaaaaagag	ttggtagctc	ttgatccggc	aaacaaacca	3900
ccgctggtag	cggtgggtttt	tttggttgca	agcagcagat	tacgcgcaga	aaaaaggat	3960
ctcaagaaga	tcctttgatc	tttctacgg	ggtctgacgc	tcagtggaa	gaaaactcac	4020
gttaagggat	tttggtcatg	aacaataaaa	ctgtctgctt	acataaacag	taatacaagg	4080
ggtgttatga	gccatattca	acgggaaacg	tcttgtctga	ggccgcgatt	aaattccaac	4140
atggatgctg	atttatatgg	gtataaatgg	gctcgcgata	atgtcgggca	atcaggtgcg	4200
acaatctatc	gattgtatgg	gaagcccgat	gcgccagagt	tgtttctgaa	acatggcaaa	4260
ggtagcgttg	ccaatgatgt	tacagatgag	atggtcagac	taaactggct	gacggaattt	4320
atgcctcttc	cgaccatcaa	gcattttatc	cgtactcctg	atgatgcatg	gttactcacc	4380
actcgcgatcc	ccgggaaaaac	agcattccag	gtattagaag	aatatcctga	ttcaggtgaa	4440
aatattgttg	atgcgctggc	agtgttcctg	cgccgggttg	attcgattcc	tgtttgtaat	4500
tgctctttta	acagcgatcg	cgtatttcgt	ctcgctcagg	cgcaatcacg	aatgaataac	4560
ggtttggttg	atgcgagtga	ttttgatgac	gagcgtaatg	gctggcctgt	tgaacaagtc	4620
tggaaagaaa	tgcataagct	tttgccattc	tcaccggatt	cagtcgtcac	tcatggtgat	4680
ttctcacttg	ataaccctat	ttttgacgag	gggaaattaa	taggttgat	tgatgttgga	4740
cgagtcggaa	tcgcagaccg	ataccaggat	cttgccatcc	tatggaactg	cctcggtgag	4800
ttttctcctt	cattacagaa	acggcttttt	caaaaatatg	gtattgataa	tcctgatatg	4860
aataaattgc	agtttcattt	gatgctcgat	gagtttttct	aagaattctc	atgtttgaca	4920
gcttatcatc	gataagcttt	aatgcggtag	tttatcacag	ttaaattgct	aacgcagtca	4980
ggcaccgtgt	atgaaatcta	acaatgcgct	catcgtcatc	ctcgccaccg	tcaccctgga	5040
tgctgtctag	aggatcccta	atacgactca	ctatag			5076

&lt;210&gt; 9

&lt;211&gt; 1026

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence; Note =  
synthetic construct

&lt;221&gt; CDS

&lt;222&gt; (1)...(1026)

**THIS PAGE BLANK (USPTO)**

**THIS PAGE BLANK (USPTO)**

&lt;400&gt; 9

atg ttc ccg ttc cag cca atg tat ccg atg cag cca atg ccc tat cgc 48  
 Met Phe Pro Phe Gln Pro Met Tyr Pro Met Gln Pro Met Pro Tyr Arg  
 1 5 10 15

aac ccg ttc gcg gcc ccg cgc agg ccc tgg ttc ccc aga acc gac cct 96  
 Asn Pro Phe Ala Ala Pro Arg Arg Pro Trp Phe Pro Arg Thr Asp Pro  
 20 25 30

ttt ctg gcg atg cag gtg cag gaa tta acc cgc tcg atg gct aac ctg 144  
 Phe Leu Ala Met Gln Val Gln Glu Leu Thr Arg Ser Met Ala Asn Leu  
 35 40 45

acg ttc aag caa cgc cgg gac gcg cca cct gag ggg cca tcc gct aag 192  
 Thr Phe Lys Gln Arg Arg Asp Ala Pro Pro Glu Gly Pro Ser Ala Lys  
 50 55 60

aaa ccg aag aag gag gcc tcg caa aaa cag aaa ggg gga ggc caa ggg 240  
 Lys Pro Lys Lys Glu Ala Ser Gln Lys Gln Lys Gly Gly Gly Gln Gly  
 65 70 75 80

aag aag aag aag aac caa ggg aag aag aag gct aag aca ggg ccg cct 288  
 Lys Lys Lys Lys Asn Gln Gly Lys Lys Lys Ala Lys Thr Gly Pro Pro  
 85 90 95

aat ccg aag gca cag aat gga aac aag aag aag acc aac aag aaa cca 336  
 Asn Pro Lys Ala Gln Asn Gly Asn Lys Lys Lys Thr Asn Lys Lys Pro  
 100 105 110

ggc aag aga cag cgc atg gtc atg aaa ttg gaa tct gac aag acg ttc 384  
 Gly Lys Arg Gln Arg Met Val Met Lys Leu Glu Ser Asp Lys Thr Phe  
 115 120 125

cca atc atg ttg gaa ggg aag ata aac ggc tac gct tgt gtg gtc gga 432  
 Pro Ile Met Leu Glu Gly Lys Ile Asn Gly Tyr Ala Cys Val Val Gly  
 130 135 140

ggg aag tta ttc agg ccg atg cat gtg gaa ggc aag atc gac aac gac 480  
 Gly Lys Leu Phe Arg Pro Met His Val Glu Gly Lys Ile Asp Asn Asp  
 145 150 155 160

gtt ctg gcc gcg ctt aag acg aag aaa gca tcc aaa tac gat ctt gag 528  
 Val Leu Ala Ala Leu Lys Thr Lys Lys Ala Ser Lys Tyr Asp Leu Glu  
 165 170 175

tat gca gat gtg cca cag aac atg ccg gcc gat aca ttc aaa tac acc 576  
 Tyr Ala Asp Val Pro Gln Asn Met Arg Ala Asp Thr Phe Lys Tyr Thr  
 180 185 190

cat gag aaa ccc caa ggc tat tac agc tgg cat cat gga gca gtc caa 624  
 His Glu Lys Pro Gln Gly Tyr Tyr Ser Trp His His Gly Ala Val Gln  
 195 200 205

tat gaa aat ggg cgt ttc acg gtg ccg aaa gga gtt ggg gcc aag gga 672  
 Tyr Glu Asn Gly Arg Phe Thr Val Pro Lys Gly Val Gly Ala Lys Gly  
 210 215 220

**THIS PAGE BLANK (USPIC,**

```

gac agc gga cga ccc att ctg gat aac cag gga cgg gtg gtc gct att      720
Asp Ser Gly Arg Pro Ile Leu Asp Asn Gln Gly Arg Val Val Ala Ile
225                      230                      235                      240

gtg ctg gga ggt gtg aat gaa gga tct agg aca gcc ctt tca gtc gtc      768
Val Leu Gly Gly Val Asn Glu Gly Ser Arg Thr Ala Leu Ser Val Val
                245                      250                      255

atg tgg aac gag aag gga gtt acc gtg aag tat act ccg gag aac tgc      816
Met Trp Asn Glu Lys Gly Val Thr Val Lys Tyr Thr Pro Glu Asn Cys
                260                      265                      270

gag caa tgg tca cta gtg acc acc atg tgt ctg ctc gcc aat gtg acg      864
Glu Gln Trp Ser Leu Val Thr Thr Met Cys Leu Leu Ala Asn Val Thr
                275                      280                      285

ttc cca tgt gct caa cca cca att tgc tac gac aga aaa cca gca gag      912
Phe Pro Cys Ala Gln Pro Pro Ile Cys Tyr Asp Arg Lys Pro Ala Glu
                290                      295                      300

act ttg gcc atg ctc agc gtt aac atc cct gct ggg agg atc agc cgt      960
Thr Leu Ala Met Leu Ser Val Asn Ile Pro Ala Gly Arg Ile Ser Arg
305                      310                      315                      320

aat tat tat aat tgg ctt ggt gct ggc tac tat tgt ggc cat gta cgt      1008
Asn Tyr Tyr Asn Trp Leu Gly Ala Gly Tyr Tyr Cys Gly His Val Arg
                325                      330                      335

gct gac caa cca gaa aca      1026
Ala Asp Gln Pro Glu Thr
                340

```

&lt;210&gt; 10

&lt;211&gt; 342

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence; Note =  
synthetic construct

&lt;400&gt; 10

```

Met Phe Pro Phe Gln Pro Met Tyr Pro Met Gln Pro Met Pro Tyr Arg
 1                      5                      10                      15
Asn Pro Phe Ala Ala Pro Arg Arg Pro Trp Phe Pro Arg Thr Asp Pro
                20                      25                      30
Phe Leu Ala Met Gln Val Gln Glu Leu Thr Arg Ser Met Ala Asn Leu
                35                      40                      45
Thr Phe Lys Gln Arg Arg Asp Ala Pro Pro Glu Gly Pro Ser Ala Lys
                50                      55                      60
Lys Pro Lys Lys Glu Ala Ser Gln Lys Gln Lys Gly Gly Gly Gln Gly
        65                      70                      75                      80

```

**THIS PAGE BLANK (USPTO)**

33

Lys Lys Lys Lys Asn Gln Gly Lys Lys Lys Ala Lys Thr Gly Pro Pro  
 85 90 95  
 Asn Pro Lys Ala Gln Asn Gly Asn Lys Lys Lys Thr Asn Lys Lys Pro  
 100 105 110  
 Gly Lys Arg Gln Arg Met Val Met Lys Leu Glu Ser Asp Lys Thr Phe  
 115 120 125  
 Pro Ile Met Leu Glu Gly Lys Ile Asn Gly Tyr Ala Cys Val Val Gly  
 130 135 140  
 Gly Lys Leu Phe Arg Pro Met His Val Glu Gly Lys Ile Asp Asn Asp  
 145 150 155 160  
 Val Leu Ala Ala Leu Lys Thr Lys Lys Ala Ser Lys Tyr Asp Leu Glu  
 165 170 175  
 Tyr Ala Asp Val Pro Gln Asn Met Arg Ala Asp Thr Phe Lys Tyr Thr  
 180 185 190  
 His Glu Lys Pro Gln Gly Tyr Tyr Ser Trp His His Gly Ala Val Gln  
 195 200 205  
 Tyr Glu Asn Gly Arg Phe Thr Val Pro Lys Gly Val Gly Ala Lys Gly  
 210 215 220  
 Asp Ser Gly Arg Pro Ile Leu Asp Asn Gln Gly Arg Val Val Ala Ile  
 225 230 235 240  
 Val Leu Gly Gly Val Asn Glu Gly Ser Arg Thr Ala Leu Ser Val Val  
 245 250 255  
 Met Trp Asn Glu Lys Gly Val Thr Val Lys Tyr Thr Pro Glu Asn Cys  
 260 265 270  
 Glu Gln Trp Ser Leu Val Thr Thr Met Cys Leu Leu Ala Asn Val Thr  
 275 280 285  
 Phe Pro Cys Ala Gln Pro Pro Ile Cys Tyr Asp Arg Lys Pro Ala Glu  
 290 295 300  
 Thr Leu Ala Met Leu Ser Val Asn Ile Pro Ala Gly Arg Ile Ser Arg  
 305 310 315 320  
 Asn Tyr Tyr Asn Trp Leu Gly Ala Gly Tyr Tyr Cys Gly His Val Arg  
 325 330 335  
 Ala Asp Gln Pro Glu Thr  
 340

&lt;210&gt; 11

&lt;211&gt; 6989

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence; Note =  
 synthetic construct

&lt;400&gt; 11

ataggcggcg	catgagagaa	gcccagacca	attacctacc	caaaatggag	aaagtccacg	60
ttgacatcga	ggaagacagc	ccattcctca	gagctttgca	gcgagcttc	ccgcagtttg	120
aggtagaagc	caagcaggtc	actgataatg	accatgctaa	tgccagagcg	ttttcgcatc	180
tggcttcaaa	actgatcgaa	acggagggtg	acccatccga	cacgatcctt	gacattggaa	240
gtgcgccgc	ccgcagaatg	tattctaagc	acaagtatca	ttgtatctgt	ccgatgagat	300
gtgcggaaga	tccggacaga	ttgtataagt	atgcaactaa	gctgaagaaa	aactgtaagg	360
aaataactga	taaggaattg	gacaagaaaa	tgaaggagct	cgccgccgtc	atgagcgacc	420
ctgacctgga	aactgagact	atgtgcctcc	acgacgacga	gtcgtgtcgc	tacgaagggc	480
aagtcgctgt	ttaccaggat	gtatacgcg	ttgacggacc	ctataactct	ctacggctaa	540
cctgaatgga	ctacgacata	gtctagtcgg	ccaagatgtc	actagtgacc	accatgtgtc	600

**THIS PAGE BLANK (USPTO)**

tgctcgccaa	tgtgacgttc	ccatgtgctc	aaccaccaat	ttgctacgac	agaaaaccag	660
cagagacttt	ggccatgctc	agcgtaaacc	ttgacaaccc	gggctacgat	gagctgctgg	720
aagcagctgt	taagtgtccc	ggaaggaaaa	ggagatccac	cgaggagctg	tttaaggagt	780
ataagctaac	gcgcccctac	atggccagat	gcatacagatg	tgcagttggg	agctgccata	840
gtccaatagc	aatcgaggca	gtaaagagcg	acgggcacga	cggttatggt	agacttcaga	900
cttcctcgca	gtatggcctg	gattcctccg	gcaacttaaa	gggcaggacc	atgcggtatg	960
acatgcacgg	gaccattaaa	gagataccac	tacatcaagt	gtcactccat	acatctcgcc	1020
cgtgtcacat	tgtggatggg	cacgggtatt	tcctgcttgc	cagggtgccc	gcaggggact	1080
ccatcaccat	ggaatttaag	aaagattccg	tcacacactc	ctgctcggtg	ccgatgaag	1140
tgaaatttaa	tcctgtaggc	agagaactct	atactcatcc	cccagaacac	ggagtagagc	1200
aagcgtgcc	agtctacgca	catgatgcac	agaacagagg	agcttatgtc	gagatgcacc	1260
tcccaggctc	agaagtggac	agcagtttgg	tttccttgag	cggcagttca	gtcaccgtga	1320
cacctcctgt	tgggactagc	gccctggtgg	aatgcgagtg	tggcggcaca	aagatctcca	1380
agaccatcaa	caagacaaaa	cagttcagcc	agtgcacaaa	gaaggagcag	tgagagcat	1440
atcggtgca	gaacgataag	tgggtgtata	attctgacaa	actgccc aaa	gcagcgggag	1500
ccaccttaaa	aggaaaactg	catgtcccat	tcttgctggc	agacggcaaa	tgaccggtgc	1560
ctctagcacc	agaacctatg	ataaccttcg	gtttcagatc	agtgtcactg	aaactgcacc	1620
ctaagaatcc	cacatatcta	accacccgcc	aacttgctga	tgagcctcac	tacacgcacg	1680
agctcatatc	tgaaccagct	gttaggaatt	ttaccgtcac	cggaaaagg	tgggagtttg	1740
tatggggaaa	ccaccgcgcg	aaaaggtttt	gggcacagga	aacagcacc	ggaaatccac	1800
atgggctacc	gcacgaggtg	ataactcatt	attaccacag	ataccctatg	tccaccatcc	1860
tgggtttgtc	aattttgtgc	gccattgcaa	ccgtttccgt	tgcagcgtct	acctggctgt	1920
tttgcatatc	tagagttgcg	tgcttaactc	cttaccggct	aacacctaac	gctaggatac	1980
cattttgtct	ggctgtgctt	tgctgcgcgc	gcactgccc	ggccgagacc	acctgggagt	2040
ccttgatca	cctatggaac	aataaccaac	agatgttctg	gattcaattg	ctgatccctc	2100
tggcgcgcct	gatcgtagt	actcgcctgc	tcaggtgcgt	gtgctgtgtc	gtgccttttt	2160
tagtcatggc	cgcgcgcgca	ggcgcgcgcg	cctacgagca	cgcgaccacg	atgccgagcc	2220
aagcgggaat	ctcgtataac	actatagtca	acagagcagg	ctacgcacca	ctccctatca	2280
gcataaacacc	aaacaaagatc	aagctgatac	ctacagtga	cttgagtag	gtcacctgcc	2340
actacaaaac	aggaatggat	tcaccagcca	tcaaatgctg	cggatctcag	gaatgcactc	2400
caacttacag	gcctgatgaa	cagtgc aaag	tcttcacagg	ggtttaccgc	ttcatgtggg	2460
gtggtgcata	ttgcttttgc	gacactgaga	acacccaagt	cagcaaggcc	tacgtaatga	2520
aatctgacga	ctgccttgcg	gatcatgctg	aagcatataa	agcgcacaca	gcctcagtgc	2580
aggcgttcct	caacatcaca	gtgggagaac	actctattgt	gactaccgtg	tatgtgaatg	2640
gagaaactcc	tgtgaatttc	aatggggtca	aattaaactgc	aggctcgcgt	tccacagctt	2700
ggacaccctt	tgatcgcaaa	atcgtgcagt	atgccgggga	gatctataat	tatgattttc	2760
ctgagtatgg	ggcaggacaa	ccaggagcat	ttggagatat	acaatccaga	acagtctcaa	2820
gctcagatct	gtatgccaat	accaacctag	tgctgcagag	acccaaagca	ggagcgatcc	2880
acgtgccata	cactcaggca	ccttcggggt	ttgagcaatg	gaagaaagat	aaagctccat	2940
cattgaaatt	taccgcccct	ttcggatgcg	aaatatatac	aaacccatt	cgcgcgaaa	3000
actgtactgt	agggtcaatt	ccattagcct	ttgacattcc	cgacgccttg	ttcaccaggg	3060
tgtcagaaac	accgacactt	tcagcggccg	aatgcactct	taacgagtgc	gtgtattcct	3120
cgcacttttg	tgggatcgcc	acgggtcaagt	actcggccag	caagtcaggc	aagtgcgcag	3180
tccatgtgcc	atcagggact	gctaccctaa	aagaagcagc	agtcgagcta	accgagcaag	3240
ggtcggcgac	tatccatttc	tcgaccgcaa	atatccaccc	ggagttcagg	ctccaaatat	3300
gcacatcata	tgttacgtgc	aaagggtgatt	gtcacccccc	gaaagaccat	attgtgacac	3360
accctcagta	tcacgccc aa	acattttacag	ccgcgggtgc	aaaaaccgcg	tggacgtggg	3420
taacatccct	gctgggagga	tcagccgtaa	ttattataat	tggcttgggtg	ctggctacta	3480
ttgtggccat	gtacgtgctg	accaaccaga	aacataattg	aatacagcag	caattggcaa	3540
gctgcttaca	tagaactcgc	ggcgattggc	atgccgcttt	aaaattttta	ttttattttt	3600
cttttctttt	ccgaatcgga	ttttgttttt	aatattttcaa	aaaaaaaaaa	aaaaaaaaaa	3660
aaaaaaaaaa	aaaaaaaaaa	aaaggggaaga	gcgcggccgc	gcgctgggct	acgtcttgct	3720
ggcgttcgcg	acgcgaggct	ggatggcctt	ccccattatg	attcttctcg	cttccggcgg	3780
catcgggatg	ccgcggttgc	aggccatgct	gtccaggcag	gtagatgacg	accatcaggg	3840
acagcttcaa	ggatcgctcg	cggctcttac	cagcctaact	tcgatcactg	gaccgctgat	3900

**THIS PAGE BLANK (USPTO)**

cgtcacggcg	atztatgccg	cctcgggcgag	cacatggaac	gggttggcat	ggattgtagg	3960
cgccgcccta	taccttgtct	gcctccccgc	gttgcgctgc	ggatgcatgga	gccggggccac	4020
ctcgacctga	atggaagccg	gcggcacctc	gctaaccgat	tcaccactcc	aagaattgga	4080
gccaatcaat	tcttgccggag	aactgtgaat	gcgcaaacca	acccttggca	gaacatatcc	4140
atcgcgccg	ccatctccag	cagccgcacg	cggcgcatct	cgggcagcgt	tgggtcctgg	4200
ccacgggtgc	gcatgatcgt	gctcctgtcg	ttgaggaccc	ggctaggctg	gcgggggtgc	4260
cttactgggt	agcagaatga	atcaccgata	cgcgagcgaa	cgtgaagcga	ctgctgctgc	4320
aaaacgtctg	cgacctgagc	aacaacatga	atgggtcttcg	gtttccgtgt	ttcgtaaagt	4380
ctggaaacgc	ggaagtgcgc	gccctgcacc	attatgttcc	ggatctgcat	cgcaggatgc	4440
tgctgggtac	cctgtggaac	acctacatct	gtattaacga	agcgtgga	ttgaccctga	4500
gtgatttttc	tctggtcccc	ccgcatccat	accgccagtt	gtttaccctc	acaacgttcc	4560
agtaaccggg	catgttcac	atcagtaacc	cgtatcgtga	gcacccctc	tcgtttcatc	4620
gggtatcatta	cccccatgaa	cagaaatccc	ccttacacgg	aggcatcagt	gaccaaacag	4680
gaaaaaaccc	cccttaacat	ggcccgcctt	atcagaagcc	agacattaac	gcttctggag	4740
aaactcaacg	agctggacgc	ggatgaacag	gcagacatct	gtgaatcgct	tcacgaccac	4800
gctgatgagc	tttaccgcag	ctgcctcgcg	cgtttcggtg	atgacgggtga	aaacctctga	4860
cacatgcagc	tcccggagac	ggtcacagct	tgtctgtaag	cggatgccgg	gagcagacaa	4920
gcccgtcagg	gcgcgtcagc	gggtgttggc	gggtgtcggg	gcgcagccat	gaccagctca	4980
cgtagcgata	gcggagtgtg	tactggctta	actatgcggc	atcagagcag	attgtactga	5040
gagtgcacca	tatatcggtg	gtgaaatacc	gcacagatgc	gtaaggagaa	aataccgcac	5100
caggcgctct	tccgcttctc	cgctcactga	ctcgctgcgc	tcggtcgttc	ggctgcggcg	5160
agcggtatca	gtcactcaa	aggcggtaat	acgggtatcc	acagaatcag	gggataacgc	5220
aggaaagaac	atgtgagcaa	aaggccagca	aaaggccagg	aaccgtaaaa	aggccgcggt	5280
gctggcgctt	ttccataggc	tccgcccccc	tgacgagcat	cacaaaaatc	gacgctcaag	5340
tcagagggtg	cgaaacccga	caggactata	aagataccag	gcgtttcccc	ctggaagctc	5400
cctcgctgcg	tctcctgttc	cgaccctgcc	gcttaccgga	tacctgtccg	cctttctccc	5460
ttcggaagc	tgggcgcttt	ctcatagctc	acgctgtagg	tatctcagtt	cgggtgaggt	5520
cgttcgctcc	aagctgggct	gtgtgcacga	accccccggt	cagcccgacc	gctgcgcctt	5580
atccggtaac	tatcgtcttg	agtccaaccc	ggtaagacac	gacttatcgc	cactggcagc	5640
agccactggg	aacaggatta	gcagagcgag	gtatgtaggc	ggtgctacag	agttcttgaa	5700
gtgggtggct	aactacggct	acactagaag	gacagtattt	ggatatctgcg	ctctgctgaa	5760
gccagttacc	ttcggaaaaa	gagttggtag	ctcttgatcc	ggcaaaaaa	ccaccgctgg	5820
tagcgggtgg	ttttttgttt	gcaagcagca	gattacgcgc	agaaaaaaag	gatctcaaga	5880
agatcctttg	atcttttcta	cggggtctga	cgctcagtgg	aacgaaaact	cacgttaagg	5940
gattttgggt	atgaacaata	aaactgtctg	cttacataaa	cagtaataca	aggggtgtta	6000
tgagccatat	tcaacgggaa	acgtcttgct	cgaggccgcg	attaaattcc	aacatggatg	6060
ctgatttata	tgggtataaa	tgggctcgcg	ataatgtcgg	gcaatcaggt	gcgacaatct	6120
atcgattgta	tgggaagccc	gatgcgccag	agttgtttct	gaaacatggc	aaaggtagcg	6180
ttgccaatga	tgttacagat	gagatgggtc	gactaaactg	gctgacggaa	tttatgcctc	6240
ttccgaccat	caagcatttt	atccgtactc	ctgatgatgc	atgggtactc	accactgcga	6300
tccccgggaa	aacagcattc	cagggtattag	aagaatatcc	tgattcaggt	gaaaatatattg	6360
ttgatgcgct	ggcagtggtc	ctgcgcgggt	tgcattcgat	tcctgtttgt	aattgtcctt	6420
ttaacagcga	tcgcgtattt	cgtctcgctc	aggcgcaatc	acgaatgaat	aacgggtttgg	6480
ttgatgcgag	tgatttttgat	gacgagcgta	atggctggcc	tggtgaacaa	gtctggaaag	6540
aaatgcataa	gcttttgcca	ttctcaccgg	attcagtcgt	cactcatggg	gattttctcac	6600
ttgataacct	tatttttgac	gaggggaaat	taataggttg	tattgatgtt	ggacgagtcg	6660
gaatcgcaga	ccgataaccag	gatcttgcca	tcctatggaa	ctgcctcggt	gagttttctc	6720
cttcattaca	gaaacggctt	tttcaaaaat	atgggtattga	taatcctgat	atgaataaat	6780
tgcagtttca	tttgatgctc	gatgagtttt	tctaagaatt	ctcatgtttg	acagcttata	6840
atcgataagc	tttaatgcgg	tagtttatca	cagttaaatt	gctaacgcag	tcaggcaccg	6900
tgtatgaaat	ctaacaatgc	gctcatcgct	atcctcggca	ccgtcaccct	ggatgctgtc	6960
tagaggatcc	ctaatacgac	tcactatag				6989

**THIS PAGE BLANK (USPTO)**

36

&lt;210&gt; 12

&lt;211&gt; 2943

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence; Note =  
synthetic construct

&lt;221&gt; CDS

&lt;222&gt; (1)...(2943)

&lt;400&gt; 12

atg tca cta gtg acc acc atg tgt ctg ctc gcc aat gtg acg ttc cca	48
Met Ser Leu Val Thr Thr Met Cys Leu Leu Ala Asn Val Thr Phe Pro	
1 5 10 15	

tgt gct caa cca cca att tgc tac gac aga aaa cca gca gag act ttg	96
Cys Ala Gln Pro Pro Ile Cys Tyr Asp Arg Lys Pro Ala Glu Thr Leu	
20 25 30	

gcc atg ctc agc gtt aac gtt gac aac ccg ggc tac gat gag ctg ctg	144
Ala Met Leu Ser Val Asn Val Asp Asn Pro Gly Tyr Asp Glu Leu Leu	
35 40 45	

gaa gca gct gtt aag tgc ccc gga agg aaa agg aga tcc acc gag gag	192
Glu Ala Ala Val Lys Cys Pro Gly Arg Lys Arg Arg Ser Thr Glu Glu	
50 55 60	

ctg ttt aag gag tat aag cta acg cgc cct tac atg gcc aga tgc atc	240
Leu Phe Lys Glu Tyr Lys Leu Thr Arg Pro Tyr Met Ala Arg Cys Ile	
65 70 75 80	

aga tgt gca gtt ggg agc tgc cat agt cca ata gca atc gag gca gta	288
Arg Cys Ala Val Gly Ser Cys His Ser Pro Ile Ala Ile Glu Ala Val	
85 90 95	

aag agc gac ggg cac gac ggt tat gtt aga ctt cag act tcc tcg cag	336
Lys Ser Asp Gly His Asp Gly Tyr Val Arg Leu Gln Thr Ser Ser Gln	
100 105 110	

tat ggc ctg gat tcc tcc ggc aac tta aag ggc agg acc atg cgg tat	384
Tyr Gly Leu Asp Ser Ser Gly Asn Leu Lys Gly Arg Thr Met Arg Tyr	
115 120 125	

gac atg cac ggg acc att aaa gag ata cca cta cat caa gtg tca ctc	432
Asp Met His Gly Thr Ile Lys Glu Ile Pro Leu His Gln Val Ser Leu	
130 135 140	

cat aca tct cgc ccg tgt cac att gtg gat ggc cac ggt tat ttc ctg	480
His Thr Ser Arg Pro Cys His Ile Val Asp Gly His Gly Tyr Phe Leu	
145 150 155 160	

ctt gcc agg tgc ccg gca ggg gac tcc atc acc atg gaa ttt aag aaa	528
Leu Ala Arg Cys Pro Ala Gly Asp Ser Ile Thr Met Glu Phe Lys Lys	
165 170 175	

**THIS PAGE BLANK (USPTO,**

gat tcc gtc aca cac tcc tgc tgc gtg ccg tat gaa gtg aaa ttt aat Asp Ser Val Thr His Ser Cys Ser Val Pro Tyr Glu Val Lys Phe Asn 180 185 190	576
cct gta ggc aga gaa ctc tat act cat ccc cca gaa cac gga gta gag Pro Val Gly Arg Glu Leu Tyr Thr His Pro Pro Glu His Gly Val Glu 195 200 205	624
caa gcg tgc caa gtc tac gca cat gat gca cag aac aga gga gct tat Gln Ala Cys Gln Val Tyr Ala His Asp Ala Gln Asn Arg Gly Ala Tyr 210 215 220	672
gtc gag atg cac ctc cca ggc tca gaa gtg gac agc agt ttg gtt tcc Val Glu Met His Leu Pro Gly Ser Glu Val Asp Ser Ser Leu Val Ser 225 230 235 240	720
ttg agc ggc agt tca gtc acc gtg aca cct cct gtt ggg act agc gcc Leu Ser Gly Ser Ser Val Thr Val Thr Pro Pro Val Gly Thr Ser Ala 245 250 255	768
ctg gtg gaa tgc gag tgt ggc ggc aca aag atc tcc aag acc atc aac Leu Val Glu Cys Glu Cys Gly Gly Thr Lys Ile Ser Lys Thr Ile Asn 260 265 270	816
aag aca aaa cag ttc agc cag tgc aca aag aag gag cag tgc aga gca Lys Thr Lys Gln Phe Ser Gln Cys Thr Lys Lys Glu Gln Cys Arg Ala 275 280 285	864
tat cgg ctg cag aac gat aag tgg gtg tat aat tct gac aaa ctg ccc Tyr Arg Leu Gln Asn Asp Lys Trp Val Tyr Asn Ser Asp Lys Leu Pro 290 295 300	912
aaa gca gcg gga gcc acc tta aaa gga aaa ctg cat gtc cca ttc ttg Lys Ala Ala Gly Ala Thr Leu Lys Gly Lys Leu His Val Pro Phe Leu 305 310 315 320	960
ctg gca gac ggc aaa tgc acc gtg cct cta gca cca gaa cct atg ata Leu Ala Asp Gly Lys Cys Thr Val Pro Leu Ala Pro Glu Pro Met Ile 325 330 335	1008
acc ttc ggt ttc aga tca gtg tca ctg aaa ctg cac cct aag aat ccc Thr Phe Gly Phe Arg Ser Val Ser Leu Lys Leu His Pro Lys Asn Pro 340 345 350	1056
aca tat cta acc acc cgc caa ctt gct gat gag cct cac tac acg cat Thr Tyr Leu Thr Thr Arg Gln Leu Ala Asp Glu Pro His Tyr Thr His 355 360 365	1104
gag ctc ata tct gaa cca gct gtt agg aat ttt acc gtc acc gga aaa Glu Leu Ile Ser Glu Pro Ala Val Arg Asn Phe Thr Val Thr Gly Lys 370 375 380	1152
ggg tgg gag ttt gta tgg gga aac cac ccg ccg aaa agg ttt tgg gca Gly Trp Glu Phe Val Trp Gly Asn His Pro Pro Lys Arg Phe Trp Ala 385 390 395 400	1200

**THIS PAGE BLANK (USPTO)**

cag gaa aca gca ccc gga aat cca cat ggg cta ccg cac gag gtg ata	1248
Gln Glu Thr Ala Pro Gly Asn Pro His Gly Leu Pro His Glu Val Ile	
405 410 415	
act cat tat tac cac aga tac cct atg tcc acc atc ctg ggt ttg tca	1296
Thr His Tyr Tyr His Arg Tyr Pro Met Ser Thr Ile Leu Gly Leu Ser	
420 425 430	
att tgt gcc gcc att gca acc gtt tcc gtt gca gcg tct acc tgg ctg	1344
Ile Cys Ala Ala Ile Ala Thr Val Ser Val Ala Ala Ser Thr Trp Leu	
435 440 445	
ttt tgc aga tct aga gtt gcg tgc cta act cct tac cgg cta aca cct	1392
Phe Cys Arg Ser Arg Val Ala Cys Leu Thr Pro Tyr Arg Leu Thr Pro	
450 455 460	
aac gct agg ata cca ttt tgt ctg gct gtg ctt tgc tgc gcc cgc act	1440
Asn Ala Arg Ile Pro Phe Cys Leu Ala Val Leu Cys Cys Ala Arg Thr	
465 470 475 480	
gcc cgg gcc gag acc acc tgg gag tcc ttg gat cac cta tgg aac aat	1488
Ala Arg Ala Glu Thr Trp Glu Ser Leu Asp His Leu Trp Asn Asn	
485 490 495	
aac caa cag atg ttc tgg att caa ttg ctg atc cct ctg gcc gcc ttg	1536
Asn Gln Gln Met Phe Trp Ile Gln Leu Leu Ile Pro Leu Ala Ala Leu	
500 505 510	
atc gta gtg act cgc ctg ctc agg tgc gtg tgc tgt gtc gtg cct ttt	1584
Ile Val Val Thr Arg Leu Leu Arg Cys Val Cys Cys Val Val Pro Phe	
515 520 525	
tta gtc atg gcc ggc gcc gca ggc gcc ggc gcc tac gag cac gcg acc	1632
Leu Val Met Ala Gly Ala Ala Gly Ala Gly Ala Tyr Glu His Ala Thr	
530 535 540	
acg atg ccg agc caa gcg gga atc tcg tat aac act ata gtc aac aga	1680
Thr Met Pro Ser Gln Ala Gly Ile Ser Tyr Asn Thr Ile Val Asn Arg	
545 550 555 560	
gca ggc tac gca cca ctc cct atc agc ata aca cca aca aag atc aag	1728
Ala Gly Tyr Ala Pro Leu Pro Ile Ser Ile Thr Pro Thr Lys Ile Lys	
565 570 575	
ctg ata cct aca gtg aac ttg gag tac gtc acc tgc cac tac aaa aca	1776
Leu Ile Pro Thr Val Asn Leu Glu Tyr Val Thr Cys His Tyr Lys Thr	
580 585 590	
gga atg gat tca cca gcc atc aaa tgc tgc gga tct cag gaa tgc act	1824
Gly Met Asp Ser Pro Ala Ile Lys Cys Cys Gly Ser Gln Glu Cys Thr	
595 600 605	
cca act tac agg cct gat gaa cag tgc aaa gtc ttc aca ggg gtt tac	1872
Pro Thr Tyr Arg Pro Asp Glu Gln Cys Lys Val Phe Thr Gly Val Tyr	
610 615 620	

**THIS PAGE BLANK (USPTO)**

ccg ttc atg tgg ggt ggt gca tat tgc ttt tgc gac act gag aac acc	1920
Pro Phe Met Trp Gly Gly Ala Tyr Cys Phe Cys Asp Thr Glu Asn Thr	
625 630 635 640	
caa gtc agc aag gcc tac gta atg aaa tct gac gac tgc ctt gcg gat	1968
Gln Val Ser Lys Ala Tyr Val Met Lys Ser Asp Asp Cys Leu Ala Asp	
645 650 655	
cat gct gaa gca tat aaa gcg cac aca gcc tca gtg cag gcg ttc ctc	2016
His Ala Glu Ala Tyr Lys Ala His Thr Ala Ser Val Gln Ala Phe Leu	
660 665 670	
aac atc aca gtg gga gaa cac tct att gtg act acc gtg tat gtg aat	2064
Asn Ile Thr Val Gly Glu His Ser Ile Val Thr Thr Val Tyr Val Asn	
675 680 685	
gga gaa act cct gtg aat ttc aat ggg gtc aaa tta act gca ggt ccg	2112
Gly Glu Thr Pro Val Asn Phe Asn Gly Val Lys Leu Thr Ala Gly Pro	
690 695 700	
ctt tcc aca gct tgg aca ccc ttt gat cgc aaa atc gtg cag tat gcc	2160
Leu Ser Thr Ala Trp Thr Pro Phe Asp Arg Lys Ile Val Gln Tyr Ala	
705 710 715 720	
ggg gag atc tat aat tat gat ttt cct gag tat ggg gca gga caa cca	2208
Gly Glu Ile Tyr Asn Tyr Asp Phe Pro Glu Tyr Gly Ala Gly Gln Pro	
725 730 735	
gga gca ttt gga gat ata caa tcc aga aca gtc tca agc tca gat ctg	2256
Gly Ala Phe Gly Asp Ile Gln Ser Arg Thr Val Ser Ser Ser Asp Leu	
740 745 750	
tat gcc aat acc aac cta gtg ctg cag aga ccc aaa gca gga gcg atc	2304
Tyr Ala Asn Thr Asn Leu Val Leu Gln Arg Pro Lys Ala Gly Ala Ile	
755 760 765	
cac gtg cca tac act cag gca cct tcg ggt ttt gag caa tgg aag aaa	2352
His Val Pro Tyr Thr Gln Ala Pro Ser Gly Phe Glu Gln Trp Lys Lys	
770 775 780	
gat aaa gct cca tca ttg aaa ttt acc gcc cct ttc gga tgc gaa ata	2400
Asp Lys Ala Pro Ser Leu Lys Phe Thr Ala Pro Phe Gly Cys Glu Ile	
785 790 795 800	
tat aca aac ccc att cgc gcc gaa aac tgt act gta ggg tca att cca	2448
Tyr Thr Asn Pro Ile Arg Ala Glu Asn Cys Thr Val Gly Ser Ile Pro	
805 810 815	
tta gcc ttt gac att ccc gac gcc ttg ttc acc agg gtg tca gaa aca	2496
Leu Ala Phe Asp Ile Pro Asp Ala Leu Phe Thr Arg Val Ser Glu Thr	
820 825 830	
ccg aca ctt tca gcg gcc gaa tgc act ctt aac gag tgc gtg tat tct	2544
Pro Thr Leu Ser Ala Ala Glu Cys Thr Leu Asn Glu Cys Val Tyr Ser	
835 840 845	

**THIS PAGE BLANK (USPTO)**

tcc gac ttt ggt ggg atc gcc acg gtc aag tac tcg gcc agc aag tca	2592
Ser Asp Phe Gly Gly Ile Ala Thr Val Lys Tyr Ser Ala Ser Lys Ser	
850 855 860	
ggc aag tgc gca gtc cat gtg cca tca ggg act gct acc cta aaa gaa	2640
Gly Lys Cys Ala Val His Val Pro Ser Gly Thr Ala Thr Leu Lys Glu	
865 870 875 880	
gca gca gtc gag cta acc gag caa ggg tcg gcg act atc cat ttc tcg	2688
Ala Ala Val Glu Leu Thr Glu Gln Gly Ser Ala Thr Ile His Phe Ser	
885 890 895	
acc gca aat atc cac ccg gag ttc agg ctc caa ata tgc aca tca tat	2736
Thr Ala Asn Ile His Pro Glu Phe Arg Leu Gln Ile Cys Thr Ser Tyr	
900 905 910	
gtt acg tgc aaa ggt gat tgt cac ccc ccg aaa gac cat att gtg aca	2784
Val Thr Cys Lys Gly Asp Cys His Pro Pro Lys Asp His Ile Val Thr	
915 920 925	
cac cct cag tat cac gcc caa aca ttt aca gcc gcg gtg tca aaa acc	2832
His Pro Gln Tyr His Ala Gln Thr Phe Thr Ala Ala Val Ser Lys Thr	
930 935 940	
gcg tgg acg tgg tta aca tcc ctg ctg gga gga tca gcc gta att att	2880
Ala Trp Thr Trp Leu Thr Ser Leu Leu Gly Gly Ser Ala Val Ile Ile	
945 950 955 960	
ata att ggc ttg gtg ctg gct act att gtg gcc atg tac gtg ctg acc	2928
Ile Ile Gly Leu Val Leu Ala Thr Ile Val Ala Met Tyr Val Leu Thr	
965 970 975	
aac cag aaa cat aat	2943
Asn Gln Lys His Asn	
980	

&lt;210&gt; 13

&lt;211&gt; 981

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence; Note =  
synthetic construct

&lt;400&gt; 13

Met Ser Leu Val Thr Thr Met Cys Leu Leu Ala Asn Val Thr Phe Pro	
1 5 10 15	
Cys Ala Gln Pro Pro Ile Cys Tyr Asp Arg Lys Pro Ala Glu Thr Leu	
20 25 30	
Ala Met Leu Ser Val Asn Val Asp Asn Pro Gly Tyr Asp Glu Leu Leu	
35 40 45	

**THIS PAGE BLANK (USPTO)**

Glu Ala Ala Val Lys Cys Pro Gly Arg Lys Arg Arg Ser Thr Glu Glu  
 50 55 60  
 Leu Phe Lys Glu Tyr Lys Leu Thr Arg Pro Tyr Met Ala Arg Cys Ile  
 65 70 75 80  
 Arg Cys Ala Val Gly Ser Cys His Ser Pro Ile Ala Ile Glu Ala Val  
 85 90 95  
 Lys Ser Asp Gly His Asp Gly Tyr Val Arg Leu Gln Thr Ser Ser Gln  
 100 105 110  
 Tyr Gly Leu Asp Ser Ser Gly Asn Leu Lys Gly Arg Thr Met Arg Tyr  
 115 120 125  
 Asp Met His Gly Thr Ile Lys Glu Ile Pro Leu His Gln Val Ser Leu  
 130 135 140  
 His Thr Ser Arg Pro Cys His Ile Val Asp Gly His Gly Tyr Phe Leu  
 145 150 155 160  
 Leu Ala Arg Cys Pro Ala Gly Asp Ser Ile Thr Met Glu Phe Lys Lys  
 165 170 175  
 Asp Ser Val Thr His Ser Cys Ser Val Pro Tyr Glu Val Lys Phe Asn  
 180 185 190  
 Pro Val Gly Arg Glu Leu Tyr Thr His Pro Pro Glu His Gly Val Glu  
 195 200 205  
 Gln Ala Cys Gln Val Tyr Ala His Asp Ala Gln Asn Arg Gly Ala Tyr  
 210 215 220  
 Val Glu Met His Leu Pro Gly Ser Glu Val Asp Ser Ser Leu Val Ser  
 225 230 235 240  
 Leu Ser Gly Ser Ser Val Thr Val Thr Pro Pro Val Gly Thr Ser Ala  
 245 250 255  
 Leu Val Glu Cys Glu Cys Gly Gly Thr Lys Ile Ser Lys Thr Ile Asn  
 260 265 270  
 Lys Thr Lys Gln Phe Ser Gln Cys Thr Lys Lys Glu Gln Cys Arg Ala  
 275 280 285  
 Tyr Arg Leu Gln Asn Asp Lys Trp Val Tyr Asn Ser Asp Lys Leu Pro  
 290 295 300  
 Lys Ala Ala Gly Ala Thr Leu Lys Gly Lys Leu His Val Pro Phe Leu  
 305 310 315 320  
 Leu Ala Asp Gly Lys Cys Thr Val Pro Leu Ala Pro Glu Pro Met Ile  
 325 330 335  
 Thr Phe Gly Phe Arg Ser Val Ser Leu Lys Leu His Pro Lys Asn Pro  
 340 345 350  
 Thr Tyr Leu Thr Thr Arg Gln Leu Ala Asp Glu Pro His Tyr Thr His  
 355 360 365  
 Glu Leu Ile Ser Glu Pro Ala Val Arg Asn Phe Thr Val Thr Gly Lys  
 370 375 380  
 Gly Trp Glu Phe Val Trp Gly Asn His Pro Pro Lys Arg Phe Trp Ala  
 385 390 395 400  
 Gln Glu Thr Ala Pro Gly Asn Pro His Gly Leu Pro His Glu Val Ile  
 405 410 415  
 Thr His Tyr Tyr His Arg Tyr Pro Met Ser Thr Ile Leu Gly Leu Ser  
 420 425 430  
 Ile Cys Ala Ala Ile Ala Thr Val Ser Val Ala Ala Ser Thr Trp Leu  
 435 440 445  
 Phe Cys Arg Ser Arg Val Ala Cys Leu Thr Pro Tyr Arg Leu Thr Pro  
 450 455 460  
 Asn Ala Arg Ile Pro Phe Cys Leu Ala Val Leu Cys Cys Ala Arg Thr  
 465 470 475 480

**THIS PAGE BLANK (USPTO)**

Ala	Arg	Ala	Glu	Thr	Thr	Trp	Glu	Ser	Leu	Asp	His	Leu	Trp	Asn	Asn	485	490	495
Asn	Gln	Gln	Met	Phe	Trp	Ile	Gln	Leu	Leu	Ile	Pro	Leu	Ala	Ala	Leu	500	505	510
Ile	Val	Val	Thr	Arg	Leu	Leu	Arg	Cys	Val	Cys	Cys	Val	Val	Pro	Phe	515	520	525
Leu	Val	Met	Ala	Gly	Ala	Ala	Gly	Ala	Gly	Ala	Tyr	Glu	His	Ala	Thr	530	535	540
Thr	Met	Pro	Ser	Gln	Ala	Gly	Ile	Ser	Tyr	Asn	Thr	Ile	Val	Asn	Arg	545	550	555
Ala	Gly	Tyr	Ala	Pro	Leu	Pro	Ile	Ser	Ile	Thr	Pro	Thr	Lys	Ile	Lys	565	570	575
Leu	Ile	Pro	Thr	Val	Asn	Leu	Glu	Tyr	Val	Thr	Cys	His	Tyr	Lys	Thr	580	585	590
Gly	Met	Asp	Ser	Pro	Ala	Ile	Lys	Cys	Cys	Gly	Ser	Gln	Glu	Cys	Thr	595	600	605
Pro	Thr	Tyr	Arg	Pro	Asp	Glu	Gln	Cys	Lys	Val	Phe	Thr	Gly	Val	Tyr	610	615	620
Pro	Phe	Met	Trp	Gly	Gly	Ala	Tyr	Cys	Phe	Cys	Asp	Thr	Glu	Asn	Thr	625	630	635
Gln	Val	Ser	Lys	Ala	Tyr	Val	Met	Lys	Ser	Asp	Asp	Cys	Leu	Ala	Asp	645	650	655
His	Ala	Glu	Ala	Tyr	Lys	Ala	His	Thr	Ala	Ser	Val	Gln	Ala	Phe	Leu	660	665	670
Asn	Ile	Thr	Val	Gly	Glu	His	Ser	Ile	Val	Thr	Thr	Val	Tyr	Val	Asn	675	680	685
Gly	Glu	Thr	Pro	Val	Asn	Phe	Asn	Gly	Val	Lys	Leu	Thr	Ala	Gly	Pro	690	695	700
Leu	Ser	Thr	Ala	Trp	Thr	Pro	Phe	Asp	Arg	Lys	Ile	Val	Gln	Tyr	Ala	705	710	715
Gly	Glu	Ile	Tyr	Asn	Tyr	Asp	Phe	Pro	Glu	Tyr	Gly	Ala	Gly	Gln	Pro	725	730	735
Gly	Ala	Phe	Gly	Asp	Ile	Gln	Ser	Arg	Thr	Val	Ser	Ser	Ser	Asp	Leu	740	745	750
Tyr	Ala	Asn	Thr	Asn	Leu	Val	Leu	Gln	Arg	Pro	Lys	Ala	Gly	Ala	Ile	755	760	765
His	Val	Pro	Tyr	Thr	Gln	Ala	Pro	Ser	Gly	Phe	Glu	Gln	Trp	Lys	Lys	770	775	780
Asp	Lys	Ala	Pro	Ser	Leu	Lys	Phe	Thr	Ala	Pro	Phe	Gly	Cys	Glu	Ile	785	790	795
Tyr	Thr	Asn	Pro	Ile	Arg	Ala	Glu	Asn	Cys	Thr	Val	Gly	Ser	Ile	Pro	805	810	815
Leu	Ala	Phe	Asp	Ile	Pro	Asp	Ala	Leu	Phe	Thr	Arg	Val	Ser	Glu	Thr	820	825	830
Pro	Thr	Leu	Ser	Ala	Ala	Glu	Cys	Thr	Leu	Asn	Glu	Cys	Val	Tyr	Ser	835	840	845
Ser	Asp	Phe	Gly	Gly	Ile	Ala	Thr	Val	Lys	Tyr	Ser	Ala	Ser	Lys	Ser	850	855	860
Gly	Lys	Cys	Ala	Val	His	Val	Pro	Ser	Gly	Thr	Ala	Thr	Leu	Lys	Glu	865	870	875
Ala	Ala	Val	Glu	Leu	Thr	Glu	Gln	Gly	Ser	Ala	Thr	Ile	His	Phe	Ser	885	890	895
Thr	Ala	Asn	Ile	His	Pro	Glu	Phe	Arg	Leu	Gln	Ile	Cys	Thr	Ser	Tyr	900	905	910

**THIS PAGE BLANK (USPTO)**

Val Thr Cys Lys Gly Asp Cys His Pro Pro Lys Asp His Ile Val Thr  
 915 920 925  
 His Pro Gln Tyr His Ala Gln Thr Phe Thr Ala Ala Val Ser Lys Thr  
 930 935 940  
 Ala Trp Thr Trp Leu Thr Ser Leu Leu Gly Gly Ser Ala Val Ile Ile  
 945 950 955 960  
 Ile Ile Gly Leu Val Leu Ala Thr Ile Val Ala Met Tyr Val Leu Thr  
 965 970 975  
 Asn Gln Lys His Asn  
 980

&lt;210&gt; 14

&lt;211&gt; 12379

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence; Note =  
 synthetic construct

&lt;400&gt; 14

```

atgggcgggcg catgagagaa gccagacca attacctacc caaaatggag aaagttcacg      60
ttgacatcga ggaagacagc ccattcctca gagctttgca gcgagcttc ccgcagtttg      120
aggtagaagc caagcaggtc actgataatg accatgctaa tgccagagcg ttttcgcac      180
tggcttcaaa actgatcgaa acggagggtgg acccatccga cacgatcctt gacattggaa      240
gtgcgcccgc ccgcagaatg tattctaagc acaagtatca ttgtatctgt ccgatgagat      300
gtgcggaaga tccggacaga ttgtataagt atgcaactaa gctgaagaaa aactgtaagg      360
aaataactga taagggaattg gacaagaaaa tgaaggagct cgccgcgcgc atgagcgacc      420
ctgacctgga aactgagact atgtgcctcc acgacgacga gtcgtgtcgc tacgaagggc      480
aagtcgctgt ttaccaggat gtatacgcgg ttgacggacc gacaagtctc tatcaccaag      540
ccaataaggg agttagagtc gcctactgga taggctttga caccaccctt tttatgttta      600
agaacttggc tggagcatat ccatcatact ctaccaactg ggccgacgaa accgtgttaa      660
cggctcgtaa cataggccta tgcagctctg acgttatgga gcggtcacgt agagggatgt      720
ccattcttag aaagaagtat ttgaaacat ccaacaatgt tctattctct gttggctcga      780
ccatctacca cgagaagagg gacttactga ggagctggca cctgccgtct gtatttcact      840
tacgtggcaa gcaaaattac acatgtcggg gtgagactat agttagttgc gacgggtacg      900
tcgttaaaag aatagctatc agtccaggcc tgtatgggaa gccttcaggc tatgtctgta      960
cgatgcaccg cgagggatcc ttgtgctgca aagtgcaga cacattcaac ggggagaggg      1020
tctcttttcc cgtgtgcacg tatgtgccag ctacattgtg tgaccaaag actggcatac      1080
tggcaacaga tgtcagtgcg gacgacgcgc aaaaactgct ggttgggctc aaccagcgta      1140
tagtcgtcaa cggtcgcacc cagagaaaca ccaataccat gaaaaattac cttttgcccg      1200
tagtggccca ggcatttgct aggtgggcaa aggaatataa ggaagatcaa gaagatgaaa      1260
ggccactagg actacgagat agacagttag tcatggggtg ttgttgggct tttagaaggc      1320
acaagataac atctatttat aagcgcccgg ataccctaac catcatcaa gtgaacagcg      1380
atttccactc attcgtgctg ccaggatag gcagtaacac attggagatc gggctgagaa      1440
caagaatcag gaaaatgta gaggagcaca aggagccgtc acctctcatt accgcccagg      1500
acgtacaaga agctaagtgc gcagccgatg agcgtaagga ggtgcgtgaa gccgagaggt      1560
tgcgcgagcgc tctaccacct ttggcagctg atgttgagga gccactctcg gaagccgatg      1620
tcgacttgat gttacaagag gctggggccg gctcagtggg gacacctcgt ggcttgataa      1680
aggttaccag ctacgatggc gaggacaaga tcggtcttta cgctgtgctt tctccgcagg      1740
ctgtactcaa gagtgaaaaa ttatcttgca tccacctctc cgctgaacaa gtcatagtga      1800
taacacactc tggccgaaaa gggcggttat cgttggaacc ataccatggg aaagtagtgg      1860
tgccagaggg acatgcaata cccgtccagg actttcaagc tctgagtga agtgccacca      1920
ttgtgtacaa cgaacgtgag ttcgtaaaca ggtacctgca ccatattgcc acacatggag      1980
gagcgctgaa cactgatgaa gaatattaca aaactgtcaa gcccgagcag cacgacggcg      2040

```

**THIS PAGE BLANK (USPTO)**

aatacctgta	cgacatcgac	aggaaacagt	gcgtcaagaa	agaactagtc	actgggctag	2100
ggctcacagg	cgagctggtg	gacccctcct	tccatgaatt	cgctacgag	agtctgagaa	2160
cacgaccagc	cgctccttac	caagtaccaa	ccataggggt	gtatggcgtg	ccaggatcag	2220
gcaagtcttg	catcattaaa	agcgcagtca	ccaaaaaaga	tctagtgggtg	agcgccaaga	2280
aaga'aaactg	tgcagaaatt	ataagggacg	tcaagaaaat	gaaagggctg	gacgtcaatg	2340
ccagaactgt	ggactcagt	ctcttgaatg	gatgcaaaaca	cccgtagag	accctgtata	2400
ttgacgaagc	ttttgcttgt	catgcaggta	ctctcagagc	gctcatagcc	attataagac	2460
ctaaaaaggg	agtgcctctg	ggggatccca	aacagtgcgg	tttttttaac	atgatgtgcc	2520
tgaaagtgca	ttttaaccac	gagatttgca	cacaagtctt	ccacaaaagc	atctctcgcc	2580
gttgcactaa	atctgtgact	tcggctcgtct	caaccttgtt	ttacgacaaa	aaaatgagaa	2640
cgacgaatcc	gaaagagact	aagatttgta	ttgacactac	cggcagtacc	aaacctaagc	2700
aggacgatct	cattctcact	tgtttcagag	gggtgggtgaa	gcagttgcaa	atagattaca	2760
aaggcaacga	aataatgacg	gcagctgcct	ctcaagggct	gacccgtaaa	ggtgtgtatg	2820
ccgttcggta	caaggtgaat	gaaaatcctc	tgtacgcacc	cacctcagaa	catgtgaacg	2880
tcctactgac	ccgcacggag	gaccgcacgc	tgtggaaaac	actagccggc	gacccatgga	2940
taaaaacact	gactgccaaag	taccttgga	atttctactgc	cacgatagag	gagtggcaag	3000
cagagcatga	tgccatcatg	aggcacatct	tggagagacc	ggacctacc	gacgtcttcc	3060
agaataaggg	aaacgtgtgt	tgggccaagg	ctttagtgcc	ggtgtgtgaag	accgctggca	3120
tagacatgac	cactgaacaa	tggaaactg	tggattattt	tgaaacggac	aaagctcact	3180
cagcagagat	agtattgaac	caactatgcg	tgaggttctt	tggactcgat	ctggactccg	3240
gtctattttc	tgcaccact	gttccgttat	ccattaggaa	taatcactgg	gataactccc	3300
cgtegcctaa	catgtacggg	ctgaataaag	aagtggctccg	tcagctctct	cgaggtacc	3360
cacaactgcc	tcgggcagtt	gccactggaa	gagctctatga	catgaacact	ggtacactgc	3420
gcaattatga	tcgcgcata	aacctagtac	ctgtaaacag	aagactgcct	catgctttag	3480
tcctccacca	taatgaacac	ccacagagtg	acttttcttc	attcgtcagc	aaattgaagg	3540
gcagaactgt	cctgggtggt	ggggaaaagt	tgtcgtctcc	aggcaaaatg	gttgactggt	3600
tgtcagaccg	cctgaggct	accttcagag	ctcggctgga	tttaggcac	ccaggtgatg	3660
tgcccaaata	tgacataata	tttggttaatg	tgaggacccc	atataaatac	catcactatc	3720
agcagtggtga	agaccatgcc	attaagctta	gcatgttgac	caagaaagct	tgtctgcac	3780
tgaatcccg	cggaacctgt	gtcagcatag	gttatggtta	cgctgacagg	gccagcgaaa	3840
gcatcattgg	tgctatagcg	cggcagttca	agttttcccg	ggtatgcaaa	ccgaaat'cct	3900
cacttgaaga	gacggaagtt	ctgtttgtat	tcattgggtta	cgatcgcaag	gcccgtacgc	3960
acaatcctta	caagctttca	tcaaccttga	ccaacattta	tacaggttcc	agactccacg	4020
aagccggatg	tgcacctca	tatcatgtgg	tgcgagggga	tattgccacg	gccaccgaag	4080
gagtgattat	aaatgctgct	aacagcaaa	gacaacctgg	cggaggggtg	tgcggagcgc	4140
tgtataagaa	attcccggaa	agcttcgatt	tacagccgat	cgaagtagga	aaagcgcgac	4200
tgggtcaaagg	tgcagctaaa	catatcattc	atgccgtagg	accaaacttc	aacaaagttt	4260
cggaggttga	aggtgacaaa	cagttggcag	aggcttatga	gtccatcgct	aagattgtca	4320
acgataacaa	ttacaagtca	gtagcgattc	cactgttgct	caccggcatc	ttttccggga	4380
acaaagatcg	actaacccaa	tcattgaacc	atttgctgac	agcttttagac	accactgatg	4440
cagatgtagc	catatactgc	agggacaaga	aatgggaaat	gactctcaag	gaagcagtgg	4500
ctaggagaga	agcagtggag	gagatatgca	tatccgacga	ctcttcagt	acagaacctg	4560
atgcagagct	ggtgagggtg	catccgaaga	gttctttggc	tggaaaggaag	ggctacagca	4620
caagcgatgg	caaaactttc	tcataatttg	aagggaacca	gtttcaccag	gcggccaagg	4680
atatagcaga	aattaatgcc	atgtggcccc	ttgcaacgga	ggccaatgag	caggtatgca	4740
tgtatatcct	cggagaaagc	atgagcagta	ttaggtcgaa	atgccccgtc	gaagagtcgg	4800
aagcctcctc	accacctagc	acgtgcctt	gcttgtgcat	ccatgccatg	actccagaaa	4860
gagtacagcg	cctaaaagcc	tcacgtccag	aacaaattac	tgtgtgetca	tcctttccat	4920
tgccgaagta	tagaatcact	ggtgtgcaga	agatccaatg	ctcccagcct	atattgttct	4980
caccgaaagt	gcctgcgtat	attcatccaa	ggaagtatct	cgtggaaaca	ccaccggtag	5040
acgagactcc	ggagccatcg	gcagagaacc	aatccacaga	ggggacacct	gaacaaccac	5100
cacttataac	cgaggatgag	accaggacta	gaacgacctga	gccgatcatc	atcgaagagg	5160
aagaagagga	tagcataagt	ttgctgtcag	atggcccagc	ccaccaggtg	ctgcaagtgc	5220
aggcagacat	tcacgggccc	ccctctgtat	ctagctcatc	ctgggtccatt	cctcatgcat	5280
ccgactttga	tgtggacagt	ttatccatac	ttgacaccct	ggaggagct	agcgtgacca	5340

**THIS PAGE BLANK (USPTO)**

gcggggcaac	gtcagccgag	actaactcct	acttcgcaaa	gagtatggag	tttctggcgc	5400
gaccggtgcc	tgcgccctga	acagtaattca	ggaaccctcc	acatcccgt	ccgcgcacaa	5460
gaacaccgtc	acttgacccc	agcagggcct	gctcgagaac	cagcctagtt	tccaccccgc	5520
cagggcgtgaa	taggggtgatc	actagagagg	agctcgaggc	gcttaccocg	tcacgcactc	5580
ctagcaggtc	ggctctcgaga	accagcctgg	tctccaaccc	gccagggcgt	aatagggtga	5640
ttacaagaga	ggagtttgag	gcgttcgtag	cacaacaaca	atgacggttt	gatgcggtg	5700
catacatctt	ttcctccgac	accggtcaag	ggcatttaca	acaaaaatca	gtaaggcaaa	5760
oggtgctatc	cgaagtgggtg	ttggagagga	ccgaattgga	gatttcgtat	gccccgcgcc	5820
tcgaccaaga	aaaagaagaa	ttactacgca	agaaattaca	gttaaattccc	acacctgcta	5880
acagaagcag	ataccagtcc	aggaaggtgg	agaacatgaa	agccataaca	gctagacgta	5940
ttctgcaagg	cctagggcat	tatttgaagg	cagaaggaaa	agtggagtgc	taccgaaccc	6000
tgcacccctgt	tcctttgtat	tcatctagt	tgaaccgtgc	cttttcaagc	cccaaggctc	6060
cagtggaaagc	ctgtaacgcc	atgttgaaag	agaactttcc	gactgtggct	tcttactgta	6120
ttattccaga	gtacgatgcc	tatttggaca	tggttgacgg	agcttcatgc	tgcttagaca	6180
ctgccagttt	ttgccctgca	aagctgcgca	gctttccaaa	gaaacactcc	tatttggaa	6240
ccacaatacg	atcggcagtg	ccttcagcga	tccagaacac	gctccagaac	gtcctggcag	6300
ctgccacaaa	aagaaattgc	aatgtcacgc	aatgagaga	attgcccgt	ttggattcgg	6360
cggccttttaa	tgtggaatgc	ttcaagaaat	atgctgttaa	taatgaatat	tgggaaacgt	6420
ttaaagaaaa	ccccatcagg	cttactgaag	aaaacgtgg	aaattacatt	accaaattaa	6480
aaggacccaaa	agctgctgct	ctttttgcga	agacacataa	tttgaatatg	ttgcaggaca	6540
taccaatgga	caggtttgta	atggacttaa	agagagacgt	gaaagtgact	ccaggaacaa	6600
aacatactga	agaacggccc	aaggtacagg	tgatccaggc	tgccgatccg	ctagcaacag	6660
cgtatctgtg	cggaatccac	cgagagctgg	ttaggagatt	aatgcggtc	ctgcttccga	6720
acattcctac	actgtttgat	atgtcggctg	aagactttga	cgctattata	gccgagcact	6780
tccagcctgg	ggattgtgtt	ctggaaactg	acatcgctc	gtttgataaa	agtgaggacg	6840
acgccatggc	tctgaccgcg	ttaatgatcc	tggaagactt	aggtgtggac	gcagagctgt	6900
tgacgctgat	tgaggcggct	ttcggcgaaa	tttcatcaat	acatttgccc	actaaaacta	6960
aattttaaatt	cggagccatg	atgaaatctg	gaatgttcct	cacactgttt	gtgaacacag	7020
tcattaacat	tgtaatcgca	agcagagtgt	tgagagaacg	gctaaccgga	tcaccatgtg	7080
cagcattcat	tggagatgac	aatatcgtga	aaggagtcaa	atcgacaaa	ttaatggcag	7140
acaggtgcgc	cacctggttg	aatatggaag	tcaagattat	agatgctgtg	gtgggcgaga	7200
aagcgcctta	tttctgtgga	gggtttattt	tgtgtgactc	cgtgaccggc	acagcgtgcc	7260
gtgtggcaga	ccccctaaaa	aggctgttta	agcttgga	acctctggca	gcagacgatg	7320
aacatgatga	tgacaggaga	agggcattgc	atgaagagtc	aacacgctgg	aaccgagtgg	7380
gtattctttc	agagctgtgc	aaggcagtag	aatcaaggta	tgaaaccgta	ggaacttcca	7440
tcatagttat	ggccatgact	actctagcta	gcagtgttaa	atcattcagc	tacctgagag	7500
gggcccctat	aactctctac	ggctaacctg	aatggactac	gacatagtct	agtcgcgcaa	7560
gatgccaatc	agtcccattg	aaactgtacc	agtaaaactg	aagccaggaa	tggatggccc	7620
aaaggttaaa	caatggccgt	taacagaagt	gaaaataaaa	gcattaacag	caatttgtga	7680
agaaatggaa	aaggaaggaa	aaattacaaa	aattgggcct	gaaaatccat	ataaactcc	7740
aatattcgcc	ataaaaaagg	aagacagcac	taagtggaga	aaattagtag	atttcagggg	7800
actcaataaaa	agaactcaag	acttttggga	ggttcaatta	ggaataccac	acccagcagg	7860
gttaaaaaaag	aaaaaatcag	tgacagtact	ggatgtggga	gatgcatatt	tttcagttcc	7920
tttagatgaa	ggcttcagga	aatatactgc	attcaccata	cctagtataa	acaatgaaac	7980
accaggggatt	agatatcaat	ataatgtgct	tccacaagga	tggaaagggt	caccagcaat	8040
attccagggt	agcatgacaa	aaatcctaga	gccctttaga	gctaaaaatc	cagaaatagt	8100
catctatcaa	catatggcgg	cattgtatgt	aggatctgac	ttagaaatag	ggcaacatag	8160
agcaaaaaata	gaagagttaa	gagaacatct	attaaagtgg	ggatttacca	caccagacaa	8220
aaaacatcag	aaagaacccc	catttctttg	gatggggtat	gaactccatc	ctgacaaatg	8280
gacagtacag	cctatacagc	tgccagaaaa	agatagtctg	actgtcaatg	acatacagaa	8340
gttagtggga	aaattaaact	ggacaagtca	gatttaccca	gggattaaag	taaggcaact	8400
ttgtaagtgc	cttaggggga	ccaaagcact	aacagacata	gtaccactaa	ctgaagaagc	8460
agaattagaa	ttggcagaga	acaggggaaat	tctaaaagaa	ccagtgcattg	gagtatatta	8520
tgacccatca	aaagacttga	tagctgaaat	acagaaacag	ggggatgacc	aatggacata	8580
tcaaattttac	caagaaccat	tcaaaaacct	gaagacagga	aagtatgcaa	aaaggaggac	8640

**THIS PAGE BLANK (USPTO)**

taccacact	aatgatgtaa	aacagttaac	agaggcagtg	caaaaaatat	ccttggaag	8700
catagtaaca	tggggaaga	ctcctaatt	tagactaccc	atccaaaaag	aaacatggga	8760
aatatggtgg	acagactatt	ggcaagccac	atggattcct	gagtgggagt	ttgttaatac	8820
ccctccccta	gtaaaactat	ggtaccagct	agaaaaagaa	cccatagcag	gagcagaaac	8880
tttctgaagg	ccggccttaa	ttaagtaacg	atacagcagc	aattggcaag	ctgcttacat	8940
agaactcgcg	gcgattggca	tgccgcttta	aaatTTTTat	tttatttttc	ttttcttttc	9000
cgaatcggat	tttgttttta	atatttcaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	9060
aaaaaaaaaa	aaaggggaaga	gcgcggccgc	gcgctgggct	acgtcttgct	ggcgcttcgcg	9120
acgcgaggct	ggatggcctt	ccccattatg	attcttctcg	cttccggcgg	catcgggatg	9180
cccgcttgct	aggccatgct	gtccaggcag	gtagatgacg	accatcaggg	acagcttcaa	9240
ggatcgctcg	cggctcttac	cagcctaact	tcgatcactg	gaccgctgat	cgtcacggcg	9300
atztatgcg	cctcggcgag	cacatggaac	gggttggcat	ggattgtagg	cgccgccccta	9360
taccttgct	gcctccccgc	gttgctgcgc	ggtgcatgga	gccgggccac	ctcgacctga	9420
atggaagccg	gcggcacctc	gctaacggat	tcaccactcc	aagaattgga	gccaatcaat	9480
tcttgcgag	aactgtgaat	gcgcaaacca	acccttggca	gaacatatcc	atcgcgctccg	9540
ccatctccag	cagccgcacg	cggcgcatct	cgggcagcgt	tggttcctgg	ccacgggtgc	9600
gcatgatcgt	gtcctctgctg	ttgaggaccc	ggttaggctg	gcggggttgc	cttactgggt	9660
agcagaatga	atcaccgata	cgcgagcgaa	cgtgaagcga	ctgctgctgc	aaaacgtctg	9720
cgacctgagc	aacaacatga	atggtcttcg	gtttccgtgt	ttcgtaaagt	ctggaaacgc	9780
ggaagtgcgc	gccctgcacc	attatgttcc	ggatctgcat	cgcaggatgc	tgctggctac	9840
cctgtggaac	acctacatct	gtattaacga	agcgctggca	ttgaccctga	gtgatttttc	9900
tctggtcccg	cgcctccat	accgccagtt	gtttaccctc	acaacgttcc	agtaaccggg	9960
catgttcac	atcagtaacc	cgtatcgtga	gcatectctc	tcgtttcatc	ggtatcatta	10020
cccccatgaa	cagaaatccc	ccttacacgg	aggcatcagt	gaccaaacag	gaaaaaacccg	10080
cccttaacat	ggcccgcttt	atcagaagcc	agacattaac	gcttctggag	aaactcaacg	10140
agctggacgc	ggatgaacag	gcagacatct	gtgaatcgct	tcacgaccac	gctgatgagc	10200
tttaccgag	ctgcctcgcg	cgtttcggtg	atgacgggtga	aaacctctga	cacatgcagc	10260
tcccgagac	ggtcacagct	tgtctgtaag	cggatgccgg	gagcagacaa	gcccgtcagg	10320
gcgcgtcagc	gggtgttggc	gggtgtcggg	gcgcagccat	gacctagtca	cgtagcgata	10380
gcggagtgtg	tactggctta	actatgcggc	atcagagcag	attgtactga	gagtgcacca	10440
tatatgcgg	gtgaaatacc	gcacagatgc	gtaaggagaa	aataccgcat	caggcgctct	10500
tccgcttct	cgctcactga	ctcgctgcgc	tcggtcgttc	ggctgcggcg	agcggtatca	10560
gctcactcaa	aggcggtaat	acggttatcc	acagaatcag	gggataacgc	aggaaagaac	10620
atgtgagcaa	aaggccagca	aaaggccagg	aaccgtaaaa	aggccgcggt	gctggcggtt	10680
ttccataggc	tccgcccccc	tgacgagcat	cacaaaaatc	gacgctcaag	tcagaggtag	10740
cgaaccgccg	caggactata	aagataccag	gcgtttcccc	ctggaagctc	cctcgtagcg	10800
tctcctgttc	cgacctgccc	gcttacccga	tacctgtccg	cctttctccc	ttcgggaagc	10860
gtggcgcttt	ctcatagctc	acgctgtagg	tatctcagtt	cgggttaggt	cgctcgctcc	10920
aagctgggct	gtgtgcacga	acccccggt	cagcccagac	gctgcgcctt	atccggtaac	10980
tatcgtcttg	agtccaaccc	ggtaagacac	gacttatcgc	cactggcagc	agccactggt	11040
aacaggatta	gcagagcgag	gtatgtaggc	ggtgctacag	agttcttgaa	gtggtggcct	11100
aactacggct	acactagaag	gacagtattt	ggtatctgcg	ctctgctgaa	gccagttacc	11160
ttcggaaaaa	gagttggtag	ctcttgatcc	ggcaaacaaa	ccaccgctgg	tagcggtggt	11220
ttttttgttt	gcaagcagca	gattacgcgc	agaaaaaaag	gatctcaaga	agatcctttg	11280
atcttttcta	cggggtctga	cgctcagtg	aacgaaaact	cacgttaagg	gattttggct	11340
atgaacaata	aaactgtctg	cttacataaa	cagtaataca	aggggtgtta	tgagccatat	11400
tcaacgggaa	acgtcttgct	cgaggccgcg	attaaattcc	aacatggatg	ctgatttata	11460
tgggtataaa	tgggctcgcg	ataatgtcgg	gcaatcaggt	gcgacaatct	atcgattgta	11520
tgggaagccc	gatgcgccag	agttgtttct	gaaacatggc	aaaggtagcg	ttgccaatga	11580
tgttacagat	gagatggtca	gactaaactg	gctgacggaa	tttatgcctc	ttccgaccat	11640
caagcatttt	atccgtactc	ctgatgatgc	atggttactc	accactgcga	tcccgggaa	11700
aaacagcattc	caggtattag	aagaatatcc	tgattcaggt	gaaaatattg	ttgatgcgct	11760
ggcagtggtc	ctgcgccggt	tgcattcgat	tctgtttgt	aattgtcctt	ttaacgcga	11820
tcgcgtattt	cgtctcgctc	aggcgcaatc	acgaatgaat	aacggtttgg	ttgatgcgag	11880
tgattttgat	gacgagcgta	atggctggcc	tgttgaacaa	gtctggaaag	aaatgcataa	11940

**THIS PAGE BLANK (USPTO)**

```

gcttttgcca ttctcaccgg attcagtcgt cactcatggt gattttctcac ttgataacct 12000
tatttttgac gaggggaaat taataggttg tattgatgtt ggacgagtcg gaatcgcaga 12060
ccgataaccag gatcttgcca tccatggaa ctgcctcggg gagttttctc cttcattaca 12120
gaaacggcctt ttcaaaaaat atgggtattga taatcctgat atgaataaat tgcagtttca 12180
tttgatgctc gatgagtttt tctaagaatt ctcagtgttg acagcttatc atcgataagc 12240
tttaatgagg tagtttatca cagttaaatt gctaaccgag tcaggcaccg tgtatgaaat 12300
ctaacaatgc gctcatcgtc atcctcggca ccgtcaccct ggatgctgtc tagaggatcc 12360
ctaatacgac tcactatag 12379

```

&lt;210&gt; 15

&lt;211&gt; 1323

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence; Note =  
synthetic construct

&lt;221&gt; CDS

&lt;222&gt; (1)...(1323)

&lt;400&gt; 15

```

atg cca atc agt ccc att gaa act gta cca gta aaa ctg aag cca gga 48
Met Pro Ile Ser Pro Ile Glu Thr Val Pro Val Lys Leu Lys Pro Gly
1 5 10 15

```

```

atg gat ggc cca aag gtt aaa caa tgg ccg tta aca gaa gtg aaa ata 96
Met Asp Gly Pro Lys Val Lys Gln Trp Pro Leu Thr Glu Val Lys Ile
20 25 30

```

```

aaa gca tta aca gca att tgt gaa gaa atg gaa aag gaa gga aaa att 144
Lys Ala Leu Thr Ala Ile Cys Glu Glu Met Glu Lys Glu Gly Lys Ile
35 40 45

```

```

aca aaa att ggg cct gaa aat cca tat aac act cca ata ttc gcc ata 192
Thr Lys Ile Gly Pro Glu Asn Pro Tyr Asn Thr Pro Ile Phe Ala Ile
50 55 60

```

```

aaa aag gaa gac agc act aag tgg aga aaa tta gta gat ttc agg gaa 240
Lys Lys Glu Asp Ser Thr Lys Trp Arg Lys Leu Val Asp Phe Arg Glu
65 70 75 80

```

```

ctc aat aaa aga act caa gac ttt tgg gag gtt caa tta gga ata cca 288
Leu Asn Lys Arg Thr Gln Asp Phe Trp Glu Val Gln Leu Gly Ile Pro
85 90 95

```

```

cac cca gca ggg tta aaa aag aaa aaa tca gtg aca gta ctg gat gtg 336
His Pro Ala Gly Leu Lys Lys Lys Lys Ser Val Thr Val Leu Asp Val
100 105 110

```

```

gga gat gca tat ttt tca gtt cct tta gat gaa ggc ttc agg aaa tat 384
Gly Asp Ala Tyr Phe Ser Val Pro Leu Asp Glu Gly Phe Arg Lys Tyr
115 120 125

```

**THIS PAGE BLANK (USPTO)**

act gca ttc acc ata cct agt ata aac aat gaa aca cca ggg att aga	432
Thr Ala Phe Thr Ile Pro Ser Ile Asn Asn Glu Thr Pro Gly Ile Arg	
130 135 140	
tat caa tat aat gtg ctt cca caa gga tgg aaa ggg tca cca gca ata	480
Tyr Gln Tyr Asn Val Leu Pro Gln Gly Trp Lys Gly Ser Pro Ala Ile	
145 150 155 160	
ttc cag gct agc atg aca aaa atc cta gag ccc ttt aga gct aaa aat	528
Phe Gln Ala Ser Met Thr Lys Ile Leu Glu Pro Phe Arg Ala Lys Asn	
165 170 175	
cca gaa ata gtc atc tat caa cat atg gcg gca ttg tat gta gga tct	576
Pro Glu Ile Val Ile Tyr Gln His Met Ala Ala Leu Tyr Val Gly Ser	
180 185 190	
gac tta gaa ata ggg caa cat aga gca aaa ata gaa gag tta aga gaa	624
Asp Leu Glu Ile Gly Gln His Arg Ala Lys Ile Glu Glu Leu Arg Glu	
195 200 205	
cat cta tta aag tgg gga ttt acc aca cca gac aaa aaa cat cag aaa	672
His Leu Leu Lys Trp Gly Phe Thr Thr Pro Asp Lys Lys His Gln Lys	
210 215 220	
gaa ccc cca ttt ctt tgg atg ggg tat gaa ctc cat cct gac aaa tgg	720
Glu Pro Pro Phe Leu Trp Met Gly Tyr Glu Leu His Pro Asp Lys Trp	
225 230 235 240	
aca gta cag cct ata cag ctg cca gaa aaa gat agc tgg act gtc aat	768
Thr Val Gln Pro Ile Gln Leu Pro Glu Lys Asp Ser Trp Thr Val Asn	
245 250 255	
gac ata cag aag tta gtg gga aaa tta aac tgg aca agt cag att tac	816
Asp Ile Gln Lys Leu Val Gly Lys Leu Asn Trp Thr Ser Gln Ile Tyr	
260 265 270	
cca ggg att aaa gta agg caa ctt tgt aag ctc ctt agg ggg acc aaa	864
Pro Gly Ile Lys Val Arg Gln Leu Cys Lys Leu Leu Arg Gly Thr Lys	
275 280 285	
gca cta aca gac ata gta cca cta act gaa gaa gca gaa tta gaa ttg	912
Ala Leu Thr Asp Ile Val Pro Leu Thr Glu Glu Ala Glu Leu Glu Leu	
290 295 300	
gca gag aac agg gaa att cta aaa gaa cca gtg cat gga gta tat tat	960
Ala Glu Asn Arg Glu Ile Leu Lys Glu Pro Val His Gly Val Tyr Tyr	
305 310 315 320	
gac cca tca aaa gac ttg ata gct gaa ata cag aaa cag ggg gat gac	1008
Asp Pro Ser Lys Asp Leu Ile Ala Glu Ile Gln Lys Gln Gly Asp Asp	
325 330 335	
caa tgg aca tat caa att tac caa gaa cca ttc aaa aac ctg aag aca	1056
Gln Trp Thr Tyr Gln Ile Tyr Gln Glu Pro Phe Lys Asn Leu Lys Thr	
340 345 350	

**THIS PAGE BLANK (USPTO)**

49

gga aag tat gca aaa agg agg act acc cac act aat gat gta aaa cag 1104  
 Gly Lys Tyr Ala Lys Arg Arg Thr Thr His Thr Asn Asp Val Lys Gln  
 355 360 365

tta aca gag gca gtg caa aaa ata tcc ttg gaa agc ata gta aca tgg 1152  
 Leu Thr Glu Ala Val Gln Lys Ile Ser Leu Glu Ser Ile Val Thr Trp  
 370 375 380

gga aag act cct aaa ttt aga cta ccc atc caa aaa gaa aca tgg gaa 1200  
 Gly Lys Thr Pro Lys Phe Arg Leu Pro Ile Gln Lys Glu Thr Trp Glu  
 385 390 395 400

ata tgg tgg aca gac tat tgg caa gcc aca tgg att cct gag tgg gag 1248  
 Ile Trp Trp Thr Asp Tyr Trp Gln Ala Thr Trp Ile Pro Glu Trp Glu  
 405 410 415

ttt gtt aat acc cct ccc cta gta aaa cta tgg tac cag cta gaa aaa 1296  
 Phe Val Asn Thr Pro Pro Leu Val Lys Leu Trp Tyr Gln Leu Glu Lys  
 420 425 430

gaa ccc ata gca gga gca gaa act ttc 1323  
 Glu Pro Ile Ala Gly Ala Glu Thr Phe  
 435 440

&lt;210&gt; 16

&lt;211&gt; 441

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence; Note =  
 synthetic construct

&lt;400&gt; 16

Met Pro Ile Ser Pro Ile Glu Thr Val Pro Val Lys Leu Lys Pro Gly  
 1 5 10 15  
 Met Asp Gly Pro Lys Val Lys Gln Trp Pro Leu Thr Glu Val Lys Ile  
 20 25 30  
 Lys Ala Leu Thr Ala Ile Cys Glu Glu Met Glu Lys Glu Gly Lys Ile  
 35 40 45  
 Thr Lys Ile Gly Pro Glu Asn Pro Tyr Asn Thr Pro Ile Phe Ala Ile  
 50 55 60  
 Lys Lys Glu Asp Ser Thr Lys Trp Arg Lys Leu Val Asp Phe Arg Glu  
 65 70 75 80  
 Leu Asn Lys Arg Thr Gln Asp Phe Trp Glu Val Gln Leu Gly Ile Pro  
 85 90 95  
 His Pro Ala Gly Leu Lys Lys Lys Lys Ser Val Thr Val Leu Asp Val  
 100 105 110  
 Gly Asp Ala Tyr Phe Ser Val Pro Leu Asp Glu Gly Phe Arg Lys Tyr  
 115 120 125  
 Thr Ala Phe Thr Ile Pro Ser Ile Asn Asn Glu Thr Pro Gly Ile Arg  
 130 135 140

**THIS PAGE BLANK (USPTO)**

50

Tyr Gln Tyr Asn Val Leu Pro Gln Gly Trp Lys Gly Ser Pro Ala Ile  
 145 150 155 160  
 Phe Gln Ala Ser Met Thr Lys Ile Leu Glu Pro Phe Arg Ala Lys Asn  
 165 170 175  
 Pro Glu Ile Val Ile Tyr Gln His Met Ala Ala Leu Tyr Val Gly Ser  
 180 185 190  
 Asp Leu Glu Ile Gly Gln His Arg Ala Lys Ile Glu Glu Leu Arg Glu  
 195 200 205  
 His Leu Leu Lys Trp Gly Phe Thr Thr Pro Asp Lys Lys His Gln Lys  
 210 215 220  
 Glu Pro Pro Phe Leu Trp Met Gly Tyr Glu Leu His Pro Asp Lys Trp  
 225 230 235 240  
 Thr Val Gln Pro Ile Gln Leu Pro Glu Lys Asp Ser Trp Thr Val Asn  
 245 250 255  
 Asp Ile Gln Lys Leu Val Gly Lys Leu Asn Trp Thr Ser Gln Ile Tyr  
 260 265 270  
 Pro Gly Ile Lys Val Arg Gln Leu Cys Lys Leu Leu Arg Gly Thr Lys  
 275 280 285  
 Ala Leu Thr Asp Ile Val Pro Leu Thr Glu Glu Ala Glu Leu Glu Leu  
 290 295 300  
 Ala Glu Asn Arg Glu Ile Leu Lys Glu Pro Val His Gly Val Tyr Tyr  
 305 310 315 320  
 Asp Pro Ser Lys Asp Leu Ile Ala Glu Ile Gln Lys Gln Gly Asp Asp  
 325 330 335  
 Gln Trp Thr Tyr Gln Ile Tyr Gln Glu Pro Phe Lys Asn Leu Lys Thr  
 340 345 350  
 Gly Lys Tyr Ala Lys Arg Arg Thr Thr His Thr Asn Asp Val Lys Gln  
 355 360 365  
 Leu Thr Glu Ala Val Gln Lys Ile Ser Leu Glu Ser Ile Val Thr Trp  
 370 375 380  
 Gly Lys Thr Pro Lys Phe Arg Leu Pro Ile Gln Lys Glu Thr Trp Glu  
 385 390 395 400  
 Ile Trp Trp Thr Asp Tyr Trp Gln Ala Thr Trp Ile Pro Glu Trp Glu  
 405 410 415  
 Phe Val Asn Thr Pro Pro Leu Val Lys Leu Trp Tyr Gln Leu Glu Lys  
 420 425 430  
 Glu Pro Ile Ala Gly Ala Glu Thr Phe  
 435 440

&lt;210&gt; 17

&lt;211&gt; 13584

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence; Note =  
 synthetic construct

&lt;400&gt; 17

atggggcggcg catgagagaa gccagacca attacctacc caaaatggag aaagttcacg 60  
 ttgacatcga ggaagacagc ccattcctca gagctttgca gcggagcttc ccgcagtttg 120  
 aggtagaagc caagcaggtc actgataatg accatgctaa tgccagagcg ttttcgcac 180  
 tggcttcaaa actgatcgaa acggaggtgg acccatccga cacgatcctt gacattggaa 240  
 gtgcgcccgc ccgcagaatg tattctaagc acaagtatca ttgtatctgt ccgatgagat 300  
 gtgcggaaga tccggacaga ttgtataagt atgcaactaa gctgaagaaa aactgtaagg 360

**THIS PAGE BLANK (USPTO)**

aaataactga	taaggaattg	gacaagaaaa	tgaaggagct	cgccgcccgtc	atgagcgacc	420
ctgacctgga	aactgagact	atgtgcctcc	acgacgacga	gtcgtgtcgc	tacgaagggc	480
aagtcgctgt	ttaccaggat	gtatacgcg	ttgacggacc	gacaagtctc	tatcaccaag	540
ccaataagg	agttagagtc	gcctactgga	taggctttga	caccacccct	tttatgttta	600
agaacttggc	tggagcatat	ccatcatact	ctaccaactg	ggccgacgaa	accgtgttaa	660
cggctcgtaa	cataggccta	tgcagctctg	acgttatgga	gcggtcacgt	agagggatgt	720
ccattcttag	aaagaagtat	ttgaaacat	ccaacaatgt	tctattctct	gttggctcga	780
ccatctacca	cgagaagagg	gacttactga	ggagctggca	cctgccgtct	gtatttcact	840
tacgtggcaa	gcaaaattac	acatgtcgg	gtgagactat	agttagttgc	gacgggtacg	900
tcgttaaaa	aatagctatc	agtcaggcc	tgtatgggaa	gccttcaggc	tatgctgcta	960
cgatgcaccg	cgagggattc	ttgtgctgca	aagtgcagca	cacattcaac	ggggagaggg	1020
tctcttttcc	cgtgtgcacg	tatgtgccag	ctacattgtg	tgaccaaata	actggcatac	1080
tggcaacaga	tgtcagtgcg	gacgacgcgc	aaaaactgct	ggttgggctc	aaccagcgta	1140
tagtcgtcaa	cggctgcacc	cagagaaaca	ccaataccat	gaaaaattac	cttttgccc	1200
tagtggccca	ggcatttgct	aggtgggcaa	aggaatataa	ggaagatcaa	gaagatgaaa	1260
ggccactagg	actacgagat	agacagttag	tcatgggggtg	ttgttgggct	tttagaaggc	1320
acaagataac	atctatttat	aagcgcccgg	atacccaaac	catcatcaaa	gtgaacagcg	1380
atctccactc	attcgtgctg	cccaggatag	gcagtaaacac	attggagatc	gggctgagaa	1440
caagaatcag	gaaaatgtta	gaggagcaca	aggagccgtc	acctctcatt	accgccgagg	1500
acgtacaaga	agctaagtgc	gcagccgatg	agcgtaaagg	gggtgcgtgaa	gccgaggagt	1560
tgcgcgcagc	tctaccacct	ttggcagctg	atgttgagga	gccactctg	gaagccgatg	1620
tcgacttgat	gttacaagag	gctggggccg	gctcagtggg	gacacctcgt	ggcttgataa	1680
aggttaccag	ctacgatggc	gaggacaaga	tcggctctta	cgtgtgtgctt	tctccgcagg	1740
ctgtactcaa	gagtgaaaaa	ttatcttgca	tccacctctc	cgtgaacaa	gtcatagtga	1800
taacacactc	tggccgaaaa	gggcgttatg	ccgtggaacc	ataccatgg	aaagtagtgg	1860
tgccagaggg	acatgcaata	cccgctccagg	actttcaagc	tctgagtga	agtgccacca	1920
ttgtgtacaa	cgaacgtgag	ttcgtaaaca	ggtacctgca	ccatattgcc	acacatggag	1980
gagcgtgaa	cactgatgaa	gaatattaca	aaactgtcaa	gcccagcgag	cacgacggcg	2040
aatacctgta	cgacatcgac	aggaaacagt	gcgtcaagaa	agaactagtc	actgggctag	2100
ggctcacagg	cgagctgggtg	gatcctccct	tccatgaatt	cgctacgag	agtctgagaa	2160
cacgaccagc	cgctccttac	caagtaccaa	ccataggggt	gtatggcgtg	ccaggatcag	2220
gcaagtctgg	catcattaaa	agcgcagtca	ccaaaaaaga	tctagtgggtg	agcgccaaga	2280
aagaaaactg	tgcagaaatt	ataagggacg	tcaagaaaat	gaaagggctg	gacgtcaatg	2340
ccagaactgt	ggactcagtg	ctcttgaaatg	gatgcaaaaca	ccccgtagag	accctgtata	2400
ttgacgaagc	ttttgcttgt	catgcaggta	ctctcagagc	gctcatagcc	attataagac	2460
ctaaaaaggc	agtgtctctgc	ggggatccca	aacagtgcgg	tttttttaac	atgatgtgcc	2520
tgaagtgca	ttttaaccac	gagatttgca	cacaagtctt	ccacaaaagc	atctctcgcc	2580
gttgcactaa	atctgtgact	tcggctcgtc	caaccttggt	ttacgacaaa	aaaatgagaa	2640
cgacgaatcc	gaaagagact	aagattgtga	ttgacactac	cggcagtacc	aaacctaaagc	2700
aggacgatct	cattctcact	tgtttcagag	gggtgggtgaa	gcagttgcaa	atagattaca	2760
aaggcaacga	aataatgacg	gcagctgcct	ctcaagggtc	gacccgtaaa	gggtgtgatg	2820
ccgttcggta	caaggtgaat	gaaaatcctc	tgtacgcacc	cacctcagaa	catgtgaacg	2880
tctactgac	ccgcacggag	gaccgcacg	tgtggaaaac	actagccggc	gacctatgga	2940
taaaaacact	gactgccaag	tacctggga	atttactgc	cacgatagag	gagtggcaag	3000
cagagcatga	tgccatcatg	aggcacatct	tggagagacc	ggacctacc	gacgtcttcc	3060
agaataaggc	aaacgtgtgt	tgggccaagg	ctttagtgcc	gggtgtgaag	accgtggca	3120
tagacatgac	cactgaacaa	tggaaactg	tggattattt	tgaacggac	aaagctcact	3180
cagcatagat	agtattgaac	caactatgctg	tgaggttctt	tggactcgat	ctggactccg	3240
gtctattttc	tgcaccact	gttccgttat	ccattaggaa	taatcactgg	gataactccc	3300
cgtcgccctaa	catgtacggg	ctgaataaag	aagtgttccg	tcagctctct	cgcaggtacc	3360
cacaactgcc	tcgggcagtt	gccactggaa	gagtcctatga	catgaacact	ggtacactgc	3420
gcaattatga	tccgcgcata	aacctagtac	ctgtaaacag	aagactgcct	catgctttag	3480
tcctccacca	taatgaacac	ccacagagtg	acttttcttc	attcgtcagc	aaattgaagg	3540
gcagaactgt	cctgggtggc	ggggaaaagt	tgtccgtccc	aggcaaaatg	gttgactgg	3600
tgtcagaccg	gcctgaggct	accttcagag	ctcggctgga	tttaggcatac	ccaggtgatg	3660

THIS PAGE BLANK (USPTO)

THIS PAGE BLANK (USPTO)

tgcccaaata	tgacataata	tttgттаатг	tgaggacccc	atataaatac	catcactatc	3720
agcagtgtga	agaccatgcc	attaagctta	gcatgttgac	caagaaagct	tgtctgcatc	3780
tgaatcccgg	cggaaacctgt	gtcagcatag	gttatggtta	cgctgacagg	gccagcgaaa	3840
gcatcattgg	tgctatagcg	cggcagttca	agttttcccg	ggatgcaaa	ccgaaatcct	3900
cacttgaaga	gacggaagtt	ctgtttgtat	tcattgggta	cgatcgcaag	gcccgtacgc	3960
acaatcctta	caagctttca	tcaaccttga	ccaacattta	tacaggttcc	agactccacg	4020
aagccggatg	tgacacctca	tatcatgtgg	tgcgagggga	tattgccacg	gccaccgaag	4080
gagtgattat	aaatgctgct	aacagcaaa	gacaacctgg	cggaggggtg	tgcgagagcg	4140
tgtataagaa	attcccggaa	agcttcgatt	tacagccgat	cgaagtagga	aaagcgcgac	4200
tggtcaaagg	tgagctaaa	catatcattc	atgccgtagg	accaaacttc	aacaaagttt	4260
cggaggttga	aggtgacaaa	cagttggcag	aggttatga	gtccatcgct	aagattgtca	4320
acgataacaa	ttacaagtca	gtagcgattc	cactgttgct	caccggcatc	ttttccggga	4380
acaaagatcg	actaacccaa	tcattgaacc	atttgctgac	agctttagac	accactgatg	4440
cagatgtagc	catatactgc	agggacaaga	aatgggaaat	gactctcaag	gaagcagtgg	4500
ctaggagaga	agcagtggag	gagatatgca	tatccgacga	ctcttcagtg	acagaacctg	4560
atgcagagct	ggtgaggggtg	catccgaaga	gttctttggc	tggaagggaag	ggctacagca	4620
caagcgatgg	caaaaactttc	tcataatttg	aagggaacca	gtttcaccag	gcggccaaag	4680
atatagcaga	aattaatgcc	atgtggcccg	ttgcaacgga	ggccaatgag	caggtatgca	4740
tgtatatcct	cgggaaaagc	atgagcagta	ttaggtcgaa	atgccccgtc	gaagagtcgg	4800
aagcctcctc	accacctagc	acgctgcctt	gcttgtgcat	ccatgccatg	actccagaaa	4860
gagtacagcg	cctaaaagcc	tcacgtccag	aacaaattac	tgtgtgctca	tcctttccat	4920
tgccgaagta	tagaatcact	ggtgtgcaga	agatccaatg	ctcccagcct	atattgttct	4980
caccgaaagt	gcctgcgtat	attcatccaa	ggaagtatct	cgaggaaaca	ccaccggtag	5040
acgagactcc	ggagccatcg	gcagagaacc	aatccacaga	ggggacacct	gaacaaccac	5100
cacttataac	cgaggatgag	accaggacta	gaacgcctga	gccgatcatc	atcgaagagg	5160
aagaagagga	tagcataagt	ttgctgtcag	atggcccagc	ccaccaggtg	ctgcaagtcg	5220
aggcagacat	tcacggggcg	ccctctgtat	ctagctcatc	ctggtccatt	cctcatgcat	5280
ccgactttga	tgtggacagt	ttatccatac	ttgacacctt	ggagggagct	agcgtgacca	5340
gcggggcaac	gtcagccgag	actaactctt	acttcgcaaa	gagtatggag	tttctggcgc	5400
gaccggtgcc	tgccgctcga	acagtattca	ggaaccttcc	acatcccgtc	ccgcgcacaa	5460
gaacaccgtc	acttgcaccc	agcagggcct	gctcgagaac	cagcctagtt	tccaccccg	5520
caggcgtgaa	taggggtgatc	actagagagg	agctcgaggc	gcttaccctg	tcacgcactc	5580
ctagcaggtc	ggtctcgaga	accagcctgg	tctccaacct	gccaggcgta	aatagggtga	5640
ttacaagaga	ggagtttgag	gcgttcgtag	cacaacaaca	atgacggttt	gatgcgggtg	5700
catatcatctt	ttcctccgac	accggtcaag	ggcattttaca	acaaaaatca	gtaaggcaaa	5760
cgggtgctatc	cgaagtgggtg	ttggagagga	ccgaattgga	gatttcgtat	gccccgcgcc	5820
tcgaccaaga	aaaagaagaa	ttactacgca	agaaattaca	gttaaattccc	acacctgcta	5880
acagaagcag	ataccagtc	aggaagggtg	agaacatgaa	agccataaca	gctagacgta	5940
ttctgcaagg	cctagggcat	tatttggaag	cagaaggaaa	agtggagtgc	taccgaacct	6000
tgcatcctgt	tcctttgtat	tcacttagtg	tgaacctgct	cttttcaagc	cccaaggctg	6060
cagtgggaagc	ctgtaacgcc	atgttgaaag	agaactttcc	gactgtggct	tcttactgta	6120
ttattccaga	gtacgatgcc	tatttggaag	tggttgacgg	agcttcatgc	tgcttagaca	6180
ctgccagttt	ttgccctgca	aagctgcgca	gctttccaaa	gaaacactcc	tatttggaac	6240
ccacaatacg	atcggcagtg	ccttcagcga	tccagaacac	gctccagaac	gtcctggcag	6300
ctgccacaaa	aagaaattgc	aatgtcacgc	aaatgagaga	attgcccgtg	ttggattcgg	6360
cggccttttaa	tgtggaatgc	ttcaagaaat	atgcgtgtaa	taatgaatat	tgggaaacgt	6420
ttaaagaaaa	ccccatcagg	cttactgaag	aaaacgtggt	aaattacatt	accaaattaa	6480
aaggacaaaa	agctgctgct	ctttttgcga	agacacataa	tttgaatatg	ttgcaggaca	6540
taccaatgga	caggtttgta	atggacttaa	agagagacgt	gaaagtgact	ccaggaaaca	6600
aacatactga	agaacggccc	aaggtaacag	tgatccaggc	tgccgatccg	ctagcaacag	6660
cgtatctgtg	cggaaatccac	cgagagctgg	ttaggagatt	aaatgcggct	ctgcttccga	6720
acattcatatc	actgtttgat	atgtcggctg	aagactttga	cgctattata	gccgagcact	6780
tccagcctgg	ggatttgtgt	ctggaaactg	acatcgcgct	gtttgataaa	agtgaggacg	6840
acgccatggc	tctgaccgcg	ttaatgattc	tggagacttt	aggtgtggac	gcagagctgt	6900
tgacgctgat	tgaggcggct	ttcggcgaaa	tttcatcaat	acatttgccc	actaaaacta	6960

**THIS PAGE BLANK (USPTO)**

aatttaaatt	cgagccatg	atgaaatctg	gaatgttcct	cacactgttt	gtgaacacag	7020
tcattaacat	tgtaatcgca	agcagagtgt	tgagagaacg	gctaaccgga	tcaccatgtg	7080
cagcattcat	tgagatgac	aatatcgtga	aaggagtcaa	atcggacaaa	ttaatggcag	7140
acaggtgctg	cacctgggtg	aatatggaag	tcaagattat	agatgctgtg	gtgggcgaga	7200
aagcgctta	tttctgtgga	gggtttattt	tgtgtgactc	cgtgaccggc	acagcgtgcc	7260
gtgtggcaga	ccccataaaa	aggctgttta	agcttggcaa	acctctggca	gcagacgatg	7320
aacatgatga	tgacaggaga	agggcattgc	atgaagagtc	aacacgctgg	aaccgagtgg	7380
gtattctttc	agagctgtgc	aaggcagtag	aatcaaggta	tgaaaccgta	ggaacttcca	7440
tcatagttat	ggccatgact	actctagcta	gcagtgttaa	atcattcagc	tacctgagag	7500
gggcccctat	aactctctac	ggctaacctg	aatggactac	gacatagtct	agtccgcca	7560
gatgagagtg	atggggatag	agaggaattg	gccacaatgg	tggaatggg	gcaccttagg	7620
cttttggtg	ataataattt	gtagggtggt	ggggaacttg	aacttgtggg	tcacagtcta	7680
ttatggggtg	cctgtgtgga	aagaagcaaa	aactactcta	ttctgtgcat	cagatgctaa	7740
agcatatgat	aaagaagtac	ataatgtctg	ggctacacat	gcctgtgtac	ccacagaccc	7800
caaccacga	gaaatagttt	tggaatatgt	aacagaaaat	tttaacatgt	ggaaaaatga	7860
catggtggat	cagatgcatg	aggatataat	cagtttatgg	gatcaaagcc	taaaaccatg	7920
tgtaaagttg	acccactct	gtgtcacttt	aaattgtaca	aatgcacctg	cctacaataa	7980
tagcatgcat	ggagaaatga	aaaattgtct	tttcaatata	accacagaga	taagagatag	8040
gaaacagaaa	gcgtatgcac	ttttttataa	acctgatgta	gtgccactta	ataggagaga	8100
agagaataat	gggacaggag	agtatatatt	aataaattgc	aattcctcaa	ccataacaca	8160
agcctgtcca	aaggtcactt	ttgacccaat	tcctatacat	tattgtgtct	cagctgggta	8220
tgcgattcta	aagtgttaata	ataagacatt	caatgggaca	ggaccatgca	ataatgtcag	8280
cacagtacaa	tgtacacatg	gaattatgcc	agtgggtatca	actcaattac	tggttaattgg	8340
tagcctagca	gaagaagaga	taataattag	atctgaaaat	ctgacaaaaca	atatcaaaac	8400
aataatagtc	caccttaata	aatctgtaga	aattgtgtgt	acaagaccca	acaataatac	8460
aagaaaaagt	ataaggatag	gaccaggaca	aacattctat	gcaacagggtg	aaataatagg	8520
aaacataaga	gaagcacatt	gtaacattag	taaaagtaac	tggaaccagta	ctttagaaca	8580
ggtaaagaaa	aaattaaaag	aacactacaa	taagacaata	gaatttaacc	cacctcagg	8640
aggggatcta	gaagttacaa	cacatagctt	taattgtaga	ggagaatttt	tctattgcaa	8700
tacaacaaaa	ctgttttcaa	acaacagtga	ttcaaacaac	gaaaccatca	cactcccatg	8760
caagataaaa	caaattataa	acatgtggca	gaaggttaga	cgagcaatgt	atgcccctcc	8820
cattgaagga	aacataacat	gtaaatcaaa	tatcacagga	ctactattga	cacgtgatgg	8880
aggaaagaat	acaacaaatg	agatattcag	accgggagga	ggaaatatga	aggacaattg	8940
gagaagtga	ttatataaat	ataaagtgg	agaaattgag	ccattgggag	tagcaccac	9000
taaatcaaaa	aggagagtgg	tggaagagaga	aaaaagagca	gtgggactag	gagctgtact	9060
ccttgggttc	ttgggagcag	caggaagcac	tatgggcgcg	gcgtcaataa	cgctgacgg	9120
acaggccaga	caactgttgt	ctggtatagt	gcaacagcaa	agcaatttgc	tgagagctat	9180
agaggcgcaa	cagcatatgt	tgcaactcac	ggctctgggg	attaagcagc	tccagacaag	9240
agtcttggct	atagagagat	acctaaggga	tcaacagctc	ctagggcttt	ggggctgctc	9300
tggaaaaatc	atctgcacca	ctgctgtgcc	ttggaactcc	agttggagta	ataaatctca	9360
agaagatatt	tggaataaca	tgacctggat	gcagtgggat	agagaaatta	gtaattacac	9420
aggcacaata	tataggttac	ttgaagactc	gcaaaaccag	caggagaaaa	atgaaaaaga	9480
tttattagca	ttggacagtt	ggaaaaactt	gtggaattgg	tttaacataa	caaattggct	9540
gtggtatata	aaaatattca	tcatgatagt	aggaggcttg	ataggtttga	gaataatttt	9600
tggtgtactc	gctatagtga	aaagagttag	gcagggatag	tcacctttgt	cgtttcagac	9660
ccttacccca	agcccagggg	gtcccgcacg	gctcgggaag	atcgaagaag	aaggtggaga	9720
gcaagacaaa	gacagatcca	ttcgattagt	gagcggattc	ttagcacttg	cctgggacga	9780
tctgcgagc	ctgtgcctct	tcagctacca	ccacttgaga	gacttcatat	tgattgcagc	9840
gagagcagcg	gaacttctgg	gacgcagcag	tctcagggga	ctgcagagag	gggtgggaagc	9900
ccttaagtat	ctgggaaatc	ttgtgcagta	tgggggtctg	gagctaaaaa	gaagtgctat	9960
taaactgttt	gataccatag	caatagcagt	agctgaagga	acagatagga	ttcttgaagt	10020
aatacagaga	attttagtag	ctatccgcca	catacctata	agaataagac	agggcctttga	10080
agcagctttg	caataattaa	ttaagtaacc	gatacagcag	caattggcaa	gctgcttaca	10140
tagaactcgc	ggcgattggc	atgccgcctt	aaaattttta	ttttattttt	tcttttcttt	10200
tccgaatcgg	attttgtttt	taatatattca	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	10260

**THIS PAGE BLANK (USPTO)**

aaaaaaaaa	aaaaaaaaa	gaagagcgcg	gccgcgcgct	gggctacgtc	ttgctggcgt	10320
tcgcgacg	aggctggatg	gccttcccc	ttatgattct	tctcgcttc	ggcgccatcg	10380
ggatgcccgc	gttgcaggcc	atgctgtcca	ggcaggtaga	tgacgacat	cagggacagc	10440
ttcaaggatc	gctcgcggt	cttaccagcc	taacttcgat	cactggaccg	ctgatcgtca	10500
cggcgattta	tgccgcctcg	gcgagcacat	ggaacgggtt	ggcatggatt	gtaggcgccg	10560
ccctatacct	tgtctgcctc	cccgcgttgc	gtcgcggtgc	atggagccgg	gccacctcga	10620
cctgaatgga	agccggcggc	acctcgctaa	cggattcacc	actccaagaa	ttggagccaa	10680
tcaattcttg	cggagaactg	tgaatgcgca	aaccaaccct	tggcagaaca	tatccatcgc	10740
gtccgccatc	tccagcagcc	gcacgcggcg	catctcgggc	agcgttgggt	cctggccacg	10800
ggtgcgcatg	atcgctgtcc	tgctcgttgag	gacccggcta	ggctggcggg	gttgccttac	10860
tggttagcag	aatgaatcac	cgatacgca	gcgaacgtga	agcgactgct	gctgcaaaac	10920
gtctgcgacc	tgagcaacaa	catgaatggt	cttcggtttc	cgtgtttcgt	aaagtctgga	10980
aacgcggaag	tcagcgccct	gcaccattat	gttcgggac	tgcatcgag	gatgctgctg	11040
gctaccctgt	ggaacacct	catctgtatt	aacgaagcgc	tggcattgac	cctgagtgat	11100
ttttctctgg	tcccgcgcga	tccataccgc	cagttgttta	ccctcacaac	gttccagtaa	11160
cggggcatgt	tcacatcag	taaccctgat	cgtgagcatc	ctctctcgtt	tcacggtat	11220
cattaccccc	atgaacagaa	atccccctta	cacggaggca	tcagtgaaca	aacaggaaaa	11280
aaccgcctt	aacatggccc	gctttatcag	aagccagaca	ttaacgcttc	tggagaaact	11340
caadgagctg	gacgcggatg	aacaggcaga	catctgtgaa	tcgcttcacg	accacgctga	11400
tgagctttac	cgcagctgcc	tcgcgcgttt	cgtgatgac	ggtgaaaacc	tctgacacat	11460
gcagctccc	gagacggcca	cagcttgtct	gtaagcggat	gccgggagca	gacaagcccc	11520
tcagggcgcg	tcagcgggtg	ttggcgggtg	tcggggcgca	gccatgaccc	agtcacgtag	11580
cgatagcgga	gtgtatactg	gcttaactat	gcggcatcag	agcagattgt	actgagagt	11640
caccatata	gcggtgtgaa	ataccgcaca	gatgcgtaag	gagaaaatac	cgcatcaggc	11700
gctcttcgc	ttcctcgctc	actgactcgc	tgcgctcggt	cgctcggctg	cggcgagcgg	11760
tatcagctca	ctcaaaggcg	gtaatacgg	tatccacaga	atcaggggat	aacgcaggaa	11820
agaacatgtg	agcaaaaggc	cagcaaaagg	ccaggaaccg	taaaaaggcc	gcgttgctgg	11880
cgtttttcca	taggctccgc	ccccctgacg	agcatcaca	aaatcgacgc	tcaagtcaga	11940
ggtggcgaaa	cccgcagga	ctataaagat	accaggcggt	tccccctgga	agctccctcg	12000
tgcgctctcc	tggtccgacc	ctgccgctta	ccggatacct	gtccgccttt	ctcccttcgg	12060
gaagcgtggc	gctttctcat	agctcacgct	gtaggatat	cagttcgggtg	taggtcgctt	12120
gctccaagct	gggctgtgtg	cacgaacccc	ccgttcagcc	cgaccgctgc	gccttatccg	12180
gtaactatcg	tcttgagtcc	aaccgcgtaa	gacacgactt	atcgccactg	gcagcagcca	12240
ctggtaacag	gattagcaga	gcgaggtatg	taggcgggtg	tacagagttc	ttgaagtgg	12300
ggcctaacta	cggctacact	agaaggacag	tatttggtat	ctgcgctctg	ctgaagccag	12360
ttaccttcgg	aaaaagagtt	ggtagctctt	gatccggcaa	acaaaccacc	gctggtagcg	12420
gtggtttttt	tggttgcaag	cagcagatta	cgcgagaaaa	aaaaggatct	caagaagatc	12480
ctttgatctt	ttctacgggg	tctgacgctc	agtggaacga	aaactcacgt	taagggattt	12540
tggtcatgaa	caataaaact	gtctgcttac	ataaacagta	atacaagggg	tggtatgagc	12600
catattcaac	gggaaacgtc	ttgctcgagg	ccgcgattaa	attccaacat	ggatgctgat	12660
ttatatgggt	ataaatgggc	tcgcgataat	gtcgggcaat	caggtgcgac	aatctatcga	12720
ttgtatggga	agcccgatgc	gccagagttg	tttctgaaac	atggcaaagg	tagcgttgcc	12780
aatgatgtta	cagatgagat	ggtcagacta	aactggctga	cggaatttat	gcctcttcog	12840
accatcaagc	attttatccg	tactcctgat	gatgcattgt	tactcaccac	tgcatcccc	12900
gggaaaacag	cattccaggt	attagaagaa	tatcctgatt	caggtgaaaa	tattgttgat	12960
gcgctggcag	tggtcctgcg	ccggttgcat	tcgattcctg	tttgtaattg	tccttttaac	13020
agcgatcgcg	tatttcgtct	cgtcaggcg	caatcacgaa	tgaataacgg	tttggttgat	13080
gcgagtgatt	tattgacga	gcgtaatggc	tggcctgttg	aacaagtctg	gaaagaaatg	13140
cataagcttt	tgccattctc	accggattca	gtcgtcactc	atggtgattt	ctcacttgat	13200
aaccttattt	ttgacgaggg	gaaattaata	ggttgatttg	atggtggacg	agtcggaatc	13260
gcagaccgat	accaggatct	tgccatccta	tggaaactgcc	tcggtgagtt	ttctccttca	13320
ttacagaaac	ggctttttca	aaaatatggt	attgataatc	ctgatatgaa	taaattgcag	13380
tttcatttga	tgctcgatga	gtttttctaa	gaattctcat	gtttgacagc	ttatcatcga	13440
taagctttta	tgcggtagtt	tatcacagtt	aaattgctaa	cgcagtcagg	caccgtgat	13500
gaaatctaac	aatgcgctca	tcgtcatcct	cggcaccgtc	accctggatg	ctgtctagag	13560

**THIS PAGE BLANK (USPTO)**

55

gateccctaatt acgactcact atag

13584

&lt;210&gt; 18

&lt;211&gt; 2532

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence; Note =  
synthetic construct

&lt;221&gt; CDS

&lt;222&gt; (1)...(2532)

&lt;400&gt; 18

atg	aga	gtg	atg	ggg	ata	cag	agg	aat	tgg	cca	caa	tgg	tgg	ata	tgg	48
Met	Arg	Val	Met	Gly	Ile	Gln	Arg	Asn	Trp	Pro	Gln	Trp	Trp	Ile	Trp	
1				5					10					15		

ggc	acc	tta	ggc	ttt	tgg	atg	ata	ata	att	tgt	agg	gtg	gtg	ggg	aac	96
Gly	Thr	Leu	Gly	Phe	Trp	Met	Ile	Ile	Ile	Cys	Arg	Val	Val	Gly	Asn	
			20					25					30			

ttg	aac	ttg	tgg	gtc	aca	gtc	tat	tat	ggg	gta	cct	gtg	tgg	aaa	gaa	144
Leu	Asn	Leu	Trp	Val	Thr	Val	Tyr	Tyr	Gly	Val	Pro	Val	Trp	Lys	Glu	
		35					40					45				

gca	aaa	act	act	cta	ttc	tgt	gca	tca	gat	gct	aaa	gca	tat	gat	aaa	192
Ala	Lys	Thr	Thr	Leu	Phe	Cys	Ala	Ser	Asp	Ala	Lys	Ala	Tyr	Asp	Lys	
		50				55					60					

gaa	gta	cat	aat	gtc	tgg	gct	aca	cat	gcc	tgt	gta	ccc	aca	gac	ccc	240
Glu	Val	His	Asn	Val	Trp	Ala	Thr	His	Ala	Cys	Val	Pro	Thr	Asp	Pro	
65				70					75					80		

aac	cca	cga	gaa	ata	gtt	ttg	gaa	aat	gta	aca	gaa	aat	ttt	aac	atg	288
Asn	Pro	Arg	Glu	Ile	Val	Leu	Glu	Asn	Val	Thr	Glu	Asn	Phe	Asn	Met	
			85					90					95			

tgg	aaa	aat	gac	atg	gtg	gat	cag	atg	cat	gag	gat	ata	atc	agt	tta	336
Trp	Lys	Asn	Asp	Met	Val	Asp	Gln	Met	His	Glu	Asp	Ile	Ile	Ser	Leu	
		100					105					110				

tgg	gat	caa	agc	cta	aaa	cca	tgt	gta	aag	ttg	acc	cca	ctc	tgt	gtc	384
Trp	Asp	Gln	Ser	Leu	Lys	Pro	Cys	Val	Lys	Leu	Thr	Pro	Leu	Cys	Val	
		115				120						125				

act	tta	aat	tgt	aca	aat	gca	cct	gcc	tac	aat	aat	agc	atg	cat	gga	432
Thr	Leu	Asn	Cys	Thr	Asn	Ala	Pro	Ala	Tyr	Asn	Asn	Ser	Met	His	Gly	
		130				135					140					

gaa	atg	aaa	aat	tgc	tct	aat	aca	acc	aca	gag	ata	aga	gat	agg		480
Glu	Met	Lys	Asn	Cys	Ser	Phe	Asn	Thr	Thr	Thr	Glu	Ile	Arg	Asp	Arg	
145				150					155				160			

**THIS PAGE BLANK (USPTO)**

aaa cag aaa gcg tat gca ctt ttt tat aaa cct gat gta gtg cca ctt	528
Lys Gln Lys Ala Tyr Ala Leu Phe Tyr Lys Pro Asp Val Val Pro Leu	
165 170 175	
aat agg aga gaa gag aat aat ggg aca gga gag tat ata tta ata aat	576
Asn Arg Arg Glu Glu Asn Asn Gly Thr Gly Glu Tyr Ile Leu Ile Asn	
180 185 190	
tgc aat tcc tca acc ata aca caa gcc tgt cca aag gtc act ttt gac	624
Cys Asn Ser Ser Thr Ile Thr Gln Ala Cys Pro Lys Val Thr Phe Asp	
195 200 205	
cca att cct ata cat tat tgt gct cca gct ggt tat gcg att cta aag	672
Pro Ile Pro Ile His Tyr Cys Ala Pro Ala Gly Tyr Ala Ile Leu Lys	
210 215 220	
tgt aat aat aag aca ttc aat ggg aca gga cca tgc aat aat gtc agc	720
Cys Asn Asn Lys Thr Phe Asn Gly Thr Gly Pro Cys Asn Asn Val Ser	
225 230 235 240	
aca gta caa tgt aca cat gga att atg cca gtg gta tca act caa tta	768
Thr Val Gln Cys Thr His Gly Ile Met Pro Val Val Ser Thr Gln Leu	
245 250 255	
ctg tta aat ggt agc cta gca gaa gaa gag ata ata att aga tct gaa	816
Leu Leu Asn Gly Ser Leu Ala Glu Glu Glu Ile Ile Ile Arg Ser Glu	
260 265 270	
aat ctg aca aac aat atc aaa aca ata ata gtc cac ctt aat aaa tct	864
Asn Leu Thr Asn Asn Ile Lys Thr Ile Ile Val His Leu Asn Lys Ser	
275 280 285	
gta gaa att gtg tgt aca aga ccc aac aat aat aca aga aaa agt ata	912
Val Glu Ile Val Cys Thr Arg Pro Asn Asn Asn Thr Arg Lys Ser Ile	
290 295 300	
agg ata gga cca gga caa aca ttc tat gca aca ggt gaa ata ata gga	960
Arg Ile Gly Pro Gly Gln Thr Phe Tyr Ala Thr Gly Glu Ile Ile Gly	
305 310 315 320	
aac ata aga gaa gca cat tgt aac att agt aaa agt aac tgg acc agt	1008
Asn Ile Arg Glu Ala His Cys Asn Ile Ser Lys Ser Asn Trp Thr Ser	
325 330 335	
act tta gaa cag gta aag aaa aaa tta aaa gaa cac tac aat aag aca	1056
Thr Leu Glu Gln Val Lys Lys Lys Leu Lys Glu His Tyr Asn Lys Thr	
340 345 350	
ata gaa ttt aac cca ccc tca gga ggg gat cta gaa gtt aca aca cat	1104
Ile Glu Phe Asn Pro Pro Ser Gly Gly Asp Leu Glu Val Thr Thr His	
355 360 365	
agc ttt aat tgt aga gga gaa ttt ttc tat tgc aat aca aca aaa ctg	1152
Ser Phe Asn Cys Arg Gly Glu Phe Phe Tyr Cys Asn Thr Thr Lys Leu	
370 375 380	

**THIS PAGE BLANK (USPTO)**

57

ttt tca aac aac agt gat tca aac aac gaa acc atc aca ctc cca tgc	1200
Phe Ser Asn Asn Ser Asp Ser Asn Asn Glu Thr Ile Thr Leu Pro Cys	
385 390 395 400	
aag ata aaa caa att ata aac atg tgg cag aag gta gga cga gca atg	1248
Lys Ile Lys Gln Ile Ile Asn Met Trp Gln Lys Val Gly Arg Ala Met	
405 410 415	
tat gcc cct ccc att gaa gga aac ata aca tgt aaa tca aat atc aca	1296
Tyr Ala Pro Pro Ile Glu Gly Asn Ile Thr Cys Lys Ser Asn Ile Thr	
420 425 430	
gga cta cta ttg aca cgt gat gga gga aag aat aca aca aat gag ata	1344
Gly Leu Leu Leu Thr Arg Asp Gly Gly Lys Asn Thr Thr Asn Glu Ile	
435 440 445	
ttc aga ccg gga gga gga aat atg aag gac aat tgg aga agt gaa tta	1392
Phe Arg Pro Gly Gly Gly Asn Met Lys Asp Asn Trp Arg Ser Glu Leu	
450 455 460	
tat aaa tat aaa gtg gta gaa att gag cca ttg gga gta gca ccc act	1440
Tyr Lys Tyr Lys Val Val Glu Ile Glu Pro Leu Gly Val Ala Pro Thr	
465 470 475 480	
aaa tca aaa agg aga gtg gtg gag aga gaa aaa aga gca gtg gga cta	1488
Lys Ser Lys Arg Arg Val Val Glu Arg Glu Lys Arg Ala Val Gly Leu	
485 490 495	
gga gct gta ctc ctt ggg ttc ttg gga gca gca gga agc act atg ggc	1536
Gly Ala Val Leu Leu Gly Phe Leu Gly Ala Ala Gly Ser Thr Met Gly	
500 505 510	
gcg gcg tca ata acg ctg acg gta cag gcc aga caa ctg ttg tct ggt	1584
Ala Ala Ser Ile Thr Leu Thr Val Gln Ala Arg Gln Leu Leu Ser Gly	
515 520 525	
ata gtg caa cag caa agc aat ttg ctg aga gct ata gag gcg caa cag	1632
Ile Val Gln Gln Gln Ser Asn Leu Leu Arg Ala Ile Glu Ala Gln Gln	
530 535 540	
cat atg ttg caa ctc acg gtc tgg ggc att aag cag ctc cag aca aga	1680
His Met Leu Gln Leu Thr Val Trp Gly Ile Lys Gln Leu Gln Thr Arg	
545 550 555 560	
gtc ttg gct ata gag aga tac cta aag gat caa cag ctc cta ggg ctt	1728
Val Leu Ala Ile Glu Arg Tyr Leu Lys Asp Gln Gln Leu Leu Gly Leu	
565 570 575	
tgg ggc tgc tct gga aaa atc atc tgc acc act gct gtg cct tgg aac	1776
Trp Gly Cys Ser Gly Lys Ile Ile Cys Thr Thr Ala Val Pro Trp Asn	
580 585 590	
tcc agt tgg agt aat aaa tct caa gaa gat att tgg gat aac atg acc	1824
Ser Ser Trp Ser Asn Lys Ser Gln Glu Asp Ile Trp Asp Asn Met Thr	
595 600 605	

**THIS PAGE BLANK (USPTO)**

tgg atg cag tgg gat aga gaa att agt aat tac aca ggc aca ata tat	1872
Trp Met Gln Trp Asp Arg Glu Ile Ser Asn Tyr Thr Gly Thr Ile Tyr	
610 615 620	
agg tta ctt gaa gac tcg caa aac cag cag gag aaa aat gaa aaa gat	1920
Arg Leu Leu Glu Asp Ser Gln Asn Gln Gln Glu Lys Asn Glu Lys Asp	
625 630 635 640	
tta tta gca ttg gac agt tgg aaa aac ttg tgg aat tgg ttt aac ata	1968
Leu Leu Ala Leu Asp Ser Trp Lys Asn Leu Trp Asn Trp Phe Asn Ile	
645 650 655	
aca aat tgg ctg tgg tat ata aaa ata ttc atc atg ata gta gga ggc	2016
Thr Asn Trp Leu Trp Tyr Ile Lys Ile Phe Ile Met Ile Val Gly Gly	
660 665 670	
ttg ata ggt ttg aga ata att ttt ggt gta ctc gct ata gtg aaa aga	2064
Leu Ile Gly Leu Arg Ile Ile Phe Gly Val Leu Ala Ile Val Lys Arg	
675 680 685	
gtt agg cag gga tac tca cct ttg tcg ttt cag acc ctt acc cca agc	2112
Val Arg Gln Gly Tyr Ser Pro Leu Ser Phe Gln Thr Leu Thr Pro Ser	
690 695 700	
ccg agg ggt ccc gac agg ctc gga aga atc gaa gaa gaa ggt gga gag	2160
Pro Arg Gly Pro Asp Arg Leu Gly Arg Ile Glu Glu Glu Gly Gly Glu	
705 710 715 720	
caa gac aaa gac aga tcc att cga tta gtg agc gga ttc tta gca ctt	2208
Gln Asp Lys Asp Arg Ser Ile Arg Leu Val Ser Gly Phe Leu Ala Leu	
725 730 735	
gcc tgg gac gat ctg cgg agc ctg tgc ctc ttc agc tac cac cac ttg	2256
Ala Trp Asp Asp Leu Arg Ser Leu Cys Leu Phe Ser Tyr His His Leu	
740 745 750	
aga gac ttc ata ttg att gca gcg aga gca gcg gaa ctt ctg gga cgc	2304
Arg Asp Phe Ile Leu Ile Ala Ala Arg Ala Ala Glu Leu Leu Gly Arg	
755 760 765	
agc agt ctc agg gga ctg cag aga ggg tgg gaa gcc ctt aag tat ctg	2352
Ser Ser Leu Arg Gly Leu Gln Arg Gly Trp Glu Ala Leu Lys Tyr Leu	
770 775 780	
gga aat ctt gtg cag tat ggg ggt ctg gag cta aaa aga agt gct att	2400
Gly Asn Leu Val Gln Tyr Gly Gly Leu Glu Leu Lys Arg Ser Ala Ile	
785 790 795 800	
aaa ctg ttt gat acc ata gca ata gca gta gct gaa gga aca gat agg	2448
Lys Leu Phe Asp Thr Ile Ala Ile Ala Val Ala Glu Gly Thr Asp Arg	
805 810 815	
att ctt gaa gta ata cag aga att tgt aga gct atc cgc cac ata cct	2496
Ile Leu Glu Val Ile Gln Arg Ile Cys Arg Ala Ile Arg His Ile Pro	
820 825 830	

**THIS PAGE BLANK (USPTO)**

ata aga ata aga cag ggc ttt gaa gca gct ttg caa  
 Ile Arg Ile Arg Gln Gly Phe Glu Ala Ala Leu Gln  
           835                                  840

2532

&lt;210&gt; 19

&lt;211&gt; 844

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence; Note =  
           synthetic construct

&lt;400&gt; 19

Met	Arg	Val	Met	Gly	Ile	Gln	Arg	Asn	Trp	Pro	Gln	Trp	Trp	Ile	Trp
1				5					10					15	
Gly	Thr	Leu	Gly	Phe	Trp	Met	Ile	Ile	Ile	Cys	Arg	Val	Val	Gly	Asn
		20						25					30		
Leu	Asn	Leu	Trp	Val	Thr	Val	Tyr	Tyr	Gly	Val	Pro	Val	Trp	Lys	Glu
		35					40					45			
Ala	Lys	Thr	Thr	Leu	Phe	Cys	Ala	Ser	Asp	Ala	Lys	Ala	Tyr	Asp	Lys
	50					55					60				
Glu	Val	His	Asn	Val	Trp	Ala	Thr	His	Ala	Cys	Val	Pro	Thr	Asp	Pro
65					70					75					80
Asn	Pro	Arg	Glu	Ile	Val	Leu	Glu	Asn	Val	Thr	Glu	Asn	Phe	Asn	Met
				85					90					95	
Trp	Lys	Asn	Asp	Met	Val	Asp	Gln	Met	His	Glu	Asp	Ile	Ile	Ser	Leu
		100						105					110		
Trp	Asp	Gln	Ser	Leu	Lys	Pro	Cys	Val	Lys	Leu	Thr	Pro	Leu	Cys	Val
		115					120					125			
Thr	Leu	Asn	Cys	Thr	Asn	Ala	Pro	Ala	Tyr	Asn	Asn	Ser	Met	His	Gly
	130					135					140				
Glu	Met	Lys	Asn	Cys	Ser	Phe	Asn	Thr	Thr	Thr	Glu	Ile	Arg	Asp	Arg
145					150					155					160
Lys	Gln	Lys	Ala	Tyr	Ala	Leu	Phe	Tyr	Lys	Pro	Asp	Val	Val	Pro	Leu
				165					170					175	
Asn	Arg	Arg	Glu	Glu	Asn	Asn	Gly	Thr	Gly	Glu	Tyr	Ile	Leu	Ile	Asn
			180					185					190		
Cys	Asn	Ser	Ser	Thr	Ile	Thr	Gln	Ala	Cys	Pro	Lys	Val	Thr	Phe	Asp
	195						200					205			
Pro	Ile	Pro	Ile	His	Tyr	Cys	Ala	Pro	Ala	Gly	Tyr	Ala	Ile	Leu	Lys
	210					215					220				
Cys	Asn	Asn	Lys	Thr	Phe	Asn	Gly	Thr	Gly	Pro	Cys	Asn	Asn	Val	Ser
225					230					235					240
Thr	Val	Gln	Cys	Thr	His	Gly	Ile	Met	Pro	Val	Val	Ser	Thr	Gln	Leu
				245					250					255	
Leu	Leu	Asn	Gly	Ser	Leu	Ala	Glu	Glu	Glu	Ile	Ile	Ile	Arg	Ser	Glu
		260						265					270		
Asn	Leu	Thr	Asn	Asn	Ile	Lys	Thr	Ile	Ile	Val	His	Leu	Asn	Lys	Ser
		275					280					285			
Val	Glu	Ile	Val	Cys	Thr	Arg	Pro	Asn	Asn	Asn	Thr	Arg	Lys	Ser	Ile
	290					295					300				

**THIS PAGE BLANK (USPTO)**

**THIS PAGE BLANK**

60

Arg Ile Gly Pro Gly Gln Thr Phe Tyr Ala Thr Gly Glu Ile Ile Gly  
 305 310 315 320  
 Asn Ile Arg Glu Ala His Cys Asn Ile Ser Lys Ser Asn Trp Thr Ser  
 325 330 335  
 Thr Leu Glu Gln Val Lys Lys Lys Leu Lys Glu His Tyr Asn Lys Thr  
 340 345 350  
 Ile Glu Phe Asn Pro Pro Ser Gly Gly Asp Leu Glu Val Thr Thr His  
 355 360 365  
 Ser Phe Asn Cys Arg Gly Glu Phe Phe Tyr Cys Asn Thr Thr Lys Leu  
 370 375 380  
 Phe Ser Asn Asn Ser Asp Ser Asn Asn Glu Thr Ile Thr Leu Pro Cys  
 385 390 395 400  
 Lys Ile Lys Gln Ile Ile Asn Met Trp Gln Lys Val Gly Arg Ala Met  
 405 410 415  
 Tyr Ala Pro Pro Ile Glu Gly Asn Ile Thr Cys Lys Ser Asn Ile Thr  
 420 425 430  
 Gly Leu Leu Leu Thr Arg Asp Gly Gly Lys Asn Thr Thr Asn Glu Ile  
 435 440 445  
 Phe Arg Pro Gly Gly Gly Asn Met Lys Asp Asn Trp Arg Ser Glu Leu  
 450 455 460  
 Tyr Lys Tyr Lys Val Val Glu Ile Glu Pro Leu Gly Val Ala Pro Thr  
 465 470 475 480  
 Lys Ser Lys Arg Arg Val Val Glu Arg Glu Lys Arg Ala Val Gly Leu  
 485 490 495  
 Gly Ala Val Leu Leu Gly Phe Leu Gly Ala Ala Gly Ser Thr Met Gly  
 500 505 510  
 Ala Ala Ser Ile Thr Leu Thr Val Gln Ala Arg Gln Leu Leu Ser Gly  
 515 520 525  
 Ile Val Gln Gln Gln Ser Asn Leu Leu Arg Ala Ile Glu Ala Gln Gln  
 530 535 540  
 His Met Leu Gln Leu Thr Val Trp Gly Ile Lys Gln Leu Gln Thr Arg  
 545 550 555 560  
 Val Leu Ala Ile Glu Arg Tyr Leu Lys Asp Gln Gln Leu Leu Gly Leu  
 565 570 575  
 Trp Gly Cys Ser Gly Lys Ile Ile Cys Thr Thr Ala Val Pro Trp Asn  
 580 585 590  
 Ser Ser Trp Ser Asn Lys Ser Gln Glu Asp Ile Trp Asp Asn Met Thr  
 595 600 605  
 Trp Met Gln Trp Asp Arg Glu Ile Ser Asn Tyr Thr Gly Thr Ile Tyr  
 610 615 620  
 Arg Leu Leu Glu Asp Ser Gln Asn Gln Gln Glu Lys Asn Glu Lys Asp  
 625 630 635 640  
 Leu Leu Ala Leu Asp Ser Trp Lys Asn Leu Trp Asn Trp Phe Asn Ile  
 645 650 655  
 Thr Asn Trp Leu Trp Tyr Ile Lys Ile Phe Ile Met Ile Val Gly Gly  
 660 665 670  
 Leu Ile Gly Leu Arg Ile Ile Phe Gly Val Leu Ala Ile Val Lys Arg  
 675 680 685  
 Val Arg Gln Gly Tyr Ser Pro Leu Ser Phe Gln Thr Leu Thr Pro Ser  
 690 695 700  
 Pro Arg Gly Pro Asp Arg Leu Gly Arg Ile Glu Glu Glu Gly Gly Glu  
 705 710 715 720  
 Gln Asp Lys Asp Arg Ser Ile Arg Leu Val Ser Gly Phe Leu Ala Leu  
 725 730 735

**THIS PAGE BLANK (USPTO)**

Ala Trp Asp Asp Leu Arg Ser Leu Cys Leu Phe Ser Tyr His His Leu  
740 745 750  
Arg Asp Phe Ile Leu Ile Ala Ala Arg Ala Ala Glu Leu Leu Gly Arg  
755 760 765  
Ser Ser Leu Arg Gly Leu Gln Arg Gly Trp Glu Ala Leu Lys Tyr Leu  
770 775 780  
Gly Asn Leu Val Gln Tyr Gly Gly Leu Glu Leu Lys Arg Ser Ala Ile  
785 790 795 800  
Lys Leu Phe Asp Thr Ile Ala Ile Ala Val Ala Glu Gly Thr Asp Arg  
805 810 815  
Ile Leu Glu Val Ile Gln Arg Ile Cys Arg Ala Ile Arg His Ile Pro  
820 825 830  
Ile Arg Ile Arg Gln Gly Phe Glu Ala Ala Leu Gln  
835 840

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

